A study of the role of ATM mutations in the pathogenesis of B-cell chronic lymphocytic leukaemia by Austen, Belinda
 
 
A study of the role of ATM mutations  
in the pathogenesis of  
B-cell chronic lymphocytic leukaemia 
 
 
by 
 
 
Belinda Austen 
 
 
 
A thesis submitted to the  
Faculty of Medicine and Dentistry 
of The University of Birmingham 
for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
 
Cancer Research UK 
Institute for Cancer Studies 
The Medical School 
The University of Birmingham 
 
October 2006  
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
Synopsis 
 
      Mutations in the ATM gene have previously been identified in CLL 
tumours. In this project, I have demonstrated that their detection would have 
prognostic value. With a prevalence of 12%, ATM mutations represent the 
commonest single gene defect to be detected in CLL tumours and they 
identified a subgroup of CLL patients that had a significant reduction in both 
treatment free and overall survival. Furthermore, ATM mutations provided 
prognostic information that was independent of age, clinical stage, the 
mutation status of the IGVH genes and TP53 mutations.  
       The temporal acquisition of the ATM mutations and their relationship with 
loss of an ATM allele via a chromosomal 11q deletion provides clues into their 
mechanism of action. There was only a partial correlation between CLL 
tumours with mutations in the ATM gene and those with a chromosome 11q 
deletion. In certain cases, the ATM mutations represented germ-line changes 
and in others were acquired very early in the disease course raising the 
possibility that they might contribute to the initial clonal transformation 
process. However, in some CLL tumours, the ATM mutations had been 
acquired after the development of the tumour clone during disease 
progression indicating that there may be a step-wise acquisition of ATM allelic 
defects during the ontogeny of CLL.   
      The ATM protein is the key coordinator of the cellular response to DNA 
double strand breaks. In this study, I showed that bi-allelic defects in the ATM 
gene lead to deficient ATM dependent responses, including the up regulation 
of p53, following both ionising irradiation and also treatment with the 
chemotherapeutic drug, Fludarabine. Thus an important mechanism 
accounting for the poor outcome in CLL patients with ATM mutations is likely 
to relate to chemo-resistance. Interestingly, there were differential responses 
to DNA damage with both irradiation and fludarabine amongst the category of 
tumours with an 11q deletion according to the status of the remaining ATM 
allele. Therefore, ATM mutations can stratify tumours with a chromosome 11q 
deletion into two functional subgroups. 
      The identification of CLL tumours with ATM mutations would therefore 
predict those patients that will have a poor clinical outcome and be both more 
likely to require early treatment for their disease. Patients whose tumours had 
bi-allelic ATM defects will be expected to have deficient responses to DNA 
damaging chemotherapeutic drugs, while those with mono-allelic ATM defects 
might identify a group in whom the use of DNA damaging agents could 
provide selective pressure for the emergence of sub-clones that have 
subsequently acquired bi-allelic ATM defects.  
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 Introduction 
 
1.1 B-Cell Chronic Lymphocytic Leukaemia 
       B-cell chronic lymphocytic leukaemia (CLL) is the commonest leukaemia 
in the western world with an incidence of approximately 3 per 100,000 per 
year. The median age of onset is 55-60 years and it is approximately 1.5 fold 
more common in men than in women. The disease results from the clonal 
expansion of mature B-lymphocytes and the diagnosis of B-CLL is confirmed 
by the demonstration of a population of clonal B cells which have a distinctive 
pattern of cell surface and cytoplasmic markers. CLL tumours cells show 
restriction of kappa or lambda immunoglobulin light chain expression and can 
be distinguished from other B-cell lymphoproliferative disorders on the basis 
of their strong positive expression of CD5 and CD23, weak positive 
expression of surface immunoglobulin and absence of CD10 or CD79b 
expression (Oscier D et al, 2004).  
 
1.2 Clinical heterogeneity of B-cell CLL  
       A characteristic feature of CLL is the marked clinical heterogeneity. This 
is manifest by variations in disease burden and distribution at diagnosis, and 
by variability in the subsequent rate and pattern of disease progression, the 
sensitivity to chemotherapeutic agents and the development of infective or 
immune complications.   
 
1.2.1 Disease presentation 
 1
      Many patients are asymptomatic at presentation and the diagnosis of CLL 
is made incidentally from the finding of a peripheral blood lymphocytosis. 
Symptomatic patients will typically present with a history of fatigue and 
sweats, and in some cases recurrent or prolonged infections. 
Lymphadenopathy may be present at diagnosis and this is usually 
symmetrical, painless and commonly involves the cervical, axillary or inguinal 
regions. Enlargement of the spleen or liver is associated with advanced 
disease but may rarely be present at diagnosis. CLL patients can also present 
with symptoms related to anaemia or thrombocytopenia and these may reflect 
extensive bone marrow infiltration with the CLL tumour clone or alternatively 
may result from autoimmune haemolytic anaemia or thrombocytopenia, which 
are both associated with CLL (D’Arena G et al. 2003). 
 
 1.2.2 Clinical Staging 
      The extent of the disease can be assessed using clinical staging systems. 
The Binet and Rai systems are commonly used and both categorise patients 
according to the degree of lymph node or organ involvement and the 
presence of peripheral blood cytopenias (Binet JL et al. 1981, Rai KR et al, 
1975). Five anatomical regions are described, namely cervical, axillary, 
inguinal lymph nodes as well as spleen and liver. In the Binet system patients 
are categorised as stage A if they have involvement of less than three 
lymphoid areas, stage B if there is nodal expansion of between three and five 
lymphoid areas and stage C if there is either an anaemia (haemoglobin 
<10g/dl) or thrombocytopenia (platelet count < 100x109/l), regardless of the 
number of lymphoid areas involved. To designate a patient as stage C, 
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implying extensive marrow infiltration with CLL, requires the exclusion of an 
immune cause for any cytopenia (Binet JL et al; 1981). Approximately 70-80% 
of patients have stage A disease at presentation and many of these patients 
will be asymptomatic with an isolated peripheral blood lymphocytosis (Oscier 
D et al, 2004).  
 
1.2.3 Disease Progression 
       The subsequent disease course after diagnosis is also highly variable, 
particularly in those patients that present with stage A disease. Some patients 
remain asymptomatic and have an entirely stable CLL clone. These 
individuals never require treatment for their disease. Other patients have an 
expansion of their clone and this may occur insidiously over many years or 
can occur much more rapidly. Tumour cells may accumulate predominantly in 
the peripheral blood or primarily within the lymph nodes or the bone marrow, 
and this pattern of disease distribution is highly variable between individuals 
(Chiorazzi N et al, 2005, Hamblin TJ, 2005). 
       The principal indication for treatment in CLL patients is the presence of 
symptoms (Oscier D et al, 2004). CLL is incurable with chemotherapy and 
there is no evidence to indicate that early treatment of patients with limited 
stage disease has any beneficial effect on outcome. Indeed there is some 
data to suggest that this could actually have a detrimental effect (CLL Trialists' 
Collaborative Group, 1999). Therefore, asymptomatic CLL patients are 
usually managed by a ‘watch and wait’ policy and as such, many stage A CLL 
patients will never require treatment. The majority of patients with stage B or 
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C disease will be symptomatic and will invariably receive treatment (Oscier D 
et al, 2004). 
 
1.2.4 Treatment of CLL patients 
       There are a number of chemotherapeutic agents, which have been 
shown to have activity in CLL and comparisons between different agents 
either alone or in combination continues to be the subject of clinical trials 
(Robak T et al, 2002, Schmitt B et al, 2002). The initial therapy used to treat 
CLL patients in the UK is usually chlorambucil or fludarabine alone or the 
combination of fludarabine with cyclophosphamide (Oscier D et al, 2004).  
These drugs all induce tumour cell death through mechanisms that involve 
DNA damage (Begleiter A et al, 1996, Pettitt AR, 2003, Yamauchi T et al, 
2001). Patients will typically be treated with up to six cycles of a given therapy 
and the degree of any response can then be assessed and classified as a 
complete response, a nodular partial response, a partial response or no 
response. 
     Although, the majority of patients will gain some degree of response to 
these first lines of treatment, their disease will inevitably progress and at some 
stage most patients will require re-treatment (Oscier D et al, 2004). Commonly 
CLL tumour cells become less sensitive to these chemotherapeutic agents 
over time and alternative drugs and combinations will be required (Montserrat 
E, 2006). These will often include agents such as high dose 
methylprednisolone and more recently the monoclonal antibodies Rituximab 
(anti-CD20) and Alemtuzumab (anti-CD52), which have been shown to have 
efficacy in CLL and induce tumour cell apoptosis by alternative mechanisms 
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from the DNA damaging chemotherapeutic agents (Thornton PD et al, 2003, 
Byrd JC et al, 2002, Lozanski G et al, 2004). Eventually patients may fail to 
respond to any of the currently available agents and will die from progressive 
disease.  
 
1.3 Clinical and Biological prognostic markers in CLL  
       Because of this marked clinical heterogeneity between different CLL 
patients, there has been considerable interest in identifying both the clinical 
and biological features of the disease that can help distinguish those patients 
that are likely to have an indolent, stable disease course from those that will 
have a progressive course. These markers are useful in the clinical setting for 
the counselling of patients at the time of diagnosis.  
    Importantly, however, the identification of prognostic features has also led 
to an increased understanding of the nature of CLL, both in terms of the 
cellular origins of the disease and the factors that influence the behaviour of 
the tumour clone (D’Arena G et al, 2003). In addition, by understanding the 
mechanisms of action of these biological prognostic markers it is likely that in 
the future they will increasingly be used to influence clinical decisions. This 
might lead to a situation where the choice of treatment for individual patients 
is made on the basis of the knowledge of specific molecular defects in their 
tumour cells (Binet JL et al, 2006). Finally, the understanding of the critical 
signalling pathways in CLL tumours that have been identified through these 
markers is already leading to the development of novel targeted agents 
(Kojima K et al, 2006, Alvi et al, 2005).  
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1.3.1 Clinical Features 
       Clinical features associated with an impaired outcome in CLL patients 
include older age, male sex, a short lymphocyte doubling time (LDT), 
advanced disease stage and a family history of CLL (Table 1.1). These 
clinical markers have predictive value and have also provided important 
insights into the nature of the disease.  
 
1.3.1.1 Age and Gender 
       Age and gender are both predictors of outcome in CLL. The poor 
outcome associated with increasing age partly reflects co-morbidity rather 
than characteristics of the tumour cell population. By comparison, the 
phenotype of CLL tumours is clearly affected by gender, and CLL is both 
commoner in males than in females and progresses more rapidly, resulting in 
a greater likelihood of patients requiring treatment. The mechanisms that 
underlie the poorer outcome in males are not known (Catovsky D et al, 1989, 
Molica S et al, 2005).  
  
1.3.1.2 Lymphocyte Doubling Time and Clinical Stage 
     Since the LDT measures the rate of expansion of the tumour clone and the 
clinical stage largely reflects the extent of the tumour burden it is not 
surprising that both these features predict for a shorter survival in CLL 
patients (Molica S et al, 2005). The stage of the disease, however, also 
reflects the distribution of tumour cells and those patients that predominantly 
have tumours cells located in lymph nodes or bone marrow have a poorer 
outcome and their tumours are more resistant to chemotherapy, than those 
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Table 1.1 – Features associated with clinical outcome in CLL  
 
Disease Feature Longer Survival Shorter Survival 
Gender Female Male 
Age  Younger age Older age 
Clinical Stage A B or C 
Lymphocyte Doubling Time > 6 months < 6 months 
Family History No family history Family history of CLL 
IGVH status Mutated Unmutated 
CD38 expression Low High 
Zap70 expression Low High 
Cytogenetic Abnormalities 13q deletion or normal 
karyotype 
17p deletion  
or 11q deletion 
TP53 mutations Wild type Mutant 
patients whose CLL cells are predominantly in a leukaemic phase (Binet JL et 
al, 1981, Rai KR et al, 1975, Molica S et al, 2005). This suggests that tumour 
cells have different characteristics according to their microenvironment.       
       It has been shown that CLL cells from the peripheral blood are non-
cycling and are arrested in G1 of the cell cycle and typically these cells are 
characterised by an apoptotic defect in vivo. By comparison, CLL cells located 
within lymph nodes have been shown to cycle and proliferate, as indicated by 
the increased expression of the proliferation marker, Ki67 (Obermann EC et 
al, 2005). Leukaemic cell turnover has also been measured in CLL patients 
using heavy water (D20), as a measure of the DNA synthesis in newly 
generated cells. This data has supported a two compartment model whereby 
tumour cells are produced in the proliferative compartment in lymph nodes 
and marrow and these are slowly released into the accumulative compartment 
in the peripheral circulation (Messmer BT et al, 2005).  
    These phenotypic differences between circulating tumour cells and those 
within the solid tissues are likely to relate to extrinsic signals from the 
microenvironment. Indeed, the apoptotic defect that is characteristic of CLL 
cells in vivo is known to be partly related to the acquisition of survival signals 
via interactions with non-tumour cells. These include the interaction of CLL 
tumour cells with T-cells, through CD40 ligand/CD40 receptor signalling, and 
with nurse-like cells and fibroblasts, through stromal derived factor 4 (SDF4) / 
chemokine receptor 4 (CXCR4) signalling. Furthermore, the stimulation of the 
CD40 receptor on CLL tumour cells by interaction with CD40 ligand has been 
shown to induce the expression of survivin, which appears to be important for 
the control of proliferation, and this is up regulated in tumour cells in the lymph 
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nodes and marrow (Ghia P et al, 2005, Munk Pedersen I, Reed J, 2004, 
Granziero L et al, 2001). 
 
1.3.1.3 Family History 
     There is evidence for a genetic predisposition in the development of CLL 
and, interestingly, a positive family history of CLL has also been shown to be 
associated with certain adverse phenotypic characteristics. 
     A number of family pedigrees with multiple cases of CLL have been 
identified and recently population studies have confirmed that CLL is up to 
seven times more common in relatives of index cases than within controls 
(Neuland CY et al, 1983, Goldin LR et al, 2004). Further evidence to support 
the concept of a heritable basis underlying the development of a proportion of 
CLL cases has come through the detection of low-level clones of CD5+, 
CD23+ B-lymphocytes within normal individuals. Interestingly, these clones, 
which share genetic and phenotypic characteristics with indolent CLL 
tumours, occur over a younger age range in individuals that have a relative 
with CLL (Rawstron AC et al, 2002). 
      By comparison to sporadic cases of CLL, familial CLL has been shown to 
be associated with a younger age of onset and an increased incidence of 
complications including secondary malignancies (Ishibe N et al, 2001). In 
addition, in certain families the phenomenon of anticipation, such that the 
disease presents at younger ages in successive generations, has been 
reported (De Tute R et al, 2006). 
 
1.3.2 Biological markers 
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      A number of biological markers have also been previously identified that 
have the ability to predict clinical outcome in CLL (Table 1.1). The most well 
established of these have been confirmed in multiple patient series and 
include the mutation status of the immunoglobulin variable heavy genes 
(IGVH), the expression of the cell surface marker CD38, the level of 
expression of Zeta associated protein 70 (Zap70) and the presence of 
cytogenetic abnormalities (Hamblin TJ et al, 1999, Damle RN et al, 1999, 
Dohner H et al, 2000, Wiestner A et al, 2003).  
 
1.3.2.1 Mutation status of the IGVH genes  
     The mutation status of the immunoglobulin heavy chain variable region 
gene (IGVH) was shown to provide prognostic information by two independent 
groups in 1999. 
      Patients were classified according to the degree of concordance between 
the sequences of the immunoglobulin heavy genes in their CLL tumour cells 
with the sequences of the nearest immunoglobulin heavy chain gene family. 
Those patients in which there was at least 98% concordance between the 
sequence of the IGVH genes in their tumour cells and the nearest family 
sequence were classified as having unmutated IGVH genes and those with 
less than 98% concordance were categorised as having mutated IGVH 
genes. The 98% cut-off level was used with the aim of distinguishing the 
group of patients whose tumour cells had not undergone the process of 
somatic hypermutation, but nevertheless had low level germ-line 
polymorphisms in their IGVH genes, from the group of patients whose tumour 
cells had acquired mutations in the IGVH genes as a consequence of somatic 
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hyper-mutation. Remarkably, those CLL patients with unmutated IGVH genes 
were shown to have a significantly shorter survival than those with mutated 
IGVH genes in their tumour cells (Figure 1.1) (Hamblin TJ et al, 1999, Damle 
RN et al, 1999). 
      Somatic hypermutation of the IGVH genes in B-lymphocytes occurs in the 
response to antigen recognition during a T-cell dependent germinal centre 
reaction. Therefore, it was believed that CLL tumours with mutated IGVH 
genes had arisen from the clonal expansion of a B-lymphocyte that was 
antigen experienced and had undergone a germinal centre reaction. In 
contrast, tumours with unmutated IGVH genes were believed to have arisen 
from antigen naïve pre-germinal B-lymphocytes. It was hypothesised that the 
differing nature of the cell that had become clonally transformed might 
account for the differences in the tumour behaviour and consequently the 
clinical outcome of the two subgroups of CLL patients (Stevenson F et al, 
1998).  
         More recent data has suggested that the relationship between IGVH 
mutations status, clinical outcome and cellular origin may be more complex in 
CLL than previously thought. Gene expression profiling has provided data 
suggesting that both IGVH unmutated and mutated CLL tumours closely 
resemble memory B-cells with only minimal differences (Rosenwald A et al, 
2001, Klein U et al, 2001). One interpretation to account for these data is that 
all CLL tumours have arisen from the transformation of antigen-experienced 
lymphocytes but there may be differences in the nature of the antigen and the 
type of response (Klein U et al, 2001). Furthermore, certain immunoglobulin 
gene families, such as VH3-21, have been shown to result in poor clinical 
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Figure 1.1 
 
The mutation status of the IGVH gene was identified as an important 
prognostic marker in CLL patients in 1999 (Hamblin TJ et al, 1999, Damle RN 
et al, 1999). Patients whose tumour cells had un-mutated IGVH genes were 
shown to have a shorter survival from diagnosis than patients whose tumour 
cells carried mutated IGVH genes. These differences were highly statistically 
significant. 
 
 
 
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK (1999). 
Unmutated IgVH genes are associated with a more aggressive form of chronic lymphocytic leukaemia.
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outcome regardless of the IGVH mutation status and, interestingly, it has also 
been found that the association of different variable (V), diversity (D) and 
junctional (J) immunoglobulin gene segments occurs in a non-random manner 
in CLL tumours (Tobin G et al, 2003, Stevenson FK, Caligaris-Cappio F, 
2004). Therefore, it is now believed that the differential outcome in patients 
according the IGVH mutation status may be related to the persistence of 
antigen recognition and consequent signalling through the B-cell receptor 
(BCR) on the tumour cells, which could convey survival signals. These 
antigens might include self-antigens and they may be more readily recognised 
by tumours with unmutated IGVH genes, because of the lower stringency for 
antigen recognition by their BCRs. Therefore, this could account for the 
poorer outcome in these CLL subgroups (Stevenson FK, Caligaris-Cappio F, 
2004).  
      Thus it can be seen that the discovery of the prognostic value of the IGVH 
mutation status has significantly increased the understanding of the nature of 
CLL. One advantage of the status of the IGVH genes as a biological marker is 
that it is determined at the time of clonal transformation and is largely stable 
over time. A disadvantage of the IGVH mutation status is that it is not always 
reliable at predicting outcome for an individual patient and, notably, a 
significant proportion of patients with mutated IGVH genes will still have an 
aggressive disease phenotype (Hamblin TJ et al, 1999, Damle RN et al, 
1999). In addition, there have also been discussions regarding the appropriate 
cut-off to define tumours with mutated and un-mutated IGVH genes. Certain 
groups have used a 95% cut-off to define mutated and unmutated IGVH 
genes on the basis of the frequency of mutations in the IGVH gene in non-
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clonal CD5 positive B-lymphocytes (Lin et al, 2002). However in this study 
patients with greater than 98% concordance with the respective IGVH family 
sequence still had the shortest survival, but patients with 95-98% 
concordance had a poorer outcome than patients with <95% concordance 
(Lin et al, 2002).  
    Nevertheless, the mutation status of the IGVH genes has remained a gold 
standard for the evaluation of new biological prognostic markers in CLL. 
   
1.3.2.2 CD38 expression  
       The IGVH mutation status is technically difficult to perform and is not 
generally available in diagnostic laboratories and there has therefore been 
interest in finding alternative markers that correlate with the mutation status of 
the IGVH genes. 
        The level of expression of the activation marker Cluster of Differentiation 
38 (CD38) was found to provide prognostic information in CLL and also to 
correlate with IGVH mutation status (Damle RN et al, 1999, Ghia P et al, 
2003). Patients whose tumours had unmutated IGVH genes were found to 
have elevated CD38 expression and also to have a poorer clinical outcome in 
comparison to those with low levels of CD38 expression on their tumour cells.  
       Subsequently, the correlation between these two prognostic markers was 
shown to be incomplete, although both markers provide independent 
prognostic information (Vilpo J et al, 2003). In addition, it was also found that 
certain patients have populations of tumour cells exhibiting bimodal patterns 
of CD38 expression. The clinical consequences of this bimodal CD38 
expression have not been fully resolved however there is some evidence to 
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suggest that they do not imply a poorer survival (Ghia P et al, 2003, Cocco AE 
et al, 2005). Interestingly, it has also recently been reported that CD38 
expression can be induced in CLL cells in certain in vitro culture systems. This 
suggests that its level of expression might be related to extrinsic signalling 
factors from the microenvironment, rather than representing an inherent 
feature of the tumour cells (Pepper C et al, 2006, Ghia P et al, 2003).  
       Despite these considerations, CD38 remains a useful prognostic marker 
that is commonly used in the clinical setting because it is readily quantifiable 
by immunophenotyping using a fluorescent activated cells sorting (FACS) 
assay and because its expression level provides information that can predict 
clinical outcome.   
 
1.3.2.3 Zap-70 expression 
        The zeta-associated protein 70 (Zap70) was identified as another 
potential surrogate marker for IGVH mutation status following gene 
expression profiling studies (Wiestner A et al, 2003). Elevated Zap70 
expression was found to predict outcome in CLL patients and to be 
associated with unmutated IGVH genes, although once again this correlation 
is incomplete (Rosenwald A, 2001, Kim SZ et al, 2004, Wiestner A et al, 
2003).  
       The mechanism through which elevated Zap70 conveys a poor prognosis 
in CLL patients may relate to its role in the transduction of signals from the 
BCR on tumour cells. Such signalling could favour the induction of an anti-
apoptotic phenotype and hence a poorer clinical outcome (Chen L et al, 
2005). Interestingly, in an analogous manner to CD38 status there is also 
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evidence to suggest that the level of expression of Zap70 can vary within an 
individual and that it is also inducible in in-vitro culture systems. This again 
suggests that its expression level may not be a stable feature of the tumour 
clone (Cocco AE et al, 2005, Pepper C et al, 2006). 
      Zap70 expression on clonal B-cells can also be quantified using FACS 
analysis, however difficulty in the development of reproducible assays to 
reliably quantitate its expression has so far impeded its widespread use as a 
prognostic marker in the clinical setting (Wiestner A et al, 2003). 
 
1.3.2.4 Cytogenetic abnormalities 
      Several recurrent chromosomal aberrations have been described in CLL 
tumours and these have also been found to provide prognostic information 
and may therefore identify specific subgroups of CLL patients whose outcome 
is more homogeneous. The most frequent changes that have been detected 
are deletions of chromosomes 13q, 11q, 17p and 6q and trisomy of 
chromosome 12 (Dohner H et al, 2000). 
     A deletion of chromosome 13q is a common finding and occurs in up to 
80% of CLL tumours. When present as an isolated change it is associated 
with a good clinical outcome which is similar to that observed in patients with 
a normal karyotype. No tumour suppressor gene candidate has been 
established on the region of deletion on chromosome 13q but, interestingly, 
two micro-RNA (mirs) genes, mirs15 and 16, have recently been identified. 
These have been shown to regulate the expression of the anti-apoptotic 
protein BCL-2, which is known to be elevated in B-CLL tumour cells, thus 
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providing a potential mechanistic advantage for the loss of chromosome 13q 
in CLL tumour cells (Croce C et al, 2005).  
     The predictive value of both trisomy of chromosome 12 and a deletion of 
chromosome 6q remains uncertain but each may have a small impact on 
patient outcome. These defects occur in CLL tumours at a frequency of up to 
16% and 7%, respectively (Dohner H et al, 2000; Dewald GW et al, 2003). 
      By comparison, deletions of chromosomes 11q and 17p have been shown 
to result in a significantly shorter survival in CLL patients in comparison to 
patients with a normal karyotype or an isolated 13q deletion (Dohner H et al, 
2000). Since both markers are associated with an aggressive disease 
phenotype their prevalence will vary according to the nature of the cohort. For 
example, their frequency has been shown to occur in 9 and 4%, respectively, 
of stage A patients compared to 20 and 5% of patients requiring first line 
treatment (Seiler T et al, 2006). Patients with a deletion of 17p have the 
shortest survival and patients with an 11q deletion have an outcome that is 
intermediate between those with a normal karyotype or 13q deletion and 
those with a 17p deletion (Dohner H et al, 2000). Deletions of chromosome 
11q have also been shown to be associated with both extensive 
lymphadenopathy and unmutated IGVH genes in CLL patients and deletions 
of 17p have been found to predict resistance to chemotherapeutic agents 
(Dohner H et al, 1997, Sturm I et al, 2003) (Figure 1.2). 
     The minimal region of deletion on chromosome 17p includes the TP53 
gene that encodes for the pro-apoptotic protein p53. Loss of one TP53 allele, 
in combination with a TP53 mutation on the second allele, will lead to 
impaired p53 function and this combination results in an apoptotic resistant 
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Figure 1.2 
 
 
Cytogenetic abnormalities have been shown to provide prognostic information 
in CLL patients. Several recurrent abnormalities have been identified, namely 
deletions of chromosomes 13q, 11q, 17p and 6q and trisomy of chromosome 
12. Patients with a deletion of chromosomes 17p or 11q have been shown to 
have a shorter survival than patients with either a normal karyotype or the 
presence of an isolated chromosome 13q deletion or trisomy 12. The shortest 
survival is seen in patients with a 17p deletion and patients with an 11q 
deletion have a survival that is intermediate between those with a 17p deletion 
and those with a normal karyotype (Dohner H et al, 1999). 
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Genomic aberrations and survival in chronic lymphocytic leukaemia.
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phenotype (Stankovic T et al, 2002). This defect in apoptosis is believed to be 
the mechanism accounting for the very poor prognosis in these patients. The 
detection of a deletion of chromosome 17p appears to be a powerful predictor 
of poor outcome for the individual patient and as a result may directly 
influence treatment decisions, particularly in young patients (Binet JL et al, 
2006). 
      The minimal region of deletion on chromosome 11q has been previously 
delineated and shown to consist of a sequence of between 2-3 megabases 
that includes a number of genes, one of which is the ATM gene (Stilgenbauer 
S et al, 1996). The ATM gene has, therefore, been identified as a putative 
tumour suppressor gene that might be associated with the poor outcome in 
this subgroup of CLL patients. The role of abnormalities in the ATM gene and 
their potential effects on the function of the ATM protein is the subject of this 
thesis.  
     These recurrent chromosomal aberrations can now be readily detected 
with a high sensitivity using interphase fluorescent in situ hybridisation (FISH) 
in CLL tumours. TP53 and ATM probes are used for the detection of 
chromosome 17p and 11q deletions and therefore any tumour found to have 
one of these deletions by FISH will, by definition, have lost one allele of the 
respective gene (Dewald GW et al, 2003). The detection of these 
chromosomal defects is increasingly being used in the clinical setting to 
identify those subgroups of patients that will have a poorer outcome and in the 
future may allow the targeted use of new therapeutic approaches.  
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1.4 The ATM protein 
        The ATM gene, located on chromosome 11q22-23, encodes for the 
370kD ATM protein. Individuals that inherit two germline mutations in the ATM 
gene have the disorder ataxia telangiectasia (AT) (Taylor AM, Edwards MJ, 
1982). The clinical and cellular phenotypes of AT individuals have provided a 
means to study the ATM gene and to understand the functions of the ATM 
protein. The increasing understanding of the biological function of ATM 
continues to facilitate the study of the role of abnormalities in the ATM gene in 
the pathogenesis of CLL and other lymphoid tumours. 
 
1.4.1 The ATM gene 
      The ATM gene has 65 exons extending over 160kb of genomic DNA and 
gives rise to a 13kb transcript which has an open reading frame of 9.138 kb. 
The ATM protein is a member of the phosphoinositide 3-kinase-like kinases 
(PIKK) family and shares sequence homology with other members of this 
group that includes DNA protein kinase catalytic sub-unit (DNA-PKcs), Ataxia 
Telangiectasia related protein (ATR), mammalian target of rapamycin (mTOR) 
and the Transactivation-transformation domain associated protein (TRRAP). 
The characteristic feature of this family of proteins is the phosphorylation of 
target proteins on serine and threonine residues, which are recognised as SQ 
(serine/glutamine) or TQ (threonine/glutamine) motifs (Shiloh Y, 2003). 
       A number of functional, or putatively functional, domains have been 
identified in the ATM gene sequence (Figure 1.3). The catalytic kinase domain 
is present at the C-terminal end of the gene and is highly conserved across 
species as well as between related family members. Within the translated 
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Figure 1.3 
 
 
Cartoon of the 370 kilo-dalton ATM protein that demonstrates the position of 
the functional domains. These include the catalytic kinase domain, which is 
located from amino acid residues 2715 to 3011 and itself includes an ATP 
binding site (residues 2716 and 2730) and a catalytic subunit (residues 2855 
and 2875). The FAT and FATc domains represent regions of close sequence 
homology between related proteins and extend from residues 1966 to 2566 
and from 3034 to 3056, respectively. Additional domains include a substrate-
binding domain at the n-terminus of the gene and a putative leucine zipper 
and proline rich domain located from residues 1218 to 1238 and from 1373 to 
1382, respectively.  
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ATM protein, this domain extends from amino acid residues 2715 to 3011 and 
includes an ATP binding site located between residues 2716 and 2730 and a 
catalytic subunit located between residues 2855 and 2875.  
     Two further domains that have been described in the ATM gene are the 
FAT domain and the FATc domain. The FAT domain extends from residues 
1966 to 2566 in the ATM protein and represents a region that is closely 
conserved between related proteins. The FATc domain is also conserved in 
PIKK proteins and is located at the extreme C terminal of the protein from 
residues 3034 to 3056. The FAT and FATc domains are believed to fold 
together in a configuration that ensures efficient function of the kinase domain 
(Lavin M et al, 2003). In addition, the FATc domain contains a substrate-
binding domain, which is involved in the interaction with the Tip60 histone 
acetyltransferase (Jiang X et al, 2006). This interaction has recently been 
reported to be important for the activation of ATM (Sun Y et al, 2005). 
     Towards the middle of the ATM protein are two further domains that may 
have a putative function. Firstly, an incomplete leucine zipper from residues 
1218 to 1238 has been detected, which theoretically could facilitate protein-
protein interactions through the outward extension of the leucine residues, 
although no such interaction has been identified to date. Secondly, a proline 
rich region, from residues 1373 to 1382, has been described and has been 
implicated in the binding of ATM to the SH3 domain of the c-Abl tyrosine 
kinase. In addition, a further substrate-binding domain has been mapped to 
the N-terminus of the ATM protein from residues 82 to 89, which is believed to 
be important for the binding of p53, BRCA1 and BLM (Lavin M et al, 2003).  
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      The function of the majority of the remaining sequence is poorly 
understood but may be mainly related to the formation of the tertiary structure 
of the ATM protein within the cell. Numerous HEAT (Huntington, elongation 
factor 3, A subunit of protein phosphatase 2A and TOR1) repeats have been 
identified within the N-terminal two thirds of the protein, and there is 
preliminary evidence to suggest that these allow the ATM protein to fold to 
form a coiled ‘head structure’ whereas the C-terminal portion of the protein 
including the catalytic domain forms a ‘tail structure’. Indeed, electron 
microscopy has directly visualised the protein in the cell and supports this 
tertiary structure of the ATM protein (Llorca O et al, 2003). 
 
1.4.2 Clinical Phenotype of AT patients 
      AT is a rare neurodegenerative disorder that is characterised by a 
progressive cerebellar ataxia and the development of dermal and ocular 
telangiectasia. Patients with ‘classical AT’ have no ATM protein in their cells 
and in these cases the ataxia is usually obvious by the age of 2 years and 
individuals will typically be unable to walk and will require a wheelchair by 
their early teens The life expectancy of patients with classical AT is 
approximately 20-25 years (Lakin ND; 1996, Taylor AM, Byrd PJ; 2005, 
Crawford TO, 2006). 
     AT patients also have primary immunodeficiency that results in an 
increased likelihood for the development of severe infections. Although there 
is a degree of heterogeneity between individuals, AT patients typically have 
impairment of both T and B-cell immunity. For example, there is impaired 
activity of CD4-helper and CD8-cytotoxic T-lymphocytes together with a 
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poorly developed or absent thymus in most AT individuals. The majority of AT 
patients also have reduced IgA, IgG2 and IgE levels, suggesting that they 
have a defect in the immunoglobulin isotype class switch process (Waldmann 
TA et al, 1983). 
      The T-lymphocytes in A-T patients are further characterised by the 
presence of chromosomal translocations which frequently involve the sites of 
the T cell receptor (TCR) genes on chromosomes 7 and 14. These occur at 
an approximately 40-fold higher frequency in AT patients compared to non-AT 
individuals. In certain cases, where the break-point on the partner 
chromosome involves an oncogene, cells harbouring these translocations can 
proliferate to form large clones. Furthermore, there is evidence that the 
formation of these clones can precede the development of the malignant 
tumour, T-cell prolymphocytic leukaemia (T-PLL), in some AT patients (Taylor 
AMR et al, 1992). Sporadic T-PLL is a rare tumour but the frequency of T-PLL 
is markedly increased in AT patients and also occurs over a younger age 
range. Therefore, the development of these chromosomal translocations is 
likely to be important in the pathogenesis of this leukaemia. 
        AT patients have a markedly increased frequency of all lymphoid 
tumours which is approximately 200-fold higher than in the general 
population. The spectrum of haematological malignancies seen in AT patients 
is shown in Figure 1.4. The most common types of tumours are T-cell 
lymphomas and leukaemias, including T-PLL. However, there is also a clear 
increase in the frequency of B-cell lymphomas in these AT individuals. 
Interestingly, there is some evidence to suggest that chromosomal 
translocations occur in B-lymphocytes, through the breakage and fusion of 
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Figure 1.4 
 
Patients with ataxia telangiectasia have a marked increase in the 
development of multiple types of cancers. The spectrum and frequency of 
tumours that develop in these individuals is shown. Haematological 
malignancies account for over two thirds of the tumours and the most 
common types are T-cell tumours including T-PLL and T-ALL. Notably these 
patients also have an increase in the development of B-cell lymphoid tumours. 
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two immunoglobulin genes, in an analogous manner to the TCR 
rearrangements in T lymphocytes. Small clones of B-lymphocytes containing 
these translocations have been described at an increased frequency in AT 
patients compared to normal individuals, and they may contribute to the 
increased frequency of B–cell tumours (Taylor AM, et al; 1996).  
       
1.4.3 Cellular phenotype of AT cells 
        The cells from AT patients characteristically have a radio-sensitive 
phenotype and the demonstration of this radio-sensitivity is a requirement in 
order to make the diagnosis of AT. Following treatment with irradiation, AT 
cells have an increased number of unrepaired DNA double strand breaks 
(DNA DSBs) compared to control cells and this in turn leads to the formation 
of chromosomal aberrations that include tri-radicals and quadri-radicals as 
well as translocations (Taylor AM et al, 1975). The specific repair defect in AT 
cells has subsequently been characterised as the persistence of those double 
strand DNA breaks that are difficult to resolve, typically accounting for around 
10% of DNA breaks. Interestingly, the kinetics of the repair of the other DSBs 
is relatively unaffected in AT cells, suggesting that ATM may not be important 
in the resolution of these simpler lesions (Riballo E et al, 2004). 
       
1.4.4 Role of ATM in the DNA damage response 
      The observations of the clinical features of AT patients and the 
radiosensitive phenotype of AT cells have provided many clues to our current 
understanding of the function of the ATM protein. The principal role of ATM is 
now known to be the rapid coordination of an integrated cellular response to 
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the presence of double strand DNA breaks. This leads to activation of multiple 
downstream proteins, which in turn result in the arrest of the cell cycle, and 
either the repair of the DNA DSBs or the induction of apoptosis, if the damage 
is extensive or difficult to resolve (Shiloh Y, 2003). 
           As a member of the PI3 kinase–like kinase family of proteins, ATM 
mediates its function through the phosphorylation of serine and threonine 
residues on target proteins. A large number of target substrates have now 
been identified and the activity of these substrates can be rapidly altered by 
ATM dependent phosphorylation (Shiloh Y, 2003, Goodarzi A et al, 2003). 
The spectrum of target proteins is shown in Figure 1.5. 
      ATM is no longer believed to be the principal sensor of DNA DSBs, and 
there is evidence that it is recruited to the sites of breaks by proteins acting 
upstream in the damage response pathway. A complex of proteins termed the 
MRN complex that consists of the proteins Mre11, Nijmegen breakage 
syndrome 1 (Nbs1) and Rad50 appears to be essential for this rapid 
recruitment of ATM (Petrini JH, Stracker TH, 2003). In the resting cell ATM 
exists as a dimer or multimer and its activation at the sites of the DNA breaks 
involves a process of auto-phosphorylation, which leads to the formation of 
ATM monomers (Bakkenist CJ, Kastan MB, 2003). The activation of ATM may 
also involve its acetylation via an interaction with Tip-60 (Sun Y et al, 2005) 
Active monomeric ATM can phosphorylate multiple downstream proteins. 
Interestingly, the MRN proteins Nbs1 and Mre11 are themselves 
phosphorylated in an ATM-dependent manner after DNA damage, suggesting 
that the MRN complex and ATM function both upstream and downstream of 
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Figure 1.5 
 
ATM is a protein kinase that alters the function of target proteins through the 
phosphorylation of specific serine or threonine residues. ATM coordinates an 
integrated cellular response following the induction of DNA double strand 
breaks. The spectrum of targets that become phosphorylated by ATM after 
this type of DNA damage is shown. These include proteins involved in DNA 
repair, such as Brca1, proteins important for the induction of cell cycle arrest, 
including p53, Chk1 and Chk2, and proteins important for the induction of 
apoptosis such as p53. 
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each other as the recognition process of DSBs proceeds (Kurz EU, Lees-
Miller SP, 2004). 
 
1.4.4.1 Formation of γH2AX foci 
    The histone variant H2AX is another substrate that becomes rapidly 
activated by ATM after the formation of DSBs. Phosphorylated H2AX, termed 
γH2AX, can be observed over several megabases flanking the DSBs at short 
times after irradiation (Rogakou EP et al, 1999). It is believed that γH2AX has 
a critical role in facilitating the assembly of large DNA repair complexes on the 
damaged DNA. Additional proteins including MDC1, 53BP1, the MRN 
complex of proteins and BRCA1 accumulate to form large foci at the sites of 
H2AX phosphorylation. There is evidence suggesting that the proteins 53BP1 
and MDC1 are also required for the activation of ATM and they are believed 
to act as adaptor proteins for the recruitment of further ATM target proteins to 
the sites of the breaks (Goldberg M et al, 2003, Stewart GS et al, 2003, 
Mochan TA et al, 2003, Foray N et al, 2003). These target proteins include 
DNA repair proteins, such as Ku70/80, DNAPKcs, XRCC4, Ligase IV or the 
Rad51 complex, and also proteins responsible for activation of cell cycle 
checkpoints and apoptosis, such as p53, Chk2, and SMC1 (Kurz EU, Lees-
Miller SP, 2004, Riballo E, et al; 2004).  
 
1.4.4.2 Redundancy of certain functions of the ATM protein 
     ATM has been described as the master regulator of the response to DNA 
DSBs due to its large number of target substrates and its role in influencing 
different cellular pathways, (Kurz EU, Lees-Miller SP, 2004). However, ATM is 
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not an absolute requirement in the cell, since ATM knock-out mice are viable 
and AT patients, with no demonstrable ATM function, are able to survive for 
up to 25 years (Dantzer F, 1999, Taylor AM, 2005). This suggests that there 
must be some redundancy between the function of ATM and related proteins. 
Related members of the PIKK family, including ATR and DNA-PKcs, can 
compensate for certain functions of the ATM protein (Koundrioukoff S et al, 
2004). For example, DNA-PKcs is known to be particularly important for the 
phosphorylation of substrates that are involved in the repair of DNA DSBs but 
recently it has been also been shown that DNA-PKcs can function in a 
redundant manner with ATM, in the process of phosphorylation of H2AX after 
the induction of DSBs (Alt F, Bassing C, 2003, Stiff T et al, 2004).  ATR is 
considered to be principally involved in the response to UV light-induced DNA 
damage but it has also been shown to be involved in the phosphorylation of 
several substrates including p53 following DNA damage with IR (Cuadrado M 
et al, 2006, Helt CE et al 2005).  
    Nevertheless, the compensation between these proteins cannot be 
complete given the known clinical phenotype of AT patients, and it is likely 
that both the target substrate specificity and the kinetics of the response to 
DSBs are important distinguishing factors between ATM and both DNA-PK 
and ATR. Indeed, a unique aspect of ATM appears to the very rapid response 
to DNA DSBs (Helt CE et al 2005, Myers JS et al, 2006). 
 
1.4.5 ATM dependent activation of p53 after DNA damage 
       One downstream substrate that is phosphorylated on multiple residues by 
ATM, both directly and indirectly, following the occurrence of DSBs is the 
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tumour suppressor protein p53. These changes lead to the up regulation of 
p53 levels in the cell nucleus. The p53 protein has both transcription-
dependent and transcription-independent activities and characteristically 
undergoes a wide range of post-translational modifications (Meek D, 2004, 
Vousden KH, 2002). There is evidence to suggest that p53 plays a critical role 
in determining the final cell fate after DNA damage. Indeed, p53 appears to be 
a crucial factor for the switch between the induction of cell cycle arrest, thus 
allowing DNA repair, and the induction of apoptosis which may occur in the 
presence of extensive or persistent DNA damage (Bree RT et al, 2004).   
      These differential functions of p53 may be executed through variations in 
post-translational modifications. For example, ATM dependent 
phosphorylation of serine 15 has been shown to enhance the transcriptional 
activity of p53 and also to promote the phosphorylation of additional p53 
residues. In comparison the ATM-Chk2 mediated phosphorylation of p53 on 
serine 20 interferes with p53 binding to the MDM2 protein, which is required 
for targeting p53 for proteasomal degradation in the cytoplasm (Bree RT et al, 
2004). The phosphorylation of p53 on other residues can influence its binding 
to specific gene promoters and, interestingly, there is evidence suggesting 
that the phosphorylation on serine 46, which is induced by high levels of 
stress, can significantly influence the outcome of the p53 pathway in favour of 
apoptosis (Oda K et al, 2000). Thus lower levels of stress may lead to 
alterations in p53 that favour the induction of expression of cell cycle check 
point proteins, such as p21, whereas high levels of stress occurring when 
there is extensive or persistent DNA damage would favour alterations that 
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induce the expression of pro-apoptotic proteins, such as Puma and Bax (Bree 
RT et al, 2004) (Meek D, 2004).  
 
1.4.6 Repair of DNA double strand breaks 
       The two major mechanisms that have evolved for the repair of DNA DSBs 
in mammalian cells are homologous recombination (HR) and non-homologous 
end joining (NHEJ). HR is an error-free repair mechanism but is restricted to 
the S and G2 phases of the cell cycle as there is a requirement for the 
presence of sister chromatids. It may therefore be less important in the repair 
of DNA DSBs in non-cycling CLL cells.  
      NHEJ is an error-prone repair pathway and is the major mechanism used 
in the repair of DNA DSBs in non-cycling cells. The principal proteins involved 
are Ku70 and 80, DNA-PKcs, Artemis, XRCC4 and DNA ligase 4. The Ku 
proteins bind to the broken DNA ends and this leads to the subsequent 
recruitment of DNA-PKcs, which has a role in bridging the broken ends 
together. Artemis is important in the processing of the DNA ends prior to their 
ligation, which is catalysed by the XRCC4 and DNA ligase 4 proteins (Bassing 
CH, Alt FW, 2003). Difficulty in the processing of complex DNA breaks may 
lead to their persistence and this is one reason that will influence the switch in 
cell fate towards apoptosis. As alluded to in the text above, ATM itself also 
has a role in the repair of certain complex DNA DSBs by NHEJ (Riballo E et 
al, 2004). 
 
1.4.7 ATM dependent DNA damage induced apoptosis 
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      If the DNA damage cannot be repaired then the cell activates 
programmed cell death or apoptosis. The persistence of DNA DSBs would 
lead to genomic instability and therefore even a single unrepaired DSB may 
be lethal.  
     The process of DNA damage-induced apoptosis occurs in a p53 
dependent manner. Through its function as a transcription factor, p53 leads to 
the induction of certain pro-apoptotic proteins, including members of the BcL-
2 family of proteins such as Puma, Noxa and Bax. This will alter the balance 
between the various pro- and anti- apoptotic members of this family of 
proteins. Pro-apoptotic proteins in this family also include the BH3-domain 
only proteins, such as Bid and Bim, and anti-apoptotic family members 
include Mcl-1, BCL-xL and Bcl-2. Alterations in the interactions between these 
related proteins on the surface of the mitochondrion, leads to the 
depolarisation of the mitochondrial membrane. This in turn results in the 
release of cytochrome C from the inter-membrane mitochondrial space into 
the cytoplasm. Here, cytochrome C associates with the apoptosis-activating 
factor (apaf), ATP and procaspase 9 to form the apoptosome structure. This 
subsequently leads to the cleavage of initiator procapases, such as 
procaspase 7. Cleaved caspase 7 can then catalyse the cleavage of the 
procaspase 3 into its active cleaved caspase counterpart. Caspase 3 is an 
effector caspase that can cleave a large number of downstream targets and 
thus induce the cascade of events that eventually results in the completion of 
the apoptotic process (Herr I, Debatin K-M, 2001, Yee KS, Vousden K, 2005, 
Tsujimoto Y, 1998). 
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     A summary of the ATM/p53 dependent DNA damage response apoptotic 
pathway is shown in Figure 1.6. 
 
 
1.5 The role of ATM mutations in the pathogenesis of CLL tumours 
     Mutations in the ATM gene have been previously detected in CLL tumours 
(Stankovic T et al, 1999, Schaffner C et al, 1999, Bullrich F et al, 2000). 
Therefore, it is possible that they could represent a molecular marker that 
might provide prognostic information in CLL patients. Furthermore, given the 
known functions of the ATM protein in the response to DNA damage, it is 
likely that abnormalities in ATM will provide important insights into the 
pathogenesis of CLL tumour clones. 
      
1.5.1 The discovery of ATM mutations in T-PLL and CLL tumours 
       The presence of mutations in the ATM gene was first described by 
independent groups in 1999 and 2000(Stankovic T et al, 1999, Schaffner C et 
al, 1999, Bullrich F et al, 2000). At that time, there were several lines of 
evidence to suggest that the ATM gene was a candidate gene that might 
harbour abnormalities in CLL. Firstly, a deletion of chromosome 11q was 
known to be a common chromosomal aberration in CLL tumours and the 
minimal region of deletion had been delineated and had been shown to 
include the ATM gene (Stilgenbauer S et al, 1996).  
       Furthermore, acquired ATM mutations had been reported to occur at a 
high frequency in the rare lymphoid tumour T-cell pro-lymphocytic leukaemia 
(T-PLL). Similarly to CLL, sporadic T-PLL is also characterised by a high 
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Figure 1.6 
 
The ATM / p53 pathway that is activated following the induction of DNA 
damage is demonstrated. DNA DSBs can occur following treatment with 
irradiation or chemotherapy or through oxidative damage. The ATM protein is 
recruited to the sites of the breaks via the MRN complex and becomes 
activated by autophosphorylation on serine 1981. It then activates various 
downstream target proteins, including H2AX, which is important for the 
formation of large foci at the sites of the DNA breaks, and SMC1, p53 and 
Nbs1.  
The phosphorylation of p53 by ATM on serine 15 leads to its up regulation in 
the nucleus where it can act as a transcription factor. This in turn leads to the 
expression of various proteins that are important for the induction of cell cycle 
arrest, such as p21, or apoptosis such as Puma, Noxa and Bax. In the 
presence of extensive or persistence DNA damage signaling through this 
pathway will lead to apoptosis. 
Apoptosis principally occurs through the intrinsic pathway, which is 
demonstrated. Alterations in the balance between pro-apoptotic BH3 domain 
proteins such as Bax, Noxa and Puma and anti-apoptotic proteins such as 
Bcl-2 and Mcl-1 leads to depolarization of the mitochondrial membrane and 
the release of cytochrome c from the intermembrane space into the 
cytoplasm. Here it forms the apoptosome structure, which eventually results in 
the cleavage of the effector procaspase 3. Cleaved caspase 3 can then 
inactivate numerous cellular proteins via a cleavage mechanism, including 
PARP1, which facilitate apoptosis. 
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frequency of chromosome 11q deletions (Stilgenbauer S et al, 1997, Stoppa-
Lyonnet D et al, 1998). As indicated above, T-PLL was also known to occur at 
a much higher frequency in individuals with Ataxia Telangiectasia (AT), and 
interestingly the T-PLL tumour cells from both AT and non-AT individuals had 
been shown to be characterised by the presence of recurrent chromosomal 
translocations involving the T-cell receptor genes. This had suggested that the 
acquired loss of ATM function, via sporadic ATM mutations, might be 
important in the development of T-PLL in non-AT individuals (Stilgenbauer S 
et al, 1997, Taylor AM et al, 1996).  
      In contrast to T-PLL, CLL was known to be a tumour that is characterised 
most commonly by chromosomal deletions rather than translocations (Dohner 
H et al, 2000). However, a distinctive feature of CLL tumour cells which had 
been described was their in vivo resistance to apoptosis (Binet JL et al, 1996). 
Since loss of functional ATM was known to impair the induction of apoptosis 
following DNA damage this provided another reason to support the belief that 
sporadic mutations in the ATM gene might occur in B-CLL, as well as in T-
PLL tumours (Rotman G, Shiloh Y, 1998). 
         
1.5.2 Nature and distribution of ATM mutations in lymphoid tumours 
       The majority of the mutations that occur in the germline of patients with 
ataxia telangiectasia are non-sense changes that lead to the generation of a 
premature stop codon and would be predicted to give rise to a truncated 
protein (Stankovic T et al, 1998). This protein is usually unstable and rapidly 
degraded and therefore patients that inherit bi-allelic truncating mutations 
have no detectable ATM protein in their cells and have absent ATM function 
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(Lakin ND, 1996). In contrast, the majority of mutations that have previously 
been identified in T-PLL, MCL and CLL tumours have been mis-sense 
changes that will give rise to an amino acid substitution in the translated 
protein (Stilgenbauer S et al, 1997, Stoppa-Lyonnet D et al, 1998, Stankovic T 
et al, 1999, Schaffner C et al, 1999, Bullrich F et al, 2000). The consequence 
of these changes on the function of the translated protein will depend on the 
location and nature of the substitution.  
     The ATM mutations that were previously detected in T-PLL had tended to 
be clustered within the more highly conserved C-terminal region of the ATM 
gene and these were invariably associated with loss of heterozygosity at the 
ATM locus (Stilgenbauer S et al; 1997, Stoppa-Lyonnet D et al; 1998). By 
comparison, the mis-sense changes that had previously been detected in CLL 
tumours were found to be distributed across the gene with no obvious 
clustering pattern (Stankovic T et al; 1999, Schaffner C et al; 1999, Stankovic 
T et al; 2002). 
 
1.5.3 Functional effects of ATM mutations in CLL tumours 
       Certain aspects relating to the role of ATM mutations in the pathogenesis 
of CLL tumours have been previously addressed.  
      In line with the known defect in response to DNA damage in AT cells, CLL 
tumours with acquired bi-allelic abnormalities in the ATM gene have been 
shown to have a reduced ability to repair chromosomal breaks that are 
induced following irradiation (Stankovic T et al, 2002). Furthermore, compared 
to tumours with wild type ATM, CLL tumours with ATM mutations have been 
shown to fail to up regulate the level of the p53 protein after the induction of 
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DNA DBSs and to fail to induce the expression of the p53 regulated p21 
protein. In addition, CLL tumours with ATM mutations also had a defect in the 
induction of apoptosis following DNA damage with irradiation and this 
apoptotic defect was noted to be less marked than the defect observed in CLL 
tumours with mutations in the TP53 gene (Stankovic T et al, 2002, Pettitt A et 
al, 2001).  
     Gene expression profiling following DNA damage with irradiation has also 
been studied and this has confirmed that CLL tumours with ATM mutations 
fail to induce p53-dependent pro-apoptotic transcriptional responses. 
Interestingly, tumours with ATM mutations also failed to activate a number of 
p53-independent pro-survival transcriptional responses such as those 
mediated by NFkappaB (NFKB) and various Heat Shock Proteins (HSPs) 
(Stankovic T et al, 2004). This dual effect of ATM in affecting both pro-
apoptotic responses and pro-survival responses would explain the 
observation that the apoptotic defect in CLL tumours with impaired ATM 
function is less marked than the defect observed in tumours with impaired p53 
function. 
       One aspect of the response to DNA damage with irradiation that has not 
been previously studied in CLL tumours is the early ATM dependent 
phosphorylation of target substrates. Since ATM directly catalyses these 
reactions, they are likely to most reliably reflect the level of ATM function in 
the CLL tumour cells. Recently, there has been development of commercial 
antibodies that bind to proteins that are phosphorylated on specific residues 
and this has now made the assessment of these responses more 
straightforward to study (Kurz EU, Douglas P, Lees-Miller SP, 2004). The 
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identification of tumours with functional impairment of these phosphorylation 
responses might therefore provide an alternative means to detect CLL 
tumours that have defective ATM function as a result of the presence of ATM 
mutations.  
 
1.5.4 Relationship between ATM mutations and prognostic features 
      The relationship of ATM mutations with other prognostic factors is a 
further area that has the potential to enhance our understanding of how ATM 
mutations might contribute to the development and progression of the CLL 
tumour clone.   
 
1.5.4.1 Clinical features of CLL 
     The potential association between ATM mutations and clinical features of 
CLL such as age, gender, LDT and disease stage has not been specifically 
addressed. However, in one published study a high proportion of patients with 
Binet stage B and C had ATM mutations (Stankovic T et al, 2002). This might 
suggest that ATM mutations are associated with a more aggressive disease 
phenotype, but ideally the assessment of such a relationship requires that the 
cohort of CLL patients studied is representative of the whole spectrum of 
different CLL phenotypes seen in haematology clinics. 
  
1.5.4.2 IGVH mutation status 
         One biological marker that has been investigated in relation to ATM 
mutations in CLL tumours is the mutation status of the IGVH genes. In a 
previous series of CLL tumours, ATM mutations were found to occur 
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exclusively in CLL tumours with un-mutated IGVH genes. However, in this 
study a high proportion of the total patient population had un-mutated IGVH 
genes and, therefore, the possibility remains that ATM mutations might occur 
in both IGVH subgroups (Stankovic T et al, 2002). An association of ATM 
mutations with un-mutated IGVH genes could indicate that ATM mutations are 
more likely to develop in those CLL tumours with unmutated IGVH genes but, 
alternatively, might suggest that the loss of ATM function is a factor in the 
transformation of process of a cell that has an impaired ability to undergo the 
process of somatic hyper-mutation (Stankovic T et al, 2002). 
 
1.5.4.3 Deletions of chromosome 11q  
       There is only limited data regarding the relationship between CLL 
tumours with an 11q deletion and tumours with ATM mutations. All tumours 
with an 11q deletion, as detected by FISH, will have loss of one ATM allele 
and therefore if ATM behaves as a tumour suppressor gene one might expect 
a close association between the two genetic subgroups of CLL tumours 
(Schaffner C et al, 1999, Dewald et al, 2003). One research group performed 
mutation screening of the C-terminal region of the ATM gene in 22 CLL 
patients with an 11q deletion and found ATM mutations in just 5 cases 
(Schaffner C et al, 1999). Conversely, in the largest previous study reporting 
on ATM mutations in CLL tumours, loss of heterozygosity at the ATM gene 
loci was only demonstrated in 2 out of 16 patients (Stankovic T et al, 2002).  
       The cellular consequences of an 11q deletion on the DNA damage 
response in CLL tumours have not been studied and the role of abnormalities 
in ATM function in accounting for the poor clinical outcome in this group of 
 33
patients remains uncertain (Dohner H et al, 1999). Specifically, any potential 
differences in the integrity of the damage response pathway between those 
11q-deleted CLL tumours with an additional ATM mutation and those 11q-
deleted tumours with a second wild type ATM allele, which are thus 
heterozygous at the ATM locus, have not been investigated. 
     The cells from AT carriers, which  are heterozygous at the ATM gene locus 
as a consequence of germ-line ATM mutations, have normal responses to 
DNA damage both in terms of the in vitro repair of chromosomal breaks and 
the activation of p53 dependent apoptosis. Furthermore, these carriers do not 
exhibit the phenotypic characteristics of AT patients (Taylor AM et al; 1975, 
Unpublished data). However, there are several lines of evidence that indicate 
that inherited heterozygous ATM germ-line mutations might indeed exert 
subtle cellular effects. For example, family and epidemiological studies have 
shown that carriers of mono-allelic germ-line ATM mutations have a small 
increased predisposition to cancer development (Thompson D et al, 2005, 
Thortenson Y et al, 2003, Dork T et al, 2001, Renwick A et al, 2006). 
Secondly, the presence of certain ATM heterozygous sequence variants in 
breast cancer patients has been linked to the development of post-
radiotherapy fibrosis (Andreassen CN et al, 2006). Finally, a recent animal 
study has demonstrated that haplo-insufficiency of the ATM gene leads to a 
two to three fold enhanced susceptibility to carcinogen induced mammary 
tumours (Lu S et al, 2006).  
 
1.5.4.4 Other genetic defects 
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       The relationship between ATM mutations and other chromosomal 
abnormalities has not been specifically addressed but notably tumours 
harbouring TP53 mutations, which commonly associate with 17p deletions, 
have been found to be generally distinct from tumours with ATM mutations. 
This suggests the possibility that the two abnormalities could be mutually 
exclusive in CLL tumours, although mutations in both genes have been 
reported in diffuse large B-cell lymphoma (DLBCL) (Gronbaek K et al; 2002).  
 
 
1.5.5 The temporal acquisition of ATM mutations in CLL tumours  
     The timing of the development of ATM mutations in relation to the ontology 
of CLL can also provide a useful insight into their contribution to the 
pathogenesis of the disease. 
 
1.5.5.1 Germ-line changes in the ATM gene 
      The possibility that ATM mutations could contribute to the genetic 
predisposition of CLL has been previously considered. One reason to support 
this suggestion is associated with the clinical phenotype of AT patients. These 
individuals, who have bi-allelic germ-line ATM mutations, have a markedly 
increased incidence of lymphoid tumours which include B-cell malignancies 
(Thompson D et al, 2005, Oscier D et al, 2004). Notably, however, there are 
no reports to date of CLL developing in an AT patient. However, it is possible 
that AT patients do not survive long enough to develop CLL, which is primarily 
a malignancy of middle and old age.  
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      Recently, it was found that a minority of the ATM mutations, which have 
been detected in CLL patients’ tumour cells, are also present in germ-line 
material of those CLL patients (Stankovic T et al, 2002). Therefore, in these 
individuals the CLL had arisen in ATM mutant heterozygous carriers. 
Furthermore, the frequency of the CLL patients that had these germ-line ATM 
mutations was higher than the previously estimated incidence of 
heterozygous ATM mutation carriers in the UK population (Stankovic T et al, 
1998). This, therefore, suggested the possibility that these carriers might be at 
an increased risk for the development of CLL. Conversely however, a recent 
publication that assessed cancer risk in the relatives of AT patients did not 
find any increase in the incidence of CLL in heterozygote ATM mutation 
carriers and in fact no cases of CLL were identified in this population 
(Thompson D et al, 2005). 
       Initial studies on CLL family pedigrees did not find any conclusive 
evidence to support a role of ATM mutations in the development of familial 
CLL. For example, in one study, there was no evidence of linkage between 
the development of CLL and the presence of specific ATM polymorphic 
markers amongst different family pedigrees. A second study investigated ATM 
mutations in CLL family pedigrees. Although, several ATM mutations were 
identified in individual CLL patients, there was no evidence for the segregation 
of any of these ATM mutations amongst affected family members (Bevan S et 
al, 1999, Yuille M et al, 2002).  
     In contrast to these initial studies, the largest report on CLL pedigrees to 
date used a genome wide linkage-scan of single nucleotide polymorphisms 
(SNPs), and this study did find some evidence of linkage of chromosome 11q, 
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although this was not statistically significant (Sellick GS et al, 2005). In 
addition, a role for the ATM gene in the development of CLL has recently 
emerged from a large case-control study. This study found evidence linking 
certain ATM SNPs with CLL patients compared to controls. The ATM gene 
was one of only three genes from a genome-wide analysis that demonstrated 
such an association (Rudd et al; 2006).  
     Therefore, current data supports the concept that abnormalities in the ATM 
gene might have a role in the predisposition for the development of CLL but 
that if this is the case it is likely to be a low penetrance effect.  
 
1.5.5.2 Acquired ATM mutations 
      The presence of germ-line ATM mutations suggests the possibility that 
they might have a role in the process of clonal transformation of CLL tumours 
(Stankovic et al; 2002). However, the majority of the ATM mutations that have 
been identified to date have been sporadic changes and in most of these 
cases the timing of their development with respect to clonal transformation 
was unknown (Stankovic T et al; 2002, Schaffner C et al; 1999, Stankovic T et 
al; 1999, Bullrich et al; 2000). Intriguingly, in one study, two of the ATM 
mutations that were detected in tumour cells were shown to be absent from 
the patient’s germ-line but to be present in non-tumour cells including T-
lymphocytes and monocytes. The pathogenic role of the mutations in the non-
tumour cells remains obscure but this data provides evidence for the 
presence of ATM mutations at the time of clonal transformation suggesting a 
potential causative role (Stankovic T et al, 2002).  
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     By comparison there is evidence to indicate that the development of other 
genetic defects, such as the loss of chromosomes 17p and 11q, often occurs 
some time after clonal transformation in CLL tumours. This is indicated by the 
fact that they are not always present in 100% of the tumour cell clone and has 
also been formally demonstrated by the analysis of serial samples from 
individual patients (Cuneo A et al, 2002, Dewald GW et al, 2003). By analogy, 
it is also therefore possible that ATM mutations could occur during disease 
progression at a time after the initial formation of the clone in certain tumours. 
However, the late acquisition of ATM mutations in CLL tumours has not been 
reported. 
 
1.5.6 Consequences of ATM mutations on disease outcome 
       The consequences of ATM mutations on disease outcome in CLL 
patients have not been previously assessed. These will be important in the 
evaluation of ATM mutations as a prospective prognostic marker in CLL. 
Furthermore, measurement of their effects on clinical outcome will also 
provide clinical evidence to corroborate the previous in vitro studies, which 
suggest that ATM mutations influence the behaviour of the CLL clone.  
        The detrimental effect of ATM mutations on the induction of apoptosis 
following DNA damage with irradiation in vitro has been demonstrated 
(Stankovic T et al, 2002). This would indicate that there could be resistance to 
tumour killing in vivo following DNA damage in patients whose tumours had 
defective ATM function. Such damage might occur intrinsically within the 
tumour cells through the generation of oxygen radicals, but could also be the 
result of extrinsic damage induced by the use of DNA-damaging 
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chemotherapeutic drugs (Barzilai A, Yamamoto KI, 2004, Kurz EU, Lees-
Miller SP, 2004). Thus, given the function of ATM, one might predict that ATM 
mutations would impair the outcome of CLL patients and that this impairment 
would be due in part to resistance to certain DNA damaging 
chemotherapeutic drugs. However this has not yet been demonstrated. 
      The majority of the previous in vitro work has focussed on the effect of 
ATM mutations on the responses to damage with irradiation, and the role of 
ATM mutations in the responses to the chemotherapeutic drugs used to treat 
CLL patients is largely unknown (Stankovic T et al, 2002, Pettitt AR et al, 
2001, Stankovic T et al, 2004).   
 
1.6 Mechanism of action of chemotherapeutic drugs in CLL tumours 
        The common first-line regimes used to treat CLL patients in the UK are 
chlorambucil or fludarabine mono-therapy, or the combination of fludarabine 
with cyclophosphamide.  
 
1.6.1 Chlorambucil 
     Chlorambucil belongs to the class of drugs known as nitrogen mustards. It 
induces alkylation of CLL lymphocyte DNA, which includes the development 
of purine-drug complexes and also the formation of both intra-strand and 
inter-strand cross links (ICLs) at N-7 guanines. The DNA ICLs are considered 
to be the most important for the cytotoxicity of chlorambucil and the cellular 
processing of these ICLs is believed to result in the generation of DNA DSBs. 
Furthermore, there is evidence that these breaks are subsequently repaired 
by non-homologous end joining proteins in a similar manner to the DSBs 
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generated by IR in CLL cells. It is therefore not unexpected that there is cross-
resistance between ionising irradiation and chlorambucil in CLL tumours. 
However the specific role of ATM in the mechanism underlying this resistance 
to chlorambucil is not known (Panasci L et al, 2001). 
 
1.6.2 Fludarabine 
        Fludarabine (9-beta-D-arabinosyl-2-fluoroadenine-5'-monophosphate) is 
a purine analogue and it is converted within the cell into its 5’-triphosphate 
derivative. Phosphorylated purine analogues primarily induce cytotoxicity due 
to their inhibition of DNA synthesis. This occurs due to a direct inhibitory effect 
on ribonucleotide reductase but also as a result of the incorporation of purine 
analogues into replicating DNA. Once incorporated into DNA there is 
cessation of further DNA strand elongation and if the cell fails to repair this 
lesion it will ultimately result in the activation of apoptosis (Pettitt AR; 2003). 
For fludarabine, there is evidence that its incorporation into DNA leads to the 
activation of p53 and also to the generation of cleaved caspase 3 and PARP1 
(Achanta G et al, 2001, Rosenwald A et al, 2004, Rao VA, Plunkett W, 2001).  
      Interestingly, the majority of circulating CLL cells is non-cycling and 
arrested in G1 and therefore there is no active DNA replication occurring in 
these cells. Therefore, it has been suggested that purine analogues become 
incorporated into the DNA in these cells during the repair process following 
DNA damage. This DNA damage might occur as a result of intrinsic cellular 
process such as the generation of oxygen radicals, or alternatively might be 
the result of damage induced by other chemotherapeutic drugs (Pettitt AR, 
2003). The combination of fludarabine with the alkylating agent 
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cyclophosphamide results in a more than additive apoptotic cell death 
compared to the sum of the effects of either drug alone, and, this has been 
shown to be the result of fludarabine inhibiting the repair of the lesions 
induced by cyclophosphamide (Yamauchi T et al, 2001). These observations 
provided the rationale for the using the combination of these drugs for treating 
CLL patients  
     The role of ATM in the response pathway to nucleotide analogue-
containing DNA has not been investigated. Interestingly, however, there is 
one study implicating the related PIKK repair protein, DNA-PK, in this 
response (Achanta G et al, 2001). Furthermore, there is also one report 
showing that CLL tumours with ATM mutations demonstrate increased 
resistance to apoptosis following treatment with fludarabine. However, in this 
study, the potential mechanism of action to account for this finding was not 
addressed (Alvi A et al, 2005). It also remains unclear whether fludarabine 
incorporation leads to the formation of DNA DSBs and, if these do occur, 
whether there is activation of ATM dependent phosphorylation responses, in a 
manner analogous to the response to the DNA DSBs induced by irradiation.  
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Aims  
       The determination of disease factors that have prognostic value has led 
to an increase in the understanding of the nature of CLL and this has had 
implications in the clinical management of patients.  
       ATM mutations have been previously identified in CLL tumours but their 
consequences on the outcome of CLL patients and their potential role as a 
prognostic marker has not been evaluated. In this project, therefore, I aimed 
to study a large cohort of CLL patients in order to address the prevalence of 
ATM mutations and their effects on clinical parameters such as the overall 
survival and treatment free survival from diagnosis. In addition my aim has 
been to investigate the relationship between ATM mutations and other 
prognostic features in CLL, in order to determine if ATM mutations can 
provide independent prognostic information.  
       An important focus was to study the relationship between CLL tumours 
with ATM mutations and those with deletions of chromosome 11q, and hence 
loss of one ATM allele. Therefore, it was my intention to address the subsets 
of CLL tumours that have a mono-allelic ATM defect, due to either a deletion 
or a mutation, and the subsets that have bi-allelic defects, due to 
combinations of mutations and deletions. The principal function of the ATM 
protein is in the coordination of the cellular response to DNA damage in the 
form of DSBs. In this project, I wanted to investigate the consequences of 
mono-allelic or bi-allelic ATM defects on the integrity of this DNA damage 
response pathway, and specifically I have aimed to study whether the 
presence of ATM mutations can stratify CLL tumours with an 11q deletion into 
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two subgroups in terms of their cellular phenotypes but also the clinical 
outcome of CLL patients.  
      Previous studies have concentrated on the effects of ATM mutations on 
the consequences of DNA damage that is induced by irradiation. In this 
project, my aim was to study the role of ATM in the response to the 
chemotherapeutic drug, fludarabine, which is used as a first line therapy in 
CLL patients. Importantly, I was interested to understand whether tumours 
with ATM mutations have impairment in the response to fludarabine and 
whether this may explain the resistance of a subset of CLL tumours to this 
chemotherapeutic drug. 
      The timing of the development of ATM mutations is important in their 
evaluation as a prognostic marker and in addition provides an important 
insight into the role of ATM in the pathogenesis of CLL tumours. I have 
therefore aimed to study whether the ATM mutations detected in CLL tumours 
represented germ-line changes or acquired changes. I also wished to 
compare the frequency of germ-line ATM gene changes between the CLL 
patients and a control population in order to address whether germ-line ATM 
mutations can predispose to the development of CLL. In the case of the 
acquired ATM mutations, I wanted to investigate whether they were present at 
the time of diagnosis or developed some time during the CLL tumour 
progression to gain further insight on how they might impact on the behaviour 
of the tumour clone.   
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Materials and Methods 
 
3.1 Samples from CLL patients and controls  
     The diagnosis of B-CLL was confirmed in each case by 
immunophenotyping. Specifically, this required the demonstration of a clonal 
population of B-lymphocytes with either Kappa or Lambda light chain 
restriction, together with the co-expression of surface CD5 with CD19 and 
CD23, in association with low density surface immunoglobulin expression. 
The studies were performed according to local ethical guidelines and written 
informed consent was obtained from all patients.  
    Two cohorts of CLL patients were studied. The first consisted of 155 CLL 
patients and included consecutive patients that attended the haematology 
outpatient clinics at Selly Oak and Heartlands Hospitals in Birmingham over 
the 14-month period from December 2001 to January 2003. On the day of 
their clinic visit, fourteen millilitres of peripheral blood was collected from each 
patient into heparinised tubes. 
     The second cohort of 53 CLL patients were all characterised by the fact 
that they had previously been found to have a deletion of chromosome 11q in 
their tumour cells by FISH analysis. The patients originated from Birmingham, 
Bournemouth and Leicester hospitals. This FISH analysis had been 
performed in regional genetics units for clinical indications or as part of 
independent studies. In many of these cases the processing of blood samples 
and the extraction of DNA had been performed at local hospitals.   
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      The control cohort consisted of 71 Caucasian healthy volunteers over 65 
years in age and 90 anonymous individuals who were blood donors. Fourteen 
millimetres of whole blood was collected from the 71 volunteers. The DNAs 
from the blood donors formed part of a pre-existing bank that was made 
available for this study.   
 
3.1.1.Separation of Mononuclear Cells from CLL blood samples 
     Whole blood samples were diluted with RPMI in a 1:1 ratio in universal 
tubes and layered on to 10mls of lymphoprep (Nycomed). Samples were 
centrifuged at 1600 rpm for 20 minutes. Mononuclear cells were retrieved 
from the interface and washed twice with RPMI. Cells were counted and 
stored at concentrations of up to 5 x 107cells/ml in 90% fetal calf serum (FCS) 
and 10% Dimethyl Sulphoxide (DMSO) in 1ml vials. Vials of cells were initially 
stored in insulated boxes at -80ºC and once frozen were transferred to liquid 
nitrogen. 
      
3.1.2. Germ-line Material 
    Buccal cells were obtained from the CLL patients using a mouth swab.  
Cells were washed in phosphate-buffered saline (PBS) and stored as a pellet 
at -20ºC.  
 
3.1.3 Diagnostic Material 
    On selected samples, archive tumour material cells was available in the 
form of DNA, or cells that had been collected at the time of diagnosis of a 
patient’s CLL. 
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 3.1.4 DNA extraction 
     Genomic DNA was extracted from frozen tumour cells using the QIAamp 
DNA blood minikit (QIAGEN, Crawley, West Sussex, UK). Samples were 
thawed and cells were washed with RPMI culture medium. 5 x 106 cells were 
diluted in 200μl of phosphate-buffered saline (PBS) and incubated with 
200µM lysis buffer and 20µM protease at 56ºC for ten minutes. 200μl of 100% 
(v/v) ethanol was added in order to precipitate the DNA. The mixture was then 
added to the QIAamp spin column in a 2ml collection tube and micro-
centrifuged at 8000rpm for 1 minute. The column was transferred to a new 
collection tube and washed initially with buffer containing ethanol provided 
with the kit. The column was placed in a 1.5ml micro-centrifuge tube and 
200μl of elution buffer was added to the DNA and incubated for 5 minutes, 
followed by micro-centrifugation at 8000rpm for 1 minute. Subsequently, 
samples were diluted with elution buffer to give a final concentration of DNA of 
approximately 50ng/μl.  
        DNA was also extracted from the control blood samples. Initially, the 
whole blood samples were spun at 1600rpm for 20 minutes to allow 
separation into plasma, buffy coat and red cell compartments. 200µl of blood 
from the buffy coat layer was then directly incubated with 200µM of the lysis 
buffer and 20µM of protease. The subsequent extraction procedure was 
similar to that described above and the final DNA was eluted into a volume of 
200μl, with no further dilution steps required. 
        Extraction of DNA from the buccal cells was performed by the same 
method but the DNA was eluted into 30µl of elution buffer. 
 46
   
 
3.2. Screening for ATM and TP53 mutations 
 
3.2.1 Polymerase Chain Reaction (PCR) for the ATM and TP53 genes 
      I performed separate PCR reactions for each of the 62 ATM coding exons 
(4-65) using 60 primer pairs (Table 3.1). Exons 4 and 5, and, exon 43 and 44 
were each expanded using a single PCR reaction using primers located 
outside both exon coding sequences, as these pairs of exons are positioned 
close together within the gene sequence.  The PCR reactions for each exon 
were performed in 96-well plates on up to 96 tumour samples at a time. Each 
reaction used 50ng of gDNA, 0.2µM of dNTPs (Roche), 0.2µM of each primer 
(Sigma), 1.5mM of MgSO4 and 1 unit of the high stringency DNA polymerase, 
Optimase (Transgenomic). These were mixed with sterile water to form a total 
reaction volume of 50µl. PCR conditions were 5 minutes at 95˚C, followed by 
40 cycles of 30 seconds at 95˚C for denaturation of dsDNA, 30 seconds at 
53˚-58˚C for primer annealing and 1 minute at 72˚C for polymerase 
dependent DNA extension, and final extension of 7 minutes at 72˚C. Primer 
annealing temperatures were predicted using the ‘Mutation Discovery’ 
software programme (Transgenomic) (Table 3.1). 
       TP53 exons 3 to 10 were amplified using 5 primer pairs (AltaBiosciences, 
University of Birmingham). These coding exons were chosen because they 
have been shown to harbour the majority of the pathogenic mutations that 
occur in the TP53 gene (Vousden KH, Lu X, 2002). Exons 3 and 4, exons 5 
and 6, and exons 8 and 9 were each amplified in a single PCR reaction using 
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Table 3.1 – PCR and DHPLC conditions for exons 4-65 of ATM gene 
 
Exon Primer Sequences PCR 
annealing 
temp (ºC) 
DHPLC 
Temp 
(ºC) 
4/5 Forward – CACACCTCTTTCTCTCTATATATGC 
Reverse-GGAAGCAAAGATAAATGTTAAGACTTACAC 
59 53.5 
6 Forward-ATTGTTCTTGTAGGAGTTAGGCCTTG 
Reverse-AAAAACTCACGCGACAGTAATCTG 
58 54.0 
7 Forward-TAAATAGTTGCCATTCCAAGTGTC 
Reverse-TGGTGAAGTTTCATTTCATGAGG 
58 54.7 
8 Forward-CCTTTTTCTGTATGGGATTATGGA 
Reverse-TACTGAGTCTAAAACATGGTCTTGC 
58 55.5 
9 Forward-TTCTTTCAGCATACCACTTCATAAC 
Reverse-TGAATGAAGAAGCAAATTCAAAACAG 
58 55.0 
10 Forward-TGGGAGCTAGCAGTGTAAACAGAG 
Reverse-CAGGAAATTTCTAAATGTGACATGAC 
58 54.6 
11 Forward-GCTCAAAAAAAAAAAAAAGAAAAAAGTGG 
Reverse-AAATGACTTAGTTCTGGTTGAGATG 
56 54.7 
12 Forward-TCCTTTAGTTTGTTAATGTGATGG 
Reverse-ACTATGAAAATGATCAGGGATATG 
56 56.2 
13 Forward-CCTCCAATAGCTTGCTTTTCAC 
Reverse-AAACAGCAGCATGCTAATGAAC 
58 55.8 
14 Forward-GTATTCTTTACATGGCTTTTGGTC 
Reverse-TACTACCCAGCTAAAATTATCATC 
56 55.0 
15 Forward-CATATAAGGCAAAGCATTAGGT 
Reverse-CCTATTTCTCCTTCCTAACAGT 
56 55.5 
16 Forward-GAATTTGTTCTTACAAAAGATAGAG 
Reverse-GAATACATTTCATTCAAATTTATCCGA 
55 55.5 
17 Forward-GTATGTCCAAGATCAAAGTACACTG 
Reverse-GGGTGACAGAGAAAGATCCTATC 
58 55.5 
18 Forward-GTTTTTATTTCTTTGTTGCTTGGTTCT 
Reverse-CAAATATGATAGCAAAACAGGAAGC 
58 55.9 
19 Forward-CTCCCAAATTGCTGAGATTACAGATG 
Reverse-ATGAGGCCTCTTATACTGCCAAATC 
58 56.4 
20 Forward-ATATATGGCTGTTGTGCCCTTCTC 
Reverse-CATCAGATAAAATCCAAGAGCTTC 
58 56.5 
21 Forward-AAACCTGATTTTTTTCCCTCCTAC 
Reverse-TTTATAAGCTTAACAGAACACATCAGT 
58 54.4 
22 Forward-AATAACTGATGTGTTCTGTTAAGC 
Reverse-AAACTTGCATTCGTATCCACAGAT 
56 55.9 
23 Forward-GTAACTTATTAATAACCTTTAAGTGAG 
Reverse-ACTCATTAACAAAACAAAGACTGCT 
56 54.6 
24 Forward-CTATTTCATATTTAACCACAGTTC 
Reverse-TATGTAAGACATTCTACTGCCATC 
56 56.7 
25 Forward-TTGTTTGTTTGTTTGCTTGCTTGTTT 
Reverse-CATATGATAACAGCAAATACATGTTAC 
56 57.4 
26 Forward-GTCAAAAAATCTGGAGTTCAGTTG 
Reverse-GGAAGCTTCTAATAAAATACTCATC 
56 55.0 
27 Forward-GAATGTTGTTTCTAGGTCCTACTC 
Reverse-GTGAGGGGGACTTGCTAAGTATTG 
58 54.0 
28 Forward-CTTGGAAAAGTTATATATAACCTG 
Reverse-AACTTAAAGGTTATATCTCATATC 
53 55.0 
29 Forward-TTTGAGCTGTCTTGACGTTCACAG 
Reverse-TTGAAATAGACATTGAAGGTGTCAAC 
58 55.5 
30 Forward-TTTTCATTTTGGAAGTTCACTGGTC 56 55.0 
Reverse-GGAATGTTCTATTATTAAACTCATC 
31 Forward-GTGTATTTATTGTAGCCGAGTATC 
Reverse-GGAAGAACAGGATAGAAAGACTGC 
56 54.5 
32 Forward-GACTTGTGAATGAATTTATTTCAGAG 
Reverse-CACTCAAATCCTTCTAACAATAC 
56 56.5 
33 Forward-TTACAGTAAGTTTTGTTGTCTTAC 
Reverse-CAGATTTTTGAAAAGTACTACTATG 
56 54.0 
34 Forward-CCAATACGTGTTAAAAGCAAGTTAC 
Reverse-AACAGGTAGAAATAGCCCATGTC 
58 57.4 
35 Forward-AAACAAAAGTGTTGTCTTCATGCT 
Reverse-TCCTATATGTGATCCGCAGTTGAC 
58 57.2 
36 Forward-GTTTTATGTATGATCTCTTACCTATG 
Reverse-GAAGTATCATTCTCCATGAATGTC 
58 55.5 
37 Forward-CAGTCCACCTTAACATTCATCAAG 
Reverse-ACAGTCATGACCCACAGCAAACAG 
58 55.6 
38 Forward-AAGGTACAATGATTTCCACTTCTC 
Reverse-CAGCACTCTTTAGATAAACAGGTC 
58 56.0 
39 Forward-AGCAGTATGTTGAGTTTATGGCAG 
Reverse-GGATTCCATCTTAAATCCATCTTTC 
58 55.2 
40 Forward-CCTTATAGCATAGTGGGAGACAG 
Reverse-CAAGTTACACTCTAGATCCTAAACG 
58 56.0 
41 Forward-TAAGCAGTCACTACCATTGTATTC 
Reverse-TACCCTTATTGAGACAATGCCAAC 
58 54.3 
42 Forward-CAGGAGCTTCCAAATAGTATGTTC 
Reverse-CACATGGCATCTGTACAGTGTCT 
58 54.5 
43/44 Forward-TAGAGTTGGGAGTTACATATTGGT 
Reverse-GCACTACACTAGTGATGGCTTTAC 
58 55.4 
45 Forward-GTTTTTCTGTTGATATCTTTGATTAC 
Reverse-GAGAGGCAAAAAAAAAAAAATCAAGTC 
56 55.7 
46 Forward-GTCCTTTGGTGAAGCTATTTATAC 
Reverse-CTCAAGTTTTCAGAAAAGAAGCCA 
58 54.7 
47 Forward-CCTCTTCTTTATTTTCAGAGTGTC 
Reverse-GTCACTATTGGTAACAGAAAAGC 
58 58.0 
48 Forward-CATTTCTCTTTGCTTACATGAACTC 
Reverse-TAGAGATCTCTATCTCTTAATGAC 
53 57.0 
49 Forward-CATGGTAGTAGTATCAGTAGTAAAAG 
Reverse-CAGTAAAACACTAATCCAGCCAAT 
58 57.5 
50 Forward-AGTTGGGTACAGTCATGGTAATGC 
Reverse-CTAAGTAACTATCTTAAGGGTTGCTC 
58 57 
51 Forward-GTGTATTACCTTAATTTGAGTGATTC 
Reverse-AAGACCAAGTCACTCTTTCTATGC 
58 56.1 
52 Forward-ATCATGTGTGATTTTGTAGTTCTG 
Reverse-TTCAAGCACAGGGTAGAATATTGG 
56 56.8 
53 Forward-TTGTGCTAATAGAGGAGCACTGTC 
Reverse-GTATTTCCATTTCTTAGAGGGAATG 
58 54.4 
54 Forward-TCTACCCACTGCAGTATCTAGAC 
Reverse-CAGCCTTGAACCGATTTTAGATG 
56 55.3 
55 Forward-TGTTGGGTAGTTCCTTATGTAATG 
Reverse-GGATTACGTTTGTGATTTTAAGCAG 
56 55.6 
56 Forward-ACTATTCCTGCTTGACCTTCAATG 
Reverse-GCCAATATTTAACCAATTTTGACC 
56 54.7 
57 Forward-TAAGTGCAAATAGTGTATCTGACC 
Reverse-CATCACTAAAACTCTAAGGGCTAAG 
56 56.3 
58 Forward-TTGCTATTCTCAGATGACTCTGTG 
Reverse-GCCTCCCAAAGCATTATGAATATG 
56 55.9 
59 Forward -CATCAAATGCTCTTTAATGGCCTT 
Reverse-TGCCAAACAAACAAAGTGCTCAATC 
58 57.3 
60 Forward-CATCTTTATTGCCCCTATATCTGTC 
Reverse-TGCCAAACAACAAAGTGCTCAATC 
58 55.0 
61 Forward-AAGAGATGGAATCAGTGATTTCAG 
Reverse-AGGCAAACAACATTCCATGATGAC 
58 54.3 
62 Forward-TTAGCTGTCAAACCTCCTAACTTC 
Reverse-TTGAGTAGCGGGATTACAGGTG 
58 57.2 
63 Forward-AGATATGTTGACAACATTGGTGTG 
Reverse-GAGATACACAGTCTACCTGGTAAG 
58 55.0 
64 Forward-GATACTGGTTCTACTGTTTCTAAG 
Reverse-AAAGGTTTCAGTGAGGTGAACAG 
58 56.3 
65 Forward-GGTGAGCAGTATTTTAAGAAGGTC 
Reverse-TCCCTACTTAAAGTAGTTGGCAG 
58 56.8 
 
primers designed to bind to sequences located outside the respective pairs of 
exons. PCR conditions were similar to those described above for the exons of 
the ATM gene, however primer annealing temperatures used for the TP53 
coding exons ranged from 58-63˚C (Table 3.2).  
 
3.2.2 Denaturing High Performance Liquid Chromatography (DHPLC) 
       PCR products were screened for sequence changes by denaturing high 
performance liquid chromatography (DHPLC) using the WAVE® DNA 
fragment analysis system (Transgenomic). DHPLC detects sequence 
changes on the basis of the differential binding characteristics of 
heteroduplexes, which form when there is a sequence mismatch between two 
alleles, and homoduplexes, which form when two alleles are perfectly 
matched. 
 
3.2.2.1 Heteroduplex formation 
       Prior to DHPLC analysis on the WAVE machine, each PCR product was 
processed in order to maximise the formation of any potential heteroduplexes. 
Samples were heated to 95˚C for 5 minutes to denature the double stranded 
DNA (dsDNA) into single stranded DNA (ssDNA). Samples were then cooled 
slowly by the decreasing the temperature by 1˚C per minute, from 95˚C to 
65˚C using the PCR machine (Figure 3.1).  
      Certain CLL tumours were known to carry a chromosome 11q deletion 
and therefore would only have one ATM allele present. Therefore, a potential 
sequence change in the remaining allele might not be detected by DHPLC, as 
there would be no wild type allele with which to form a heteroduplex. 
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 Table 3.2 – PCR and DHPLC conditions for exons 3-10 of TP53 gene 
 
Exon Primer Sequence DHPLC 
Temp 
(ºC) 
PCR 
annealing 
Temp (ºC) 
3 and 4 Forward-CCTAGCAGAGACCTGTGGGAAGCG 
Reverse-GCATTGAAGTCTCATGGAAGCCAGC 
60 63 
5 and 6 Forward-CTTTATCTGTTCACTTGTGCCCTGAC 
Reverse-GGGCCACTGACAACCACCCTTAAC 
60 63 
7 Forward-CTCCCCAAGGCGCACTGGCCTCATC 
Reverse-CAGGCCAGTGTGCAGGGTGGCAAG 
58 60 
8 and 9 Forward-CTGATTTCCTTACTGCCTCTTGCTTC 
Reverse-CTGGAAACTTTCCACTTGATAAGAGGTC 
60 63 
10 Forward-CTCAGGTACTGTGTATATACTTACTTC 
Reverse-GAATGGAATCCTATGGCTTTCCAAC 
58 59 
 
Figure 3.1 
 
a. If there is a sequence change in one allele of a gene then a mixture of 
heteroduplexes and homoduplexes will form following denaturation and 
re-annealing.  
 
b. The melting characteristics of exon 55 of the ATM gene are shown. 
Parts of the exon will be more completely denatured into single 
stranded DNA at a given temperature depending on the G-C content. 
At 53.5ºC, the whole of the coding region of the PCR product consists 
of dsDNA. At 55.5ºC, part of the exon remains as dsDNA, but part has 
denatured into ssDNA. Typically heteroduplexes are estimated to 
denature at a temperature 1ºC lower than homoduplexes. Therefore, at 
55.5ºC, it might not be possible to detect all sequence changes 
because part of the exon had already completed denatured in the 
homoduplex. The ideal temperature to analyse this exon by 
chromatography would be thus be approximately 54.5 ºC.  
 
c. Heteroduplexes can be resolved from homoduplexes by 
chromatography because they will be more denatured over a given 
temperature range and will therefore elute earlier from a DNA binding 
column. In this example it would be possible to detect the presence of 
heteroduplexes over the range of temperature from 53 - 58 ºC. 
 
ac
b
Figure 3.1
Therefore for these samples, 10µl of the final PCR product for each exon was 
mixed with 10µl of the product from a sample that was known to have both 
ATM alleles present, prior to the heteroduplex reaction. Subsequently both the 
mixed and unmixed products were analysed by DHPLC (Xiao W, Oefner PJ, 
2001). 
 
3.2.2.2 DHPLC 
     Heteroduplexes and homoduplexes have different properties that are 
exploited by DHPLC to screen for potential mutations. Due to the presence of 
a mismatch, heteroduplexes will denature into ssDNA over a lower 
temperature range than perfectly matched homoduplexes. Therefore, for a 
given temperature the heteroduplexes will be more completely denatured than 
homoduplexes. The WAVE machine (Transgenomic) has a DNASep column 
that contains hydrophobic divinylbenzene beads that bind DNA. The strength 
of the binding of DNA to the beads in the column will vary according to both 
the length of the DNA but also according to the degree of denaturation of the 
DNA.   
       During the process of chromatography the proportions of 2 buffers (Buffer 
A (0.1M Triethylammonium actetate (TEAA)) and Buffer B (0.1M TEAA and 
25% acetonitrile) (Transgenomic)) are programmed to alter. Increasing the 
concentration of this Buffer B causes any DNA bound to the column to elute. 
However, due to the differential denaturation properties of heteroduplexes and 
homoduplexes, heteroduplexes will elute earlier than homoduplexes over 
certain temperature ranges. Therefore in order to detect sequence changes, 
the chromatography is performed at a programmed temperature that is 
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selected by the operator. This is chosen based on the denaturing 
characteristics of each exon. The ideal temperature will be one where the 
degree of denaturation is predicted to be the greatest between a homoduplex 
and a heteroduplex.  This can be identified using the Wavemaker software 
(Figure 3.1). The choice of temperature is not always straightforward due to 
variations in the denaturing characteristics across any given exon. However, 
there is typically a range of temperatures over which it is theoretically possible 
to resolve the heteroduplexes from the homoduplexes. The temperatures for 
the DHPLC for each ATM exon are shown in Table 3.1. 
        The presence of the DNA that is eluted from the column is detected 
using a UV lamp and converted to a read-out on the screen, termed the 
chromatogram. Peaks can be seen that correspond to the heteroduplexes and 
homoduplexes. A single peak pattern is present if there are only 
homoduplexes present in the sample. Any alteration in this single peak 
pattern is indicative of the presence of heteroduplexes in the sample (Figure 
3.2). 
        In this study, all chromatograms were analysed visually and 
chromatograms were compared across large numbers of samples for each 
exon. The PCR product was subsequently sequenced for all cases where a 
variant pattern demonstrated was detected.  
 
3.2.3 DNA Sequencing 
3.2.3.1 Purification and quantification 
      Prior to sequencing, all PCR products were purified using High Pure 
purification kit (Roche). Briefly, 40μl of each PCR product was mixed with 
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Figure 3.2 
 
An example of a chromatogram is demonstrated for exon 10 of the ATM gene. 
In the absence of a sequence change a single peak pattern is seen that 
corresponds to the presence of perfectly matched homoduplexes. The 
injection spike, primer peak and the wash-off peak are also demonstrated.  
By comparison in the presence of a sequence change an alteration in this 
single peak pattern is seen due to the presence of heteroduplexes and 
homoduplexes. In this example a triple peak pattern is seen. 
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200μl of binding buffer and spun at 14,000 rpm in a microcentrifuge. Products 
were washed twice with ethanol and the purified DNAs were eluted into 35 μl 
of the elution buffer. 
     The purified products were quantified visually by electrophoresing on an 
agarose gel. The agarose gel mix was made to a final concentration of 1.0% 
(w/v) in 0.5 x TBE containing ethidium bromides. 3μl of the PCR products and 
molecular weight marker were mixed with 2μl of Bromophenol loading dye, 
containing 0.25% (w/v) bromophenol and 40% (w/v) sucrose in SDW, and run 
at 80V for approximately 20 minutes. The gel was visualised by a UV 
transilluminator and recorded using Polaroid film (Genetic Research).  
 
3.2.3.2 Labelling and precipitation of products 
     Sequencing was performed using the 3100 capillary sequencer from PE 
Applied Biosystems. 
     The labelling reactions were set up using 2μl Big DyeTMTerminator v3.1 
Cycle sequencing kit (PE Applied Biosystems), 6μl of 2.5Xsequence buffer 
(200mM Tris HCl, 5mM MgCl2 pH9.0), 1μl primer (0.1μg/μl) and between 1-
7μl of DNA (30-50ng) plus sterile water to make a total reaction volume of 
20μl. Separate reactions were set up using forward and reverse primers for 
each exon. The labelling PCR was carried out for 25 cycles at 96˚C for 10 
seconds, 50˚C for 5 seconds and 64˚C for 4 minutes.  
    The labelled products were precipitated with a 62.5μl of 100% (v/v) ethanol 
and 3μl 3M sodium acetate (pH 4.6) in 0.75ml tubes at room temperature for 
15 minutes. The samples were then microcentrifuged at 14,000 rpm for 
20minutes. The supernatant was removed and pellets were washed with 250 
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μl 75% (v/v) ethanol, followed by microcentrifugation at 14,000 rpm for 5 
minutes. The supernatant was removed and the pellets were dried for 20 
minutes. 
  
3.2.3.3 The 3100 ABI prismTM DNA capillary sequencer  
     Prior to loading in the capillary sequencer, 10μl of ‘High DyeTM’ was added 
to the pellet. Samples were denatured by heating to 100˚C for 5 minutes and 
put on ice for 2 minutes before being left at room temperature ready for use. 
The buffer chambers were first filled with 2.5x EDTA buffer (PE Applied 
Biosystems) and the water chambers filled accordingly. 3100 POP 6TM 
Performance Optimized Polymer was used to fill the 50cm sequencer capillary 
array (PE Applied Biosystems). The 3100 data collection software version 1.0 
was set for sequencing at: Dye Set, E; Mobility file, DT3100POP6(BD)v2.mob; 
BIOLIMS Project, 3100_Project 1; Rum Module1, StdSeq50_POP6Default 
Module and Analysis Module 1, BC-3100_SeqOff.saz. The samples were 
loaded into the appropriate 96 well plates and run for approximately 2.5 hours. 
Following the run, the extracted samples were analysed using the ABI 
sequencing analysis version 3.6.1.  
    
3.3 Protein chemistry techniques 
  
3.3.1 Tissue Culture 
    Cells were thawed, washed once with culture media (RPMI with 10% FCS 
plus 1.2% penicillin and streptomycin, 1.2% L-Glutamine), re-suspended and 
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cultured in 24 well plates. Cells were cultured in incubators at 37ºC with 5% 
CO2 and humidified air. 
 
3.3.2 Tumour cell viability 
      Prior to further biochemical analysis the viability of the cells was assessed 
in each case. 10μl of suspended cells were mixed with 10μl of trypan blue and 
the cells were then visualised with a light microscope. Cells stained with 
trypan blue (dark) were considered as non-viable. Further biochemical 
experiments were only performed on samples where the baseline viability was 
demonstrated to be >80%.   
  
3.3.3 DNA damage with irradiation 
      For experiments, involving the assessment of the response to DNA 
damage, each tumour sample was divided into aliquots according to the 
number of time points that were to be studied. Aliquots of cells were placed in 
up to 1 ml of culture media in universal containers and irradiated at a dose of 
5 Gray using a Precisa 217 with source-emitting gamma-type rays (Pantatron, 
Gosport, Hampshire, UK). Following irradiation, cells were returned to the 
incubator and aliquots of cells were removed and processed at the 
appropriate time points.  
 
3.3.4 Treatment with fludarabine 
     For experiments involving the investigation of the responses to fludarabine, 
tumour cells were cultured at a concentration of 1.25x106 cells per ml of 
media. 2mls of re-suspended cells was aliquoted into each well of a 24-well 
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plate. Fludarabine (Schering) was re-suspended and diluted in culture media 
and added to the culture wells to give a concentration of 10 -20µM.  
      
3.3.5 Protein extraction 
      Protein extraction from CLL samples was performed at defined time points 
according to individual experiments. At the appropriate time point, samples 
were transferred to universal containers and put on ice.  
      Two techniques were used for protein extraction in this project. In initial 
experiments, exactly 2x106 cells were used for each time point. Cells were 
centrifuged at 1400 rpm for 5 minutes at 4ºC and the supernatant was 
removed, without washing in order to minimise any loss. Protein was 
extracted using a modified RIPA buffer containing 25mM Tris HCL (ph 7.6), 
5mM disodium EDTA, 50mM sodium chloride, 30mM sodium pyrophosphate, 
50mM sodium fluoride, and 1mM sodium orthovanadate plus 0.1 ml of 1% 
NP40 (Calbiochem), and 5µg of aprotinin and 10µg of Phenyl Methane 
Sulfonyl Fluoride (PMSF) in a volume of 10mls. 15µl of buffer was added to 
each pellet of cells and samples were thoroughly mixed by pipetting and 
transferred to 1.5ml microcentrifuge tubes. Samples were left on ice for 30 
minutes and then spun at 12,000 rpm for 15 minutes in a microcentrifuge at 
4ºC. The supernatant consisting of the protein lysate was removed and 
transferred to new 1.5ml tubes that had been previously placed on ice. 
Lysates were snap frozen in liquid nitrogen and subsequently stored until 
required at -80ºC. 
       In later experiments, cell pellets were washed once with cold phospho-
buffered saline (PBS) and re-pelleted prior to protein extraction. Protein was 
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extracted using a TGN buffer (pH 7.5) consisting of 5ml 1M Tris (ph 
7.5)(50mM), 5 ml 1M glycerophosphate (50mM), 6 ml 2.5M sodium chloride 
(150mM), 10 ml 10 % glycerol (BDH Laboratories), 1 ml 1% Tween 20, and 
200µl NP40, together with water to form a total volume of 100mls.  At the time 
of protein extraction the following protease and phosphotase inhibitors were 
added to 14.5mls of TGN buffer, namely 15µl Dithiothreitol (DTT) (1M), 150µl 
sodium orthanoate (0.1M), 300µl sodium fluoride (0.5M), 15µl 4-(2-
Aminoethyl) Benzenesulfonyl Fluoridehydrochloride (AEBSF) (0.1M), 15µl 
Aprotinin (10mg/ml), 7.5µl Leucopeptin (10mg/ml) and 15 µl Pepstatin A 
(2mg/ml). Between 30 and 50µl of cold TGN buffer was added to each cellular 
pellet and mixed by pipetting. Lysates were subsequently obtained as 
described above.            
     The quantity of protein in the lysate was determined for all experiments 
that had not used fixed numbers of cells. A set of standard samples with a 
known protein concentration were established by diluting volumes of bovine 
serum albumin (BSA) (New England Biolabs) 1mg/ml with volumes of water in 
different ratios. These ranged from 0 to 500mg/ml. The test samples were 
diluted with H20 in a ratio of 1:9. 10µl of each sample was added to a 96-well 
plate and all samples were analysed in triplicate. Bradford’s reagent (Bio-Rad) 
was diluted with 1:4 with water and 200µl was added to each sample. The 
colour intensity was measured using a 595 filter with an automated reader. 
The mean absorbance value for each of the standard samples was plotted 
against the protein concentration using Cricket Graph software. The value of 
the equation y=mx+c was calculated for the best-fit line.  
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      The protein levels in the test samples were then determined using the 
equation:  
           (Protein Concentration (µg/µl) x 10)/1000 = (Mean Absorbance – c) / m  
 
3.3.5 Western blotting  
       Proteins were separated using 6% or 8% Sodium Dodecyl Sulphate – 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) gels. Six percent gels were 
used in experiments that required the separation of large molecular weight 
proteins such as ATM, and 8% gels were used in experiments investigating 
the levels of small molecular weight proteins such as p21 and cleaved 
caspase 3. The gels were made using 27ml or 24.6 ml of high purity H20 and 
8ml or 10.7mls of polyacrylamide (Bio-Rad) (6% or 8% gels, respectively), 
plus 4ml 1M Tris-Biscine, 400µl 10%-SDS, 80µl N N N N -Tetra-methyl-
ethylene-diamine (Temed) and 200µl 10% Ammonium persulphate (APS) 
(Bio-Rad). The wells of the gels were subsequently washed with running 
buffer (50ml of 1M Tris-Biscine, 5ml of 10% SDS and 450ml H20) 
      The protein lysates were defrosted briefly at 37ºC and 30µg of each 
sample was aliquoted into microcentrifuge tubes. In the experiments that had 
involved the use of fixed numbers of cells per time point, the entire lysate 
(15µl) was used. Six microlitres of 4x sample buffer (0.25M Tris HCl ph 6.8, 
8% SDS, 40% glycerol, 0.4M DTT and 0.04% Bromophenol blue) was added 
to each lysate and the proteins were denatured in a heat block at 100 ºC for 5 
minutes and loaded into the wells of the gel using a Hamilton Syringe. A 
rainbow marker (Amersham) was run on each gel to indicate protein size. 
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Running buffer was added and electrophoresis was performed at 30mA for 
approximately 4 hours.  
      After electrophoresis, the gel was blotted onto a nitrocellulose filter 
(Gelman) at 200mA for 12 hours in an Hoeffer transblot electroblotter in 
blotting buffer (1400ml methanol (Riedel de Haen), 40.6 gm Tris, 203 gm 
Glycine made up to a volume of 7 litres with water. 
    After blotting the filter was stained with Ponceau stain (1% Ponceau Red in 
3% (w/v) trichloroacetic acid) for 2 min on a rocker, and then de-stained briefly 
with water to visualise the blotted proteins. The filters were subsequently cut 
according to the size of the protein under investigation and were washed 3 
times (ten minutes) with either Tris Buffered Saline Tween (TBST) (pH7.6), 
containing 10l of water, 24.2g Tris, 80g NaCl and 10ml (0.1%) of Tween 20, or 
Phospho Buffered Saline Tween (PBST), containing 10l of water, 1 pot of 
PBS tablets (Oxoid) and 10ml (0.1%) of Tween-20, in order to completely 
remove the stain. TBST was used for experiments that involved the 
assessment of phosphorylated proteins. The filters were then blocked in 
PBST or TBST with 5% milk at room temperature for 2 hours on a rocker and 
washed three times, prior to incubation at the appropriate time and 
temperature with the primary (1º) antibody diluted in milk block. After a further 
3 washes filters were incubated with the appropriate horse-radish peroxidase-
labelled anti-species antibody conjugate (secondary antibody) diluted in milk 
block for one hour. This was following by a further washing in PBST or TBST 
three times for 10 minutes. The blots were then developed using an enhanced 
chemiluminescence (ECL) detection system (Pharmacia) according to the 
manufacturer’s instructions and exposed to X-omat film (Kodak).  
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      The primary antibodies used for Western blotting in this project were as 
follows: rabbit antibody to serine 15 phosphorylated p53 (Sigma Aldrich), 
sheep antibody to p53 (donated by DP Lane, University of Dundee), rabbit 
antibody to serine 1981 phosphorylated ATM (Sigma Aldrich), mouse 
monoclonal ATM antibody (developed in our laboratory), mouse rabbit 
antibody to serine 966 phosphorylated structural maintenance of chromosome 
1 (SMC1) (Bethyl Laboratories), rabbit antibody to SMC1 (Upstate), rabbit 
antibody to serine 343 phosphorylated Nbs1 (Santa Cruz) rabbit antibody to 
Nbs1 (Novus Biologicals), mouse monoclonal antibody to γH2AX, rabbit 
polyclonal antibody to p21 (Santa Cruz), mouse antibody to MDM2 (Donated 
by R Grand), mouse antibody to PUMA (Upstate), mouse antibodies to 
PARP1 (poly ADP ribose polymerase 1) (R&D systems), rabbit antibody to 
procaspase 7 and caspase 3 (New England, Biolabs), mouse monoclonal 
antibody to actin (Sigma Aldrich). 
       The secondary antibodies were goat polyclonal to mouse IgG (Sigma 
Aldrich), rabbit polyclonal to sheep IgG (DAKO) and porcine polyclonal to 
rabbit IgG (DAKO). 
      Optical density of protein bands was measured using Quantitiy One 
Imaging and Analysis Software (Bio-Rad) in order to quantify responses 
between tumours. Comparisons were made between samples on the same 
blot to control for any differences in antibody efficacy or exposure times. 
Changes in the level of a protein were expressed relative to any changes in 
either actin, or in the case of experiments studying phosphorylated proteins, 
relative to the level of the total un-phosphorylated protein.  
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3.4 Immunofluorescence 
      Immunofluorescence was used to assess the formation of γH2AX foci.  
      Buffers were prepared in advance. Pre-extraction buffer was made to a 
volume of 250mls (pH6.8) with Pipes (10mM), Sucrose (300mM), NaCl 
(20mM), MgCl2 (3mM) and 0.5% Triton x-100. Fixation buffer consisted of 
3.6% Paraformaldehyde in PBS. High purity water (300ml) was heated with 
300μl NaCl and 10.8g paraformaldehyde and 3 PBS tablets (Oxoid) were 
added. After cooling, the pH of the buffer was adjusted to 7.2. This buffer 
should be stored at -20˚C. 
     Before usage, immunofluorescence slides were cleaned in 70% Ethanol / 
1% Hydrochloric acid for 1 hour. They were subsequently washed x 4 for 20 
minutes per wash in H20 and dried thoroughly (37˚C). Poly-L-lysine was then 
placed on each well that was to be used and left for 20 minutes. Wells were 
washed with water and allowed to dry thoroughly (37˚C). 
      Approximately 1 x 105 cells were used per time point. Cells were 
transferred from culture plates into universal tubes and spun at 1000 rpm for 4 
minutes.  The majority of the supernatant was removed and the cell pellet was 
re-suspended in 30μl of residual supernatant. The cells were transferred to 
the wells on the slides and left to adhere for 20 minutes. 
       Slides were placed in extraction buffer for 5 minutes and subsequently 
fixed in ice-cold paraformaldehyde for 10 minutes. The slides were then 
washed x 3 (5minutes per wash) in Tris buffered saline (TBS) before being 
transferred into fetal calf serum (FCS) blocking solution (FCS diluted to 10% 
in TBS for 1 hour).  
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       After washing three times for 5 minutes, excess TBS buffer was wiped 
from the wells and 10μl of the appropriate primary antibody (anti-phospho-
Histone H2AX (Ser 139) (Upstate) diluted 1:500 in TBS) was added to each 
well.  Slides were incubated for 1 hour in a dark moist box. After a further 
three washes slides, 30μl of secondary antibody, (Fluorescent conjugated 
Alexa 594 anti-mouse antibody diluted 1:1000 in TBS) was added to each well 
and slides were incubated for a further hour.  
       Slides were washed as previously and excess buffer removed from the 
slides. A DAPI/Vector shield mix (DAPI stain (1μg/ml in water) 1:4 
Vectorshield) was made and 1 drop was placed over each well. Slides were 
covered with a coverslip, which was sealed with nail varnish, and stored in the 
dark at 4˚C. Slides were examined using a fluorescent microscope and 
images were stored using ‘Open lab’ software. 
       
3.5 Fluorescent in situ hybridisation (FISH) 
       A cytospin was initially prepared for each sample. Up to 2x 107 thawed 
tumour cells were washed twice with PBS and subsequently re-suspended in 
between 5-7mls PBS. 2 drops of this cell suspension was then used to make 
a cytospin. Cells were subsequently fixed in a mixture of methanol and acetic 
acid (3:1) at 4ºC for one hour. The slides with the fixed cells were stored in the 
dark at -20ºC. 
      Slides were prepared for FISH by incubating them in 2xSSC buffer 
(Sodium chloride (0.3M), Tri -Sodium Citrate (Sigma) (0.03M)) for 30 minutes 
at 37ºC. They were subsequently washed in increasing concentrations of 
ethanol, 70%, 80% and 100% for 2 minutes each. After drying, the position of 
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the cells was marked on the slide and 10μl of hybridisation buffer (50% 
formamide plus 2XSSC) was placed over the cells using a cover slip, whose 
edges were sealed. Slides were heated for 5 minutes at 70ºC to allow 
denaturation. Commercial probes (Qbiogene) were denatured by heating to 
96ºC for two minutes. This product contains an ATM probe that will bind to the 
ATM gene localised on the minimal region of deletion on chromosome 11q22-
23, together with a chromosome 11 centromeric probe. The hybridisation 
buffer was removed from the slide and a new coverslip, on which with 5μl of 
the commercial probe mixture had been added, was placed over the cells. A 
seal was placed around the edge of the coverslip and the slides were heated 
to 70ºC for 5 minutes to allow co-denaturation. Slides were left in the dark 
overnight to allow probe hybridisation. 
      Following hybridisation, the slides were first placed in 2xSSC in order to 
remove the cover slips and then in a mixture of 0.4xSSC and NP40 at 65ºC 
for 5 minutes. After cooling in 2xSSC, Vectoshield (containing DAPI) was 
placed over the cells with a new coverslip.  
      The cells were visualised under a fluorescent microscope and the number 
of centromeric (green) probes and ATM (red) probes in each cell were 
counted. Examples of cells were photographed using ISIS software. 
 
3.6 Clinical Data and Statistical Analysis 
     I collected clinical data including dates of birth, dates of diagnosis, gender, 
age at diagnosis, clinical stage at diagnosis, treatment history, and survival 
data from hospital case notes and recorded these in a CLL patient database. 
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The IGVH mutation status had been determined for a majority of CLL patients 
as part of independent studies. Tumours were classified as IGVH un-mutated 
if there was at least 98% concordance between the tumour DNA and the 
respective family sequence, and IGVH mutated if there was less than 98% 
concordance. 
    The Kaplan Meier method was used to compare the overall survival (OS) 
and treatment free survival (TFS) between subgroups of patients according to 
their genetic subgroup. The log rank test was used to compare the 
significance of any differences in survival between these subgroups. The 
Fisher’s exact test was used to confirm any association between ATM 
mutation status and IGVH mutation status, the Chi-squared test to determine 
any associations between ATM mutations and clinical stage at diagnosis, and 
the Mann-Whitney U Test to determine any association between ATM 
mutations and age at diagnosis. The Kruskall-Wallis test was used to 
determine if there were significant differences between the median levels of 
PARP1 cleavage between the three genetic groups. 
     Multivariate analysis by Cox’s proportional hazards regression was used to 
analyse the unselected cohort and assess the inter-dependence of various 
prognostic factors in order to determine whether ATM mutations could provide 
any independent information (The statistical analysis was done with the help 
of Dr Judith Powell, Department of Epidemiology and Public Health, University 
of Birmingham). 
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Results 1 
 
The prevalence and nature of ATM mutations in CLL cohorts 
 
 4.1 Introduction 
     Although sporadic mutations in the ATM gene have been reported to occur 
in CLL tumours (Stankovic T et al, 1999, Schaffner C et al, 1999, Bullinger F 
et al 1999) their prevalence has not been established. Previous studies of 
ATM mutations in CLL have involved small cohorts of patients that have 
consisted primarily of patients with aggressive disease features, such as 
advanced stage disease (B or C) and un-mutated IGVH genes. In contrast, a 
number of large studies have investigated the prevalence of a deletion of 
chromosome 11q that leads to the loss of one copy of the ATM gene (Dohner 
H et al, 2000, Dewald GW et al. 2003). However, the precise relationship 
between mutations in the ATM gene and deletions of an ATM allele via loss of 
chromosome 11q in CLL tumours remains obscure. For example, there 
remains uncertainty regarding the proportion of tumours with an 11q deletion 
that also have an ATM mutation in the remaining allele.  
     The primary aims of the work described in this chapter, therefore, has 
been to establish the prevalence of ATM mutations within (1) a large 
unselected cohort of CLL tumours and (2) a selected cohort of CLL tumours, 
which all had a deletion of chromosome 11q. In addition, I have investigated 
the nature of the ATM sequence changes and their distribution across the 
ATM gene within the two CLL cohorts. 
 63
    The majority of the ATM mutations that have been described in CLL 
tumours have been shown to be sporadic changes that were acquired within 
the tumour cell. One study has also reported the presence of germ-line ATM 
mutations in a small proportion of cases. Although numbers were small, these 
germ-line changes were present at a higher frequency in the CLL patients 
than had been previously reported to occur within the general population, 
suggesting the possibility of a causative role for ATM mutations in the 
development of CLL (Stankovic T et al, 2002). In addition, specific germ-line 
polymorphic alterations in the ATM gene sequence have been linked to the 
development of malignancies including CLL (Scott SP et al, 2002, Rudd MF et 
al, 2006). To date, however, there has been no direct comparison between 
the ATM sequence changes occurring in CLL patients with those occurring in 
a control population, which has used a screening technique designed to 
detect all changes present. Such an approach would allow the assessment of 
the potential of a causative role of ATM variants in CLL.  
    A secondary aim that is addressed in this chapter, therefore, has been to 
determine whether there are differences in either the nature or frequency of 
germ-line ATM sequence alterations between CLL patients and a control 
population.  
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4.2 Nature of the cohorts  
 
4.2.1 Cohort of unselected CLL patients 
    To determine the prevalence of ATM mutations in unselected CLL patients, 
I established a cohort that was representative of the clinical CLL phenotype 
spectrum and was of sufficient size to provide adequate power to determine 
mutation prevalence. The cohort consisted of 155 patients with CLL that had 
attended a haematology outpatient clinic at either Selly Oak or Heartlands 
Hospitals between the dates of December 2001 and January 2003. As far as 
possible, all CLL patients attending one of these clinics during the study 
period were included and therefore the cohort included both newly diagnosed 
patients and also many patients that had originally been diagnosed with CLL 
at varying times prior to the study period.  
 
4.2.2 Cohort of CLL patients with a deletion of chromosome 11q 
    To establish the prevalence of ATM mutations in the subgroup of CLL 
patients that all had loss of one copy of the ATM gene, I formed a second CLL 
cohort, selected by the presence of a deletion of chromosome 11q in their 
tumour cells. This cohort consisted of 53 CLL patients and the detection of the 
deletion of chromosome 11q by FISH in the tumour cells had been previously 
performed in diagnostic laboratories using an ATM probe. The patients 
originated from hospitals in the West Midlands, Hampshire and Leicestershire 
and included a mixture of recently diagnosed patients and those that been 
diagnosed some years previously.  
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    Ten patients fulfilled the entry criteria for both cohorts and were, therefore, 
included in both patient groups. Thus, in total 198 CLL patients were analysed 
for ATM mutations in this study. 
 
4.2.3 Cohort of control individuals  
    The control cohort consisted of 71 Caucasian healthy volunteers over 65 
years in age and 90 anonymous individuals who were blood donors making a 
total of 161 controls. 
 
4.3 Nature of ATM sequence changes in the CLL patients 
    Altogether 198 CLL tumours from the two cohorts were screened for ATM 
mutations by a combination of DHPLC and direct sequencing as described. At 
least one sequence change in the ATM gene was detected in 138 of these 
cases, and in 59 cases more than one change was present. There were sixty-
nine different sequence alterations detected which included unique alterations 
present in a single individual and certain common changes, such as 5557G/A, 
occurring in 23% of the entire group.  Fifty-six of the changes were present 
within the coding exonic sequence and thirteen within flanking intronic 
sequences. Sixty changes were nucleotide substitutions, eight were 
nucleotide deletions and one change was a nucleotide insertion.  
 
4.3.1 Distinguishing mutations from polymorphisms 
    ATM is a highly polymorphic gene and distinguishing a mutation, which will 
lead to impaired function of the translated protein, from a polymorphism, with 
no functional consequences, is not always straightforward. Non-sense 
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changes result in the generation of a premature stop codon, either through an 
out of frame deletion or insertion or a nucleotide substitution that causes the 
direct formation of a stop codon. These changes are predicted to lead to a 
truncated protein and therefore are likely to represent a mutation. Mis-sense 
changes are due to nucleotide substitutions and are predicted to lead to an 
amino acid substitution in the translated protein. Depending on the site and 
nature of the change within the protein, such an amino acid change may or 
may not have consequences on the function of the translated protein. 
Alterations in the charge or polarity of an amino acid and / or the involvement 
of a residue that is conserved across species might be predicted to be more 
likely to have an effect on protein function. Other sequence changes can 
represent mutations by interfering with the process of exon splicing. Splicing 
is determined by the presence of consensus sequences that form donor and 
acceptor sites for RNA splicing and in certain cases also require additional 
splicing enhancer and silencer sequences. A sequence change at or near an 
intron / exon boundary can lead to disruption of the splicing process which 
can lead to skipping of a whole exon (Thortenson YR et al, 2003).  
     
In this study, a sequence change was designated as a mutation if it: 
a) Led to the generation of a premature stop codon  (Non-sense change), 
b) Caused an amino acid substitution (Mis-sense change) or in-frame 
deletion or insertion that had not been reported as polymorphism nor 
was present in 200 normal alleles, or 
c) Had been previously reported to result in abnormal exon splicing 
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4.3.2 ATM mutations in the CLL patients 
    Using these criteria, 36 changes were categorised as mutations and 33 
changes as polymorphisms in the CLL patients (Tables 4.1 and 4.2). Amongst 
the changes designated to be mutations there were 10 non-sense changes, 
21 mis-sense changes in the coding sequence, one in-frame insertion, one in-
frame deletion and 3 changes that were predicted to interfere with splicing.  
 
4.3.2.1 Non-sense ATM mutations  
    There were six out of frame deletions in the coding sequence of the ATM 
gene (1058delGT, 3651delC, 5290delC, 6815delA, 7883del5, 8833del34), 
which would generate a downstream stop codon, and four nucleotide 
substitutions (1120C/T (Q374X), 2308G/T (E770X), 4591C/T (Q1531X) 
8977C/T (R2993X)) leading to the direct generation of a stop codon. All these 
changes were unique in a single individual and, notably, the mutation 
5290delC has been previously reported in AT patients. 
 
4.3.2.2 Mis-sense ATM mutations 
    Twenty-one changes were classified as mis-sense mutations resulting from 
an nucleotide substitution which would be predicted to result in an amino acid 
substitution in the translated in protein (1009C/A, 2417T/G, 3383A/G, 
3964C/A, 5041A/G, 5044G/T, 5224G/C, 5228C/T, 5882A/G, 5980A/G, 
6067G/A, 6106T/A, 7047C/G, 7313C/A, 8056T/C, 8249T/C, 8600G/A, 
8839A/T, 8861A/G, 9022C/T, 9023G/A). Each of the changes was present in 
a single tumour except for the 8249T/C and 5980A/G substitutions that were 
each detected in two CLL tumours. Two of the changes (5228C/T, 9022C/T) 
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Table 4.1 – Sequence changes designated as mutations in the ATM gene 
in the CLL patients 
 
Nucleotide 
Change 
Type of 
mutation 
Protein Change Number 
of 
Patients 
With  
Change 
Conserved 
between 
Human 
and Mouse 
sequence 
Present 
in Germ 
line 
Previous reports of 
change 
1009C/A Mis-sense R337S 1 Yes No Not reported 
1058DelGT Non-sense Truncation 1 na Yes Reported (in this patient) 
1120C/T Non-sense Q374X 1 na No Reported in AT patients 
IVS16-10T/G Splicing Splice defect 1 na nk Reported in AT patients 
2308G/T Non-sense E770X 1 na No Not reported 
2417T/G Mis-sense L806W 1 Yes No Not reported 
2929Ins9 Insertion Insertion 3 1 na nk Not reported 
3383A/G Mis-sense Q1128R 1 No nk Not reported 
3651delC Non-sense Truncation 1 na No Not reported 
3883Del3 Deletion Deletion L 1 na nk Not reported 
3964C/A Mis-sense L1322F 1 Yes Yes Not reported 
4591C/T Non-sense Q1531X 1 na nk Not reported 
5041A/G Mis-sense I1681V 1 No No Not reported 
5044G/T Mis-sense D1682Y 1 Yes No Reported in T-PLL 
5224G/C Mis-sense A1742P 1 na No Reported (in this patient) 
5228C/T Mis-sense T1743I 1 Yes No Reported in AT patients 
5290del C Non-sense Truncation 1 na No Reported in AT patients 
5882A/G Mis-sense Y1961C 1 Yes Yes Not reported 
5980A/G Mis-sense K1994E 2 Yes No Not reported 
6067G/A Mis-sense G2023R 1 Yes Yes Breast Cancer, DLBCL 
6106T/A Mis-sense Y2036N 1 Yes No Not reported 
6815DelA Non-sense Truncation  1 na No Not reported 
7047C/G Mis-sense C2349W 1 Yes No Not reported 
7313C/A Mis-sense T2438K 1 Yes nk Not reported 
7883del5 Non-sense Truncation 1 na No Not reported 
8056T/C Mis-sense F2686L 1 Yes No Not reported 
8249T/C Mis-sense L2750S 2 Yes Yes (1/2) Not reported 
8592C/T Splicing Splice defect 1 Na Nk Reported, splicing variant 
8600G/A Mis-sense G2867E 1 Yes No Reported (in this patient) 
IVS62-1G/T Splicing Splice defect 1 na nk Reported in AT patient 
8839A/T Mis-sense T2946S 1 Yes No Reported (in this patient) 
8833Del34 Non-sense Truncation 1 na No Not reported 
8861A/G Mis-sense Y2954C 1 Yes No Not reported 
8977C/T Non-sense R2993X 1 na nk Not reported 
9022C/T Mis-sense R3008C 1 Yes No Reported in AT patients 
9023G/A Mis-sense R3008H 1 Yes No AT patients, MCL, CLL 
 
Table 4.2 - Sequence changes designated as polymorphisms in the ATM   
gene in the CLL patients 
 
Nucleotide 
Change 
Protein Change Number 
of 
Patients 
With the 
Change 
Previous reports of change 
146C/G S49C 1 Known polymorphism 
378T/A D126E 3 Known polymorphism 
IVS8+38T/C Intron 2 Known polymorphism 
795T/C I265I 2 Known polymorphism 
998C/T S332F 1 Known polymorphism 
1176C/G G392G 1 Known polymorphism 
1254A/G E418E 1 Known polymorphism 
1986T/C F662F 1 Known polymorphism 
2119T/C S707P 6 Known polymorphism 
IVS19-17G/T Intron 1 Known polymorphism 
2572T/C F858L 9 Known polymorphism 
2805G/C T935T 1 Known polymorphism 
3161C/G P1054R 7 Known polymorphism 
IVS25-15delA Intron 26 Known polymorphism 
IVS29-33C/T Intron 1 Intronic location (Not reported) 
4138C/T H1380Y 2 Known polymorphism 
4258C/T L1420F 11 Known polymorphism 
4578C/T P1526P 15 Known polymorphism 
IVS33+25A/G Intron 1 Intronic location (Not reported) 
4802G/A S1601N 1 Known polymorphism 
5071A/C S1691R 1 Known polymorphism 
IVS38-8T/C Intron 4 Known polymorphism 
5352C/T N1784N 1 No amino acid change (Not reported) 
5557G/A D1835N 46 Known polymorphism 
5558A/T D1853V 1 Known polymorphism 
5793T/C A1931A 5 Known polymorphism 
5821G/C V1941L 2 Present in controls (Not reported)  
6820G/A A2274T 1 Known polymorphism 
IVS52+4A/G Intron 1 Intronic location (Not reported) 
IVS54+8G/T Intron 1 Present in controls (Not reported) 
IVS61+9T/G Intron 1 Intronic location (Not reported) 
IVS62+8A/C Intron 19 Known polymorphism 
9200C/G 3’UTR 4 Known polymorphism 
have been previously found in AT patients and four of the changes have been 
reported in association with haematological tumours, (5044G/C (T-PLL), 
6067G/A (DLBCL), 9022C/T (T-PLL and MCL) and 9023G/A (MCL and CLL)).  
     In 19 of the 21 mis-sense changes that were predicted to lead to amino 
acid substitutions the amino acid residue involved was one that was 
conserved between the human and mouse ATM gene sequence (1009C/A 
(R337S), 2417T/G (L806W), 3964C/A (L1322F), 5044G/T (D1682Y), 
5224G/C (A1742P), 5228C/T (T1743I), 5882A/G (Y1961C), 5980A/G 
(K1994E), 6067G/A (G2023R), 6106T/A (Y2036N), 7047C/G (C2349W), 
7313C/A (T2438K), 8056T/C (F2686L), 8249T/C (L2750S), 8600G/A 
(G2867E), 8839A/T (T2946S), 8861A/G (Y2954C), 9022C/T (R3008C), 
9023G/A (R3008H)). This provides further support that these sequence 
changes represent mutations and that an alteration in one of these conserved 
residues will affect the function or stability of the ATM protein in the cell.  
     Two of the sequence changes (3383A/G (Q1128R) and 5041A/G (I1681V)) 
involved the substitution of an amino acid that was not conserved between the 
mouse and human ATM sequence. Nevertheless, these changes were still 
considered to be mutations as they fulfilled the ‘mutation criteria’ that had 
been defined for this study. For the change 3383A/G (Q1128R), the mutation 
would result in the substitution of one charged hydrophilic residue for another, 
whereas the change 5041A/G (I1681V) would result in the exchange of 
uncharged hydrophobic residues. Interestingly, this second sequence change 
occurred in combination with the 5044G/T (D1682Y) mutation, involving the 
conserved adjacent amino acid residue in the same individual. As such it is 
possible that it is the combination of the two amino acid substitutions which 
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impacts on ATM function. The 5041A/G sequence change was also shown to 
be an acquired alteration that was absent from the patient’s germ-line DNA, 
thus providing further evidence that this change was indeed a mutation rather 
than a polymorphism. Unfortunately, there was no germ-line material available 
on the patients with the 3383A/G sequence alteration so it was not possible to 
determine if this represented an acquired or germ-line change. 
 
4.3.2.3 Other ATM mutations  
     In addition to the nucleotide substitutions there was one mutation that 
resulted in an in-frame change in the coding sequence due to an insertion of 
nine nucleotides (2929Ins9), which would be predicted to result in an insertion 
of three amino acids, and one mutation that resulted in an in-frame change 
due to a deletion of three nucleotides (3883Del3), which would be predicted to 
result in a deletion of an amino acid in the translated protein. Neither of these 
changes had been previously reported. 
    Three of the sequence changes were classified as mutations because they 
have been previously reported to cause abnormal exon splicing (IVS16-
10T/G, IVS62-1G/T, 8592C/T). The changes IVS16-10T/G and IVS62-1G/T 
have been reported in AT patients. The IVS16-10T/G change, leads to an 
insertion of three amino acids and results in the generation of a new splice 
acceptor site (Telatar M et al, 1998) and the IVS62-1G/T change is known to 
cause aberrant exon splicing (Sandoval N et al, 1999). The 8592C/T 
sequence change has not been reported in AT patients but has been 
previously detected in association with cancer and is predicted to result in the 
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disruption of an exon splicing enhancer sequence (Thorstenson Y et al, 
2003).  
 
4.3.3 ATM polymorphic changes in the CLL patients 
    Thirty-three changes were classified as polymorphisms including 23 within 
the coding sequence (146C/G, 378T/A, 795T/C, 998C/T, 1176C/G, 1254A/G, 
1986T/C, 2119T/C, 2572T/C, 2805G/C, 3161C/G, 4138C/T, 4258C/T, 
4578C/T, 4802G/A, 5071A/C, 5352C/T, 5557G/A, 5558A/T, 5793T/C, 
5821G/C, 6820G/A, 9200C/G) and ten within flanking intronic sequences 
(IVS8+38T/C, IVS19-17G/T, IVS25-15delA, IVS29-33C/T, IVS33+25A/G, 
IVS38-8T/C, IVS52+4A/G, IVS54+8G/T, IVS61+9T/G, IVS62+8A/C). Sixteen 
of these changes were detected in multiple CLL patients and twenty-six of the 
changes have been reported to be polymorphisms in the literature (Table 4.2). 
Two changes in the coding sequence (5352C/T, 5821G/C) and five within 
introns (IVS29-33C/T, IVS33+25A/G, IVS52+4A/G, IVS54+8G/T, 
IVS61+9T/G) were also classified as polymorphisms in this study, although 
they had never been previously reported as such. The 5352C/T is a silent 
change that would not result in a change of amino acid in the translated 
protein. The 5821G/C was initially considered to be a mutation but was 
subsequently re-classified as a polymorphism because it was not only 
detected in two CLL patients but also within an individual from the control 
population. Furthermore, this change was present in the germ-line as well as 
within the tumour material in both CLL patients. The change IVS54+8G/T has 
been reported in the germ-line of patients with breast cancer but since it was 
also detected in two individuals from the control population in this study it was 
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classified as a polymorphic change (Teraoka S et al, 2001). The remaining 
intronic changes were also absent from the control population. However, 
although they had not been previously reported, since they were located 
within the intronic sequence and unlikely to impact on the protein they were 
designated as polymorphisms rather than mutations. 
 
 
4.4 Prevalence and distribution of ATM mutations in the cohorts 
      Having screened the tumour samples for sequence changes in the ATM 
gene and categorised the changes as mutations and polymorphisms, I was 
then able to determine the prevalence of the ATM mutations in each of the 
two CLL patient cohorts.  
 
4.4.1 The unselected cohort of 155 CLL patients 
    There were twenty-two ATM mutations in eighteen of the CLL tumours from 
the unselected cohort of 155 patients and this represented a prevalence of 
CLL tumours carrying ATM mutations of 12%. Five mutations were non-sense 
changes, fourteen mutations were mis-sense changes, one mutation was an 
in-frame insertion, and two mutations were predicted to interfere with exon 
splicing.  
    In seven tumours there was a predicted loss of both functional ATM alleles; 
in three cases (CLLs 96, 11 and 77) due to more than one ATM mutation 
detected and in four cases (CLLs 07, 15, 57 and 152) due to an ATM mutation 
in combination with a deletion of the remaining ATM allele on chromosome 
11q. In the remaining ten tumours a single ATM mutation was detected but 
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there was no loss of the remaining ATM allele through a chromosome 11q 
deletion (Table 4.3).  
    In this cohort the mutations were distributed across the coding sequence of 
the gene and even when considering only the mis-sense changes there was 
an absence of clear clustering within the conserved C terminal region of the 
gene including the kinase and FAT domains. There were 3 mutations 
(9022C/T (R3008C), 8839A/T (T2946S) and 8600G/A (G2867E)) in the kinase 
domain and 3 mutations (5980A/G (K1994E), 7047C/G (C2349W) and 
7313C/A (T2438K)) in the FAT domain. The distribution of all the 14 mis-
sense changes plus the in-frame insertion from this cohort is shown in Figure 
4.1. Interestingly, three of the changes within these two functional domains 
were in tumours that also had a deletion of chromosome 11q and were 
therefore common to both cohorts. 
 
 
4.4.2 The selected CLL cohort of 53 tumours 
    I detected mutations in the ATM gene in 20 out of 53 tumours in the cohort 
of tumours that all had loss of one ATM allele, indicating a prevalence of 38% 
(Table 4.4).  Six of the mutations were predicted to lead to a truncated protein 
(CLLs 166, 183, 178, 198, 57, 170), one mutation was localised at an exon-
intron boundary and had previously been reported to result in abnormal exon 
splicing (CLL 192), one mutation was an in-frame deletion (CLL180) and the 
remaining twelve mutations were mis-sense changes. All the mis-sense 
changes detected in this cohort involved residues that were conserved across 
species. 
 73
Table 4.3 - ATM mutations in unselected cohort of 155 CLL tumours 
Tumour 
 
Nucleotide 
change 
Protein change Mutation in 
germ-line 
Conserved 
between 
human and 
mouse 
sequence 
Loss of 
heterozygosity 
through a 
deletion of 
chromosome 
11q 
CLL77* 
 
1058delGT 
5224G/C 
Truncated  
A1742P 
Yes 
No 
NA 
Conserved 
No 
CLL96* 
 
2929ins9 
5041A/G 
5044G/T 
Inframe insertion 
I1681V 
D1682Y 
No 
No 
No 
NA 
Not conserved 
Conserved 
No 
CLL11* 
 
7313C/A 
8833del34 
T2438K 
Truncated  
No 
No 
Conserved 
NA 
No 
CLL57*¹ 2308G/T 
 
E770X No NA Yes 
CLL15*¹ 7047C/G 
 
C2349W No Conserved Yes 
CLL07*¹ 8600G/A 
 
G2867E No Conserved Yes 
CLL152*¹ 8839A/T 
 
T2946S No Conserved Yes 
CLL27 3383A/G 
 
Q1128R NK Not conserved No 
CLL75 1009C/A 
 
R337S No Conserved No 
CLL69 6815delA 
 
Truncated  No NA No 
CLL119 9022C/T 
 
R3008C No Conserved No 
CLL93 
 
5290del C Truncated  No NA No 
CLL92 5980A/G 
 
K1994E No Conserved No 
CLL124 5228C/T 
 
T1743I No Conserved No 
CLL84 8592C/T 
 
Splicing defect NK NA No 
CLL113 3964C/A 
 
L1322F Yes Conserved No 
CLL147 IVS16-10T/G Splicing defect 
 
NK NA NK 
CLL81 5882A/G Y1961C Yes Conserved 
 
¹ Denotes tumours common to both cohorts 
* Denotes tumours with loss of both functional ATM alleles 
 
No 
Figure 4.1 
The mis-sense changes detected in the unselected cohort of 155 patients 
were distributed across the whole protein and were not clustered within the 
functional domains. 
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Figure 4.1
    In each tumour there was only one ATM mutation detected but since all the 
tumours had loss of heterozygosity at the ATM gene locus, all 20 tumours 
with an ATM mutation would be predicted to have lost both functional alleles. 
In the remaining 33 tumours, no mutation was detected in the second ATM 
allele and therefore these tumours were heterozygous at the ATM gene as a 
result of a single allele deletion. 
     In contrast to the unselected cohort, within this cohort of tumours that all 
had a monoallelic loss of an ATM allele through a deletion of chromosome 
11q, there was a tendency for the sequence changes to be clustered towards 
the C terminal region of the gene most particularly when only the missense 
changes were considered. Six mis-sense changes were located in the kinase 
domain (9023G/A (R3008H), 8861A/G (Y2954C), 8839A/T (T2947S), 
8600G/A (G2867E) and 8249T/C (L2750S) (x2)), and four within the FAT 
domain (7047C/G (C2349W), 6106T/A (Y2036N), 6067G/A (G2023R) and 
5980A/G (K1994E)). The distribution of the 12 mis-sense changes and the in-
frame deletion is shown in figure 4.2. 
 
4.4.3 Comparison between the two CLL cohorts 
     In this study, ATM mutations were greater than three fold more common in 
the selected cohort of tumours, which all had an 11q deletion, compared to 
the unselected CLL tumours. This suggests that either loss of one allele at the 
ATM locus predisposes to the development of ATM mutations, or that those 
tumours with ATM mutations are at risk of developing a chromosome 11q 
deletion. The nature of the mutations was similar in both cohorts, with mis-
sense changes being the most common genetic alteration. However, the 
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Table 4.4 - ATM mutations in selected cohort of 53 CLL patients with a 
deletion of chromosome 11q 
Tumour 
 
Nucleotide 
Change 
Protein 
Change 
Mutation 
in 
germline 
Conservation 
between  
human and mouse 
CLL189 9023G/A R3008H No Conserved 
 
CLL166 8977C/T R2993X ND NA 
 
CLL174 8861A/G Y2954C No Conserved 
 
CLL152¹ 8839A/T T2947S No Conserved 
 
CLL192 IVS62-1G/T Splice defect No NA 
 
CLL07¹ 8600G/A G2867E No Conserved 
 
CLL200 8249T/C L2750S Yes Conserved 
 
CLL182 8249T/C L2750S ND Conserved 
 
CLL193 8056T/C F2686L No Conserved 
 
CLL183 7883del5 Truncated ND NA 
 
CLL15¹ 7047C/G C2349W No Conserved 
 
CLL162 6106T/A Y2036N No Conserved 
 
CLL203 6067G/A G2023R Yes Conserved 
 
CLL169 5980A/G K1994E No Conserved 
 
CLL178 4591C/T Q1531X ND NA 
 
CLL180 
 
3883del3 Deletion L ND NA 
CLL198 3649delC 
 
Truncated No NA 
CLL173 2417T/G 
 
L806W No Conserved 
CLL57¹ 2308G/T 
 
E770X No NA 
CLL170 1120C/T Q374X No 
 
 
NA 
 
¹ Denotes tumours common to both cohorts 
 
 
Figure 4.2 
There was clustering of the predicted mis-sense changes across the ATM 
protein in the cohort of tumours that all had a deletion of chromosome 11q. 
There were six mis-sense mutations within the kinase domain and four 
mutations detected within the FAT domain of the protein. 
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Figure 4.2
distribution of the mutations varied between the two cohorts. The mis-sense 
changes in the unselected cohort were distributed across the coding 
sequence whereas the mis-sense changes in the 11q deleted cohort were 
clustered at the C- terminal part of the gene, in a pattern reminiscent to that 
reported in T-PLL, a tumour that is also characterised by loss of 
heterozygosity at the ATM locus.  
     There is marked homology of the ATM kinase domain, FAT and FATc 
domains between PIKK family members. The conservation of the gene 
sequence in these domains suggests that an alteration of even a single amino 
acid may be poorly tolerated and have an impact on the function of the 
protein.    
     My results show that sporadic mutations in the conserved kinase and FAT 
domains are invariably accompanied by loss of heterozygosity in CLL 
tumours. In the absence of such loss of heterozygosity, ATM mutations may 
fail to provide the tumour cell with any ‘proliferative’ or ‘survival’ advantage 
because the wild type allele is sufficient for normal ATM activity. By 
comparison, mutations located outside these domains might have a different 
mechanism of action. The function of the majority of the N-terminal two thirds 
of the gene appears to be related to the tertiary structure of the protein and, 
therefore, mutations in this region might affect the stability of the protein in the 
cell and it is possible that a pathogenic effect might occur in the absence of 
loss of the remaining ATM allele. 
 
4.5 Frequency of sequence changes in CLL patients and controls 
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    A secondary aim described in this chapter was to study the relationship 
between the frequency of germ-line ATM sequence changes between CLL 
patients and controls. The presence of a higher frequency of germ-line ATM 
mutations in CLL patients compared to controls could indicate that 
heterozygous mutations in ATM act as a predisposing factor for the 
development of CLL. Furthermore, it is also possible that ATM polymorphisms 
could contribute to the development of CLL and an increased association of a 
polymorphism with CLL patients compared to controls would support this 
concept. (The DHPLC mutation screening of the ATM gene in the control 
population was performed by technicians in our laboratory.) 
 
 4.5.1 Germ-line ATM mutations in CLL patients  
      I obtained germ-line material from 26 CLL patients with identified ATM 
mutations and in these cases it was therefore possible to determine whether a 
mutation was sporadic and acquired in tumour cells or whether the patient 
was a heterozygous carrier of a germ-line mutation. Twenty-three of the ATM 
mutations detected in patients’ tumour cells from 21 patients, were shown to 
be sporadic and had thus been acquired during some stage of tumorigenesis 
(1009C/A, 1120C/T 2308G/T 2417T/G, 3651delG, 5041A/G, 5044G/T, 
5224G/C, 5228C/T 5290delC, 5980A/G, 6106T/A, 6815DelA, 7047C/G, 
7313C/A, 8056T/C, 8600G/A, 8833Del34, 8861A/G, 8839A/T, 9022C/T, 
9023G/A, IVS62-1G/T). The confirmation of the acquired nature of these 
sequence changes provides further evidence that they are indeed likely to 
represent mutations with a pathologic effect.   
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      Five of the ATM sequence changes classified as mutations in this study in 
the CLL tumour cohorts were also present in the same patient’s germ line 
namely, 1058DelGT, 3964C/A (L1322F), 5882A/G (Y1961C), 6067G/A 
(G2023R) and 8249T/C (L2750S).  
 
4.5.2 Germ-line ATM mutations in the control population 
      There were 8 sequence changes (162T/C (Y54Y), 609C/T (D203D), 
1727T/C (I576T), 3419A/G (N1140S), 4167A/G (T1389T), 4980C/T (N1660N), 
7390T/C (C2464R), IVS49+13insT) that were detected in the control 
population that were absent from the CLL population and had not been 
previously reported as a polymorphism. Four of the changes (162T/C (Y54Y), 
609C/T (D203D), 4167A/G (T1389T), 4980C/T (N1660N)) would not result in 
an amino acid substitution in the translated protein and have not been 
reported to affect splicing and therefore these changes almost certainly 
represent rare polymorphisms. The sequence alterations IVS49+13insT has 
not been previously reported but due to its intronic location is likely to be a 
polymorphism. The sequence change 3419A/G (N1140S) was present in four 
of the controls and therefore, although this alteration had not been previously 
reported, due to this high frequency I considered that it was more likely to be 
a polymorphism rather than a mutation. The remaining two mis-sense 
changes (1727T/C (I576T), 7390T/C (C2464R)) were present in a single 
individual and were designated as germ-line ATM mutations. The 7390T/C is 
located within the FAT domain in the ATM gene and has been previously 
reported in patients with breast cancer, thus increasing the likelihood that this 
is a true mutation (Teroka S et al, 2001). By comparison, the 1727T/C 
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sequence change is not located within any known functional ATM domain and 
has never been previously reported, however this change does involve a 
residue that is conserved between human and mouse species. 
     Altogether, therefore, I found that 2 out of 161 (1.2%) controls and 5 out of 
198 (2.5%) CLL patients had a germ-line ATM mutation (Table 4.5). These 
differences were not statistically significant (Chi-squared test). The small 
number of patients with germ-line ATM mutations detected in this study would 
indicate that a much larger study would be required to assess whether there 
was indeed a true difference between the two populations. The frequency of 
heterozygous ATM mutation carriers in the UK population has previously been 
estimated to be in the order of 0.5% and the frequency in the CLL patients in 
the previous study of 50 patients was 6% (3/50) (Stankovic et al, 1998, 
Stankovic et al, 2002). These estimates had indicated that there would be the 
possibility of detecting a significant difference between the two populations by 
a case-control comparison, where the size of those two populations was in the 
order that were studied in this project. However, this did not prove possible 
due to the lower frequency of germ-line ATM mutations detected in the CLL 
patients in my study. 
        There were several CLL patients where mutations were detected in the 
tumour cells but where there was no germ-line material available in this study. 
These mutations could have potentially represented germ-line changes and 
could therefore have resulted in an underestimation of germ-line mutations in 
the patient population. Alternatively, it is possible that some of the changes 
categorised as germ-line mutations in both patients and controls could have 
actually represented rare polymorphisms and this particularly applies to the 
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 Table 4.5 – Germ-line ATM mutations in CLL patients and controls 
 
Sequence 
Change 
 
Protein Change CLL patient or 
Control 
Domain Conserved 
between 
human and 
mouse 
1058DelGT Truncation CLL patient  n/a  n/a 
1727T/C I576T Control None Yes 
3964C/A L1322F CLL patient None Yes 
5882A/G  Y1961C CLL patient None Yes 
6067G/A  G2023R CLL patient FAT Yes 
7390T/C C2464R Control FAT Yes 
8249T/C L2750S CLL patient  Kinase Yes 
 
mis-sense changes located outside of any functional ATM gene domains. It 
can be difficult to classify germ-line sequence alterations and, ideally, one 
would like to test the consequences of any potential germ-line mutations using 
an in vitro modelling system, as discussed later. 
     
4.5.3 ATM polymorphisms in the CLL patients and controls 
    I also compared the allelic frequency of polymorphic changes between the 
unselected CLL patient cohort and the control population (Table 4.6). I was 
aware that in order to detect a potentially significant association of any 
individual polymorphism with the CLL patients it is likely to require larger 
populations than studied here, unless there is a very marked difference. 
However, given the size of the ATM gene, a large case-control study to 
address the total ATM allelic differences between a control and CLL 
population is a longer-term project. Therefore, the purpose of this part of the 
study was to provide a preliminary observation that could hopefully aid large 
population based comparisons of the frequency of specific ATM variants. 
         The polymorphisms in the CLL patients were detected in the tumour 
cells rather than in germ-line material and I made the assumption that these 
polymorphisms would also be present in the patients’ germ-line. Since all the 
tumours with an 11q deletion had loss of one ATM allele, the 53 11q-deleted 
tumours were not included in this comparison due to their potential to 
negatively bias the frequency of a polymorphism in the CLL patients. 
Therefore, a comparison was made between 145 CLL patients and 161 
controls. By using the DHPLC technique, there was also the theoretical 
possibility of underestimating any polymorphism that was a homozygous 
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Table 4.6 – Comparison of the frequency of polymorphisms in CLL 
patients and control individuals 
Sequence 
Change 
Amino 
Acid 
change 
Frequency 
in 145 CLL 
patients 
CLL 
Allelic 
Frequenc
y 
(n/290) 
Frequency 
in 161 
controls 
Control 
Allelic 
Frequenc
y 
(n/322) 
Ratio 
CLL / 
Control 
146C/G S49C 1/145 0.0034 2/161 0.0062 0.55 
162T/C Y54Y 0/145 0 1/161 0.0031 0 
609C/T D203D 0/145 0 1/161 0.0031 0 
378T/A D126E 2/145 0.0068 0/161 0 na 
998C/T S332F 1/145 0.0034 0/161 0 na 
1176C/G G393G 1/145 0.0034 0/161 0 na 
1254A/G E418E 1/145 0.0034 0/161 0 na 
2119T/C S707P 4/145 0.014 7/161 0.022 0.64 
2572T/C F858L 6/145 0.021 5/161 0.016 1.3 
2805G/C T935T 1/145 0.0034 0/161 0 na 
3161C/G P1054R 7/145 0.024 12/161 0.037 0.64 
3419A/G N1140S 0/145 0 4/161 0.012 0 
4138C/T H1380Y 1/145 0.0034 0/161 0 na 
4167A/G T1389T 0/145 0 1/161 0.0031 0 
4258C/T L1420F 8/145 0.028 9/161 0.028 1 
4578C/T P1526P 11/145 0.038 14/161 0.043 0.88 
4980C/T N1660N 0/145 0 1/161 0.0031 0 
5071A/C S1691R 0/145 0 2/161 0.0062 0 
5352C/T N1734N 1/145 0.0034 0/161 0 na 
5557G/C D1853N 33/145 0.11 66/161 0.20 0.55 
5558A/T D1853V 1/145 0.0034 0/161 0 na 
5793T/C A1931A 4/145 0.014 1/161 0.0031 4.5 
5821G/C V1941L 2/145 0.0068 1/161 0.0031 2.2 
6820G/A A2274T 1/145 0.0034 2/161 0.0062 0.55 
IVS8+38T/C  1/145 0.0034 0/161 0 na 
IVS19-17G/T  1/145 0.0034 0/161 0 na 
IVS21-22 del T  0/145 0 4/161 0.012 0 
IVS25-15delA  26/145 0.089 18/161 0.056 1.59 
IVS29-33C/T  1/145 0.0034 0/161 0 na 
IVS38-15G/C  0/145 0 1/161 0.0031 0 
IVS38-8T/C  3/145 0.010 11/161 0.034 0.29 
IVS49+13insT  0/145 0 1/161 0.0031 0 
IVS52+4A/G  1/145 0.0034 0/161 0 na 
IVS54+8G/T  1/145 0.0034 2/161 0.0062 0.55 
IVS61+9T/G  1/145 0.0034 0/161 0 na 
IVS62+8A/C  
 
15/145 0.052 6/161 0.019 2.74 
3’UTR 
9200C/G 
 3/145 0.010 2/161 0.0062 1.61 
variant in an individual. This would mainly apply to the most common 
sequence changes such as 5557G/A, and any effect would be expected to 
impact equally on patient and control groups. 
      For the majority of polymorphisms the frequency was comparable 
between the CLL patients and the controls (Table 4.6). Thirteen of the 
changes were absent from the control population and only present in the CLL 
population but in all cases they were only present in 1 or 2 CLL patients. Four 
of these polymorphisms (378T/A, 4138C/T, IVS8+38T/C and IVS19-17G/T) 
were associated with ethnic origin and the polymorphisms were found in CLL 
patients of Afro-Caribbean ethnicity, whereas no individuals were known to be 
Afro-Caribbean amongst the control population. By contrast, nine 
polymorphisms were present in the controls that were absent from the patient 
population. Once again the majority of these changes were only present in 1 
or 2 controls suggesting that this is likely to be a chance effect. Two changes 
(3419A/G and IVS21-22delT) were present in 4 controls and no CLL patients 
but it is unlikely that the absence of a polymorphism could have any 
pathological effect and therefore this is also likely to be a chance association. 
Fifteen changes were present in both patient and control populations and for 
these cases the CLL to Control frequency ratio ranged from 0.29 to 4.5 (Table 
4.6). Six changes were more common in CLLs than controls, namely 2572T/C 
(F585L) (ratio 1.3), 5793T/C (A1931A) (ratio 4.5), 5821G/C (ratio 2.2), IVS25-
15delA (ratio 1.59), IVS62+8A/C (ratio 2.74) and 9200C/G (ratio 1.61). The 
5793T/C, 5821G/C and 9200C/G sequence changes were each only present 
in up to 5 individuals and therefore any potential significance is hard to 
interpret. Of the remaining three polymorphisms only the IVS62+8A/C change 
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was present at a statistically significantly higher level in the CLL patients 
compared to controls (Chi-squared text, X2 = 4.24 [0.01>p< 0.05]). This 
intronic change has not been previously found to be associated with 
malignancy but due to its location there is a possibility that this change could 
interfere with exon splicing.  
     Interestingly the 2572T/C (F585L), which occurred in 6 patients and 5 
controls in this study, has been previously found to be significantly associated 
with CLLs compared to controls in a much larger case-control study using 
SNP arrays (Rudd MF et al, 2006). This same study also found an association 
between the 3161C/G (P1045R) change and CLL, but in my project this 
alteration was actually more common in the control population.  
      
4.6 Conclusion 
    By analysing the two large CLL cohorts I have been able to show that ATM 
mutations are present in 12% of unselected CLL tumours and in 38% of 
tumours that have all lost one ATM allele through a chromosomal 11q 
deletion. Thus, the presence of loss of heterozygosity at the ATM locus is 
associated with a greater than three-fold increased frequency of ATM 
mutations in CLL tumours. The majority of these mutations were mis-sense 
changes and, interestingly, whilst there was no clustering pattern of mis-sense 
mutations observed within the unselected CLL tumours, within the tumours 
with loss of heterozygosity at the ATM locus, mis-sense ATM mutations 
showed a tendency to cluster within functional domains of the ATM gene at 
the C-terminus in this study. This latter pattern is reminiscent of the pattern 
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seen in T-PLL and MCL, whereas the former pattern resembles that which 
has been previously described in CLL series. 
    Most of the ATM mutations described here were acquired sporadic 
changes but there were a small number that represented germ-line changes. 
There was a small increase in the frequency of germ-line ATM mutations in 
the CLL patients by comparison to a control population but this was not 
statistically significant. A comparison of allelic variants, in this study, showed 
that the IVS62+8A/C change was more common in the CLL patients than in 
the control population. 
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Results 2 
 
The clinical consequences and time of acquisition of ATM 
mutations in CLL patients  
 
5.1 Introduction 
      A key aspect of my project has been to assess the consequences of ATM 
mutations on clinical outcome in CLL patients. Previously, ATM mutations 
have been found to be associated with certain poor prognostic features in CLL 
patients such as advanced stage and unmutated IGVH genes (Stankovic T et 
al, 2002, Pettitt AR et al, 2001) but their direct clinical impact has never been 
determined. By comparison, the detrimental effect on clinical outcome in CLL 
patients as a result of an 11q deletion, which results in the mono-allelic loss of 
a number of genes including ATM, is well established (Dohner H et al, 1999, 
Stilgenbauer S et al, 1996). Interestingly, it also remains unknown whether, 
within the subgroup of CLL patients that have an 11q deletion, there is a 
further impact on clinical outcome in those patients, which in addition to loss 
of one ATM allele, also have a mutation in the second ATM allele.  
     In order to compare the potential effect of a biological marker in a 
heterogeneous group of patients one can measure outcome parameters from 
diagnosis such as time to requirement of treatment (treatment free survival 
[TFS]) or overall survival [OS]). For these measures to reliably determine the 
effect of the marker, such as an ATM mutation, requires that the marker is 
present at the time of diagnosis. As I concluded in the last chapter, the 
majority of ATM mutations in CLL tumours were acquired within the tumour 
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cells and only a minority represented germ-line mutations. The timing of the 
acquired ATM mutations relative to the disease course is therefore important 
when assessing their potential impact on clinical outcome in CLL patients.            
      In this chapter, therefore, I have investigated the clinical effects of the 
ATM mutations in CLL patients. Initially, I have evaluated the impact of ATM 
mutations by assessing TFS and OS in the 155 patients from the unselected 
cohort and, subsequently, I have investigated the associations of ATM 
mutations with other prognostic parameters.  
      In addition, I investigated the clinical outcome in the cohort of 53 patients 
that all had a deletion of chromosome 11q. Here, I aimed to address the 
specific question, as to whether the addition of a mutation in the remaining 
ATM allele could further impact on outcome in this subgroup of CLL patients 
that already have a poor outlook. 
    Finally, I have studied the timing of the ATM mutations in relation to CLL 
ontology to determine both how this impacts on measurements of disease 
outcome and also to gain further insight into disease biology in order to 
assess how this may affect future treatment strategies. 
 
  
5.2 Nature and clinical characteristics of the unselected CLL cohort 
    The nature of the unselected CLL cohort and the way that it was 
established is described in results chapter one. Briefly, patients were included 
on the basis of having a diagnosis of CLL and attending specific outpatient 
clinics over a defined study period. This led to a cohort where patients had 
originally been diagnosed with their disease over a considerable range of 
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time. From the cohort of 155 patients, 49 patients were diagnosed prior to 
1996, 54 patients between 1997 and 2000, and 51 patients between 2001 and 
2003. The assessment of disease outcome was based on survival and 
treatment status on December 1st 2004. Therefore, this represented a 
retrospective study with outcome measures taken from diagnosis. Due to the 
variation in the time of diagnosis, there was consequently considerable 
variation in the length of follow up, which ranged from a minimum of 25 
months to a maximum of 217 months. The median follow up from diagnosis 
was 71 months. 
    The cohort of 155 patients consisted of 91 men and 64 women and the age 
ranged from 28 to 92 years, with a median age of 67 years.  At diagnosis, 120 
patients had Binet stage A disease, and 31 patients had more advanced 
stage disease (Binet stages B or C). The IGVH mutation status had been 
determined on the majority of the patients that formed this cohort. Forty-one 
patients were found to have unmutated IGVH genes and 97 patients to have 
mutated IGVH genes. Unfortunately, FISH data was not available on all 
patients but either karyotypic or FISH data was obtained on 77 patients from 
this cohort and 9 patients (12%) were known to have a chromosome 11q 
deletion. At the time of data analysis, 71 patients had received treatment for 
their disease and 34 patients had died (Table 5.1). 
 
 
5.3 Impairment of clinical outcome in patients with ATM mutations 
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Table 5.1 – Clinical characteristics of the cohort of 155 CLL patients 
Parameter 
 
155 CLL cohort 
Male : Female 91:64 
 
Median age at 
Diagnosis (years) 
67 
Age range at 
Diagnosis (years) 
28 - 92 
Stage at diagnosis 
A 
B or C 
(n=151) 
120 
31 
Stage at genetic analysis 
A 
B or C 
(n=147) 
73 
74 
IGVH mutation status 
Unmutated 
Mutated 
(n=138) 
41 
97 
Chromosome 11q status 
Deletion 
No deletion 
(n=77) 
9 
68 
Era of diagnosis 
Pre 1996 
1997-2000 
2001-2003 
 
49 
54 
51 
Median follow up (months) 
 
71 
Range of follow up (months) 
 
25 - 217 
Number of patients treated 
(December 2004) 
(n=152) 
71 
Percentage treated 
 
47 
Median time to treatment 
(months) 
90 
Number of patients died 
(December 2004) 
(n=154) 
34 
Percentage died 
(%) 
22 
Median Survival 
(months) 
>220 
 
    In order to investigate the clinical impact of ATM mutations, I compared 
overall survival and treatment free survival between patients with ATM 
mutations and those that had wild type ATM.     
    Altogether, 34 out of 155 CLL patients had died at the time of the data 
analysis on December 1st, 2004. Amongst the patients with wild type ATM, 
26/137 individuals had died, representing 19%, and amongst patients with 
ATM mutations 8/17 individuals had died, representing 47% (Table 5.2).  Due 
to the variation in the length of follow up between patients, it was necessary to 
plot Kaplan Meier survival curves and use the log rank test to determine if 
there was a significant difference in survival outcome according to ATM 
mutation status. Using these methods, I was able to confirm that patients with 
ATM mutations had a significantly shorter survival from diagnosis compared 
to patients with wild type ATM (p=0.0034) (Figure 5.1).    
    In addition, I was able to show that patients with an ATM mutation in their 
tumour cells had a statistically significant reduction in treatment free survival, 
p=0.007, compared to patients whose tumours retained a wild type ATM gene 
(Figure 5.2). Altogether, 71 of 152 CLL patients from the cohort (47%) had 
received treatment for their disease at the time of data analysis and amongst 
the patients with wild type ATM 59/135 (44%) patients had been treated 
compared to 12/17 (71%) of patients with ATM mutations (Table 5.2).  
 
5.4 Relationship between ATM mutations and other biomarkers 
    I reasoned that the poorer overall and treatment free survival observed in 
the patients with ATM mutations could be due to a positive association 
between ATM mutations with other prognostic factors including age, gender, 
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Table 5.2 – Clinical characteristics of the cohort of 155 CLL patients 
according to the mutation status of the ATM gene 
 
Parameter Wild type (n=137) ATM mutant (n=18) 
 
Male : Female 
(M/F ratio) 
81:56 10:8  
Median age at 
diagnosis (years) 
 66 68 
Stage at Diagnosis 
A 
B or C 
(n=134) 
107 
27 
(n=17) 
13 
4 
Stage at genetic 
analysis 
A 
B or C 
(n=130) 
 
66 
64 
(n=17) 
 
7 
10 
IGVH gene 
Unmutated 
Mutated 
(n=120) 
31 
89 
(n=18) 
10 
8 
11q deletion (n=77) 
present 
absent 
(n=60) 
5 
55 
(n=17) 
4 
13 
TP53 status 
Mutant 
Wildtype 
(n=137) 
4 
133 
(n=18) 
2 
16 
Era of diagnosis 
Pre-1996 
1997-2000 
2001-2003 
 
44 
47 
46 
 
5 
7 
5 
Median follow up 
(months) 
68.5 79 
Range of follow up 
(months) 
25-217 26-156 
Number of patients 
treated 
(n=135) 
59 
(n=17) 
12 
Percentage treated 
(%) 
44 71 
Median time to 
treatment (months) 
(n=152) 
130 (n=135) 40 (n=17) 
Number of patients 
died 
(n=137) 
26 
(n=17) 
8 
Percentage died 
(%) 
19 47 
Median Survival 
(months) 
(n=154) 
>217 (n=137) 
 
85 (n=17) 
 
Figure 5.1 
 
There is reduced overall survival of CLL patients whose tumour cells have 
ATM mutations in comparison to those with wild type ATM. This difference is 
statistically significant (p=0.0034). 
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Figure 5.2 
 
There is significantly reduced treatment free survival of CLL patients whose 
tumour cells have ATM mutation in comparison to those with wild type ATM 
(p=0.007). 
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stage, IGVH mutation status, TP53 mutation status and cytogenetic 
abnormalities. Increased age, male sex, advanced clinical stage, unmutated 
IGVH genes and TP53 mutations are all known to be associated with a poorer 
outcome in CLL patients (Catovsky D et al, 1989, Chiorazzi N et al, 2005, 
Sellick GS et al, 2006, Hamblin T et al, 1998, Dohner H et al, 1999).  The 
cytogenetic changes that are associated with poor clinical outcome are 
deletions of chromosome 17p, which lead to the loss of the TP53 gene and 
are associated with tumours with TP53 mutations, and deletions of 11q that 
lead to the loss of one ATM allele. The relationship between ATM mutations 
and these prognostic factors in the cohort of 155 unselected patients is 
considered below and summarised in Tables 5.2 and 5.3.  
     
5.4.1 Age and Gender 
    There was no difference in the median age at diagnosis between patients 
with ATM mutations (68 years) and those with wild type ATM genes (66 
years). The male to female ratio (M:F) in the CLL patients whose tumours had 
ATM wild type genes was approximately 7:5, and a slightly higher proportion 
of women was noted amongst the ATM mutant CLLs (M:F 5:4). Since women 
are known to have a better outcome then men in CLL, the higher proportion of 
women in the ATM mutant group would be expected, if anything, to reduce 
the negative impact of an ATM mutation.   
 
5.4.2 Disease Stage 
    There was no significant difference in the proportion of patients with limited 
stage disease (Binet stage A) versus those with advanced stage disease 
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Table 5.3 – Clinical parameters in patients with an ATM mutation from 
the 155 unselected cohort 
 
 
Patient 
 
Sequence 
change 
 
Protein  
 
Age at  
diagnosis 
 
Stage at 
diagnosis 
 
IGVH mutation 
status and 
family 
 
OS 
 
change mths 
TFS 
mths 
CLL77 
 
1058DelGT 
5224G/C 
Truncated 
protein 
A1742P 
62 B 99%, VH1-2, 83+ 0 
CLL96 
 
2929Ins9 
5041A/G 
5044G/T 
Inframe 
insertion 
I1681V 
D1682Y 
75 A 96%, VH4-61 79 33 
CLL11 
 
7313C/A 
8833Del34 
T2438K 
Truncated 
protein 
59 A 98%, VH3-15 156+ 108 
CLL57* 2308G/T 
 
Truncated 
protein 
68 A 97%, VH4-59 101+ 76 
CLL15* 7047C/G 
 
C2349W 61 A 100%, VH1-69 75 40 
CLL07* 8600G/A 
 
G2867E 74 A 99%, VH3-11 96 0 
CLL152* 8839A/T 
 
T2946S 77 C 99%, VH1-6 79+ 35 
CLL75 1009C/A 
 
R337S 52 B 98%, VH3-30 39 0 
CLL69 6815DelA 
 
Truncated 
protein 
67 A 100%, VH3-15 72+ 39 
CLL119 9022C/T R3008C 
 
62 A 97%, VH3-64 47+ 36 
CLL93 
 
5290del C Truncated 
protein 
69 A 100%, VH5-51 26+ 26+ 
CLL92 5980A/G 
 
K1994E 86 A 99%, VH1-69 24 24+ 
CLL124¹ 5228C/T 
 
T1743I 85 A 85%, VH3-15 48+ 48+ 
CLL84¹ 8592C/T 
 
Splicing 
defect 
89 A 93%, VH3-7 17 14 
CLL27 3383A/G 
 
Q1128R 74 C 99%, VH3-21 77 0 
CLL113 3964C/A 
 
L1322F 68 A 91%, VH3-7 24 24+ 
CLL147 IVS16-10T/G Exon skip 
 
nk nk 94%, VH5-51 NA NA 
CLL81 5882A/G Y1961C 65 A 93%, VH3-15 36+ 
 
36+ 
 
* Denotes tumours with an 11q deletion, ¹ Denotes tumours with a TP53 mutation 
nk  - not known,  + either still alive or untreated 
(Binet stages B and C) at the time of diagnosis between patients with ATM 
mutations (13 vs 4) and patients with wild type ATM genes (107 vs 27). At the 
time of genetic analysis, there was a slightly higher proportion of patients with 
ATM mutations with advanced stage versus limited stage disease (10 vs 7) 
compared to patients with wild type ATM genes (64 vs 66) however these 
differences remained non-significant. The date of the genetic analysis was an 
arbitrary one with respect to the course of any individual’s disease but 
occurred some time after the diagnosis for the majority of cases.  
 
5.4.3 IGVH mutation status 
    In contrast to age and stage, there was a significant association between 
ATM mutations and IGVH mutation status. In this study tumours were 
classified as having unmutated IGVH genes if there was 98% or greater 
concordance with the germ-line sequence and having mutated IGVH genes if 
there was less than 98% concordance with the germline sequence. 
Altogether, the IGVH mutation status was known on 138 patients and 41 
(30%) had unmutated IGVH genes. There was a higher proportion of tumours 
with unmutated IGVH genes among the subgroup of ATM mutant tumours 
56% (10/18) compared to either the ATM wild type tumours 26% (31/120). 
Therefore 10 of the 41 tumours with IGVH unmutated genes had ATM 
mutations (24%), compared to 8 of the 97 tumours with IGVH mutated 
tumours that had an ATM mutation (8%). Using Fisher’s exact test it was 
possible to show that there was statistically significant positive association 
between the tumours with unmutated IGVH genes and those with ATM 
mutations (p=0.024).  
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 5.4.3.1 ATM mutations and IGVH status in relation to clinical outcome 
      It was possible, therefore, that the poorer overall and treatment free 
survival in the genetic subgroup of patients with ATM mutations was due to 
the positive association of ATM mutations with unmutated IGVH genes, rather 
than resulting from the biological consequences of the ATM mutations 
themselves. To investigate this possibility the survival data was subjected to 
further analysis. 
    Firstly, the prognostic value of the mutation status of the IGVH genes was 
analysed in this series. As expected, regardless of the ATM mutation status, 
the TFS survival was significantly shorter in patients with IGVH un-mutated 
than in patients with IGVH mutated genes (p<0.0001). Surprisingly, however, 
the difference in OS between the IGVH unmutated and mutated subgroups 
did not reach significance in this series although, nevertheless, there was a 
trend for poorer OS survival in patients with unmutated IGVH genes (p<0.19). 
Interestingly, the 10-year OS for mutated IGVH patients in our cohort was 
shorter (72%, vs 85%) compared to a previously published report (Hamblin T 
et al, 1999). In contrast, there was no difference in the 10-year OS for the 
patients with unmutated IGVH genes between this series and the previously 
published one. Thus the failure of IGVH gene mutation status to significantly 
predict OS in my series appeared to be due to an excess of deaths in the 
group with mutated IGVH genes rather than a decreased death rate in those 
with unmutated IGVH genes. This could be reflection of the fact that the mean 
and median ages in my cohort were slightly higher than in the previous report. 
In support of this idea, the subgroup analysis of only younger patients (<65 
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years) in this study demonstrated that IGVH mutation status was significantly 
predictive of OS (p=0.034).  
      Multivariate analysis using Cox regression was then performed on the 135 
patients where information on age, disease stage, IGVH mutation status and 
ATM mutation status, was available. After adjustment for age, stage and 
IGVH mutation status, ATM mutations were still significantly predictive of OS 
(p=0.0025). The adjusted relative hazard (risk of death) for patients with ATM 
mutations, as compared to wild type, was 3.0 (95% confidence interval 1.23-
7.29). In other words, patients with ATM mutations had a 3 fold higher risk of 
death at any point during their disease course than patients without ATM 
mutations even after adjusting for age, stage and IGVH mutation status. This 
confirmed that ATM mutations are an independent predictor of OS in CLL 
patients, with respect to these parameters. 
    Multivariate analysis was also used to assess if ATM mutations were an 
independent predictor of TFS. Since advanced stage is a specified criterion 
for treatment in CLL, clinical stage was not included in the multivariate 
analysis for TFS (Oscier D et al, 2004).  By this method, it was possible to 
show that even after adjustment for age and IGVH status, ATM mutations 
were still significantly predictive of a shortened TFS (p=0.035). The relative 
hazard (risk of commencing treatment) for patients with ATM mutations, 
compared to wild type, was 2.44 (95% confidence interval 1.07-5.60). Thus, 
patients with ATM mutations were 2.44 times more likely to receive treatment 
than patients without ATM mutations even after adjustment for age and IGVH 
mutation status. This confirmed that ATM mutations are also an independent 
predictor of TFS in CLL patients with respect to age and IGVH status. 
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5.4.4 TP53 mutation status 
     Abnormalities in the TP53 gene that encodes the pro-apoptotic protein p53 
are also known to occur in CLL tumours and have been shown to be 
associated with a poor prognosis and treatment resistance in CLL patients. 
Previously, ATM mutations and TP53 mutations have occurred in distinct CLL 
tumour subgroups suggesting that they are identifying independent subgroups 
in CLL patients. In this project, I also screened the DNA from the 155 tumours 
for mutations in the TP53 gene and subsequently compared the outcome in 
the three genetic subgroups.  
         I found six TP53 mutations from the cohort of 155 tumours, which 
represented a prevalence of 4% (Table 5.4). Interestingly, I found that two of 
the tumours with a TP53 mutation (CLL 84 and 124) also had a heterozygous 
ATM mutation (Tables 5.3 and 5.4). This combination of genetic defects has 
not been previously described in CLL tumours. Altogether, from the 155 
tumours, there were therefore 16 tumours with an ATM mutation and wild type 
TP53, 4 tumours with a TP53 mutation and wild type ATM and 2 tumours with 
a mutation in both the ATM and TP53 genes. The prevalence of ATM 
mutations and TP53 mutations in the cohort of 155 patients was 12% and 4%, 
respectively. 
      I next compared the OS and TFS between the three genetic subgroups, 
namely the ATM mutant, TP53 mutant and ATM/TP53 wild type. Since TP53 
mutations are known to have a detrimental effect on survival, I categorised the 
2 tumours with an ATM and a TP53 mutation into the group of TP53 mutant 
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Table 5.4 - TP53 mutations in the cohort of 155 CLL patients 
 
Patient Sequence 
change 
Protein change  
 
 CLL29 807ins12 Inframe insertion 
CLL84¹ 797G/A G266Q  
CLL110 536A H179L 
 CLL124¹ 403T/C C135R 
 
 
        ¹ Denotes tumours with an ATM mutation – CLL84 (ATM mutation 8592C/T) and CLL124 
(ATM mutation 5228C/T) 
 
 
CLL70 739A/T N247Y 
CLL146 455C/T P152L 
tumours when making a comparison of the three genetic subgroups thereby 
preventing any bias towards adverse outcome in the ATM mutant group.  
       The difference in overall survival between all three genetic subgroups 
was also highly statistically significant (p<0.0001). The patients whose 
tumours carried TP53 mutations had the shortest OS, and the patients with 
ATM mutations had an OS that was intermediate with the two other genetic 
subgroups. The median OS was 85 months for patients with an ATM 
mutation, 44 months for patients with TP53 mutations and was not reached at 
greater than 12 years for patients with ATM/TP53 wild-type tumours (Figure 
5.3). There was also highly statistically significant difference in treatment free 
survival (p=0.00153) between the three genetic groups (Figure 5.4). The 
median TFS was 40 months for both patients with an ATM mutation and 
patients with a TP53 mutation in their tumour cells compared to 130 months 
for patients that had wild type ATM/TP53 genes.  
       These results show that ATM mutations have an adverse effect on 
survival in CLL patients, which is less severe than the effect of TP53 
mutations, and is also independent of TP53 mutations. 
 
5.4.5 Chromosome 11q deletion 
        CLL patients with a chromosome 11q deletion have a poor clinical 
outcome. By definition, these patients have loss of one ATM allele because it 
is an ATM probe that is used for the detection of the deletion. Therefore, I was 
interested to investigate the relationship between ATM mutations and 11q 
deletions in CLL patients, in terms of clinical parameters. From the cohort of 
155 patients, there was information on cytogenetic abnormalities on 77 
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Figure 5.3 
 
The overall survival of patients with ATM mutations was intermediate between 
the survival of patients with TP53 mutations and the survival of patients with 
wild type ATM and TP53 genes. In this analysis the two patients with a 
mutation in both TP53 and ATM genes were included in the category of 
patients with TP53 mutations. Therefore the poor outlook of the patients with 
ATM mutations was independent of TP53 mutations in this cohort. The 
differences between all three genetic subgroups were highly statistically 
significant (p<0.001). 
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Figure 5.4 
 
The effects of ATM mutations on treatment free survival were also 
independent of the presence of TP53 mutations. Both patients with ATM 
mutations and those with TP53 mutations had a significantly shorter treatment 
free survival than those patients with wild type ATM and TP53 genes.  
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tumours and there were 9 tumours that were known to have a deletion of 
chromosome 11q. Four of these nine tumours (44%) also had an ATM 
mutation, and 5 (56%) had wild type ATM. FISH analysis was available on 17 
patients with an ATM mutation and therefore 24% (4/17) also had a deletion 
of chromosome 11q. These results indicate that there is only a partial 
correlation between tumours with ATM mutations and those with an 11q 
deletion in this cohort. However, the 11q status was not known on all the 
patients that had wild type ATM in this study. Therefore in order to investigate 
the relationship between these two prognostic markers, I established the 
second cohort of 53 tumours that all had an 11q deletion.    
        This selected cohort of 53 patients with an 11q deletion consisted of 31 
men and 22 women. The median age at diagnosis was of 64 years and 
ranged from 24 to 90 years. The median follow-up from diagnosis was 78.5 
months and ranged from 12 to 324 months. The clinical stage at diagnosis 
was known for 47 patients, and 32 patients (68%) had limited stage A disease 
compared to 15 patients (32%) with advanced stage disease (B and C). The 
immunoglobulin VH status was known in 38 patients and 28 (74%) had un-
mutated VH genes (98% or greater concordance with the germ-line 
sequence) whereas 10 (26%) had mutated VH genes (less than 98% 
concordance with the germ-line sequence) The clinical characteristics of this 
total cohort and the two subgroups according to the status of the remaining 
ATM allele are summarised in Tables 5.5, 5.6 and 5.7. There were no 
significant differences in parameters such as age, clinical stage or IGVH 
mutation status between the two subgroups.  
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Table 5.5 – Clinical characteristics of 53 CLL patients with an 11q 
deletion 
 
Parameter 
 
Total cohort 
(n=53) 
Subgroup 
with a mutant 
ATM allele 
(n=20) 
Subgroup with 
a wild type 
ATM allele 
(n=33) 
Male : Female 
 
31:22 11:9 20:13 
Median age at 
Diagnosis (years) 
64 68 61 
Age range 
 
24-90 49-90 24-91 
Stage at diagnosis 
A 
B or C 
(n=47) 
32 
15 
(n=18) 
12 
6 
(n=29) 
20 
9 
IGVH mutation status 
Unmutated 
Mutated 
(n=38) 
28 
10 
(n=15) 
12 
3 
(n=23) 
16 
 7 
Range of follow up 
(months) 
 
12 - 324 15-273 12-324 
Number of patients 
treated 
 
(n=51) 
39 
(n=19) 
15 
(n=32) 
24 
Percentage treated 
 
76 79 75 
Median time to treatment 
(months) 
30 22 32 
Number of patients died 
 
(n=51) 
28 
 
(n=19) 
12 
(n=32) 
16 
Percentage died 
 
55 63 50 
Median Survival 
(months) 
 
88 83 117 
  
Table 5.6 - Clinical parameters in patients with an 11q deletion and an 
ATM mutation 
Patient 
 
Nucleotide 
Change 
 
Protein  
Change 
 
Age at 
diagnosis 
 
 
Stage at 
diagnosis 
 
IGVH 
status
 
% of cells 
with 11q 
deletion 
 
Overall 
survival 
(months) 
CLL189 
 
9023G/A R3008H 67 A UM 88 17+ 
CLL166 
 
8977C/T R2993X 51 B nk 99 56 
CLL174 
 
8861A/G Y2954C 86 A M 54 43 
CLL152 
 
8839A/T T2947S 77 C UM 99 82 
CLL192 
 
IVS62-
1G/T 
Splice 
defect 
63 A UM 43 30+ 
CLL07 
 
8600G/A G2867E 74 A UM 92 96 
CLL200 
 
8249T/C L2750S 71 A UM 86 55 
CLL182 
 
8249T/C L2750S 49 nk nk 69 17+ 
CLL193 
 
8056T/C F2686L 90 A UM nk 21 
CLL183 
 
7883del5 Truncated 84 nk nk 84 14+ 
CLL15 
 
7047C/G C2349W 61 A UM 95 75 
CLL162 
 
6106T/A Y2036N 68 A M 86 46 
CLL203 
 
6067G/A G2023R 52 C UM 45 88 
CLL169 
 
5980A/G K1994E 86 A UM 100 30 
CLL178 
 
4591C/T Q1531X 54 B nk nk 85+ 
CLL180 
 
3883del3 Deletion L nk A nk 96 nk 
CLL198 3651delG 
 
Truncated 49 C UM nk 69+ 
CLL173 2417T/G 
 
L806W 54 A UM 26 86 
CLL57 2308G/T 
 
E770X 68 A M 90 110+ 
CLL170 1120C/T Q374X 79 B UM 
 
UM unmutated; M mutated; ND not done; nk not known; + still alive 
 
nk 128 
Table 5.7 - Clinical parameters in patients with an 11q deletion and no 
ATM mutation 
 
 
Patient 
 
Age at 
Diagnosis 
 
Stage at 
diagnosis 
 
IGVH 
status
 
% cells 
with 11q 
deletion 
 
 
 
Overall 
survival 
(months) 
CLL160 56  A M 34 78 
CLL161 48 A UM 95 32+ 
CLL163 79  A UM 87 117 
CLL164 49 nk NK 47 14+ 
CLL165 39 A UM 95 163 
CLL19 61 
 
C UM 95 34 
CLL167 nk nk nk 47 nk 
CLL168 82  A nk 41 116+ 
CLL25 49 B UM 97 50+ 
CLL171 83  nk nk 10 12+ 
CLL37 47 B UM 75 44+ 
CLL172 77 B UM 40 65 
CLL175 76 
 
nk nk 11 6 
CLL176 79 A UM nk 134 
CLL177 77  A 
 
 
 
 
 
 
 
 
UM unmutated; M mutated; ND not done; nk not known; + still alive 
UM 74 45 
CLL179 68 A nk nk 275 
CLL185 42 A nk 90 25+ 
CLL186 24 A UM nk 149 
CLL187 72 B M 21 169 
CLL65 91 A M 91 28 
CLL188 42 A M 7 124+ 
CLL190 48 B nk 50 25+ 
CLL71 64 A UM 60 36+ 
CLL191 56 C nk 94 32+ 
CLL194 52 A nk 23 65+ 
CLL195 73 B UM nk  26 
CLL196 52 A M 44 322+ 
CLL197 76 A UM nk 117 
CLL199 70 A M 22 49 
CLL201 75 A M nk 46 
CLL138 34 C UM 80 128+ 
CLL202 28 A UM nk 27+ 
CLL204 61 A UM nk 4+ 
     In this second cohort of patients with an 11q deletion there were a higher 
number of patients that had poor prognostic disease features compared to the 
unselected cohort, irrespective of ATM mutation status. In the 11q-deleted 
cohort, 74% of patients had un-mutated IGVH genes compared to only 30% of 
patients in the unselected cohort. There were also more patients that had 
advanced stage disease at diagnosis in the 11q-deleted cohort compared to 
the unselected cohort, 32% vs 21%, respectively. However there was no 
difference in the ages at diagnosis (median 64 years for the selected cohort 
vs 67 years for the unselected cohort) or gender distribution (male:female 
1.41:1 for the selected cohort vs 1.42:1 for the unselected cohort) between 
the two cohorts (Tables 5.1 and 5.5). 
       Altogether from this cohort of tumours with an 11q deletion, 39 out of 51 
(76%) patients had been treated and 28 out of 51 (55%) patients had died at 
the time of the data analysis on 01.09.05. The median overall survival was 88 
months and the median treatment free survival was 30 months. These were 
both markedly shorter than within the unselected cohort where the median 
overall survival had not been reached at 220 months of follow up and where 
the median treatment free survival was 90 months. Thus the poor prognosis of 
a chromosome 11q deletion was confirmed in this study.  
      I next compared clinical parameters between the two subgroups of 11q-
deleted tumours, those with a second mutant ATM allele and those with a 
second wild type ATM allele. Interestingly, there was a trend for a shorter 
overall survival, which approached significance, for the group of patients with 
an 11q deletion and an additional mutant ATM allele compared to the group 
with a second wild type ATM allele (p=0.059) (Figure 5.5). The median overall 
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Figure 5.5 
 
There was a trend for a poorer overall survival amongst patients with an ATM 
mutation in addition to an 11q deletion in comparison to patients with an 11q 
deletion that had a second wild type ATM allele. However the differences in 
survival for this cohort of 53 patients did not reach statistical significance 
(p=0.059). 
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Figure 5.5
survival was 83 months (95% confidence interval (CI) 50.2 -115.9) in patients 
with a mutant ATM allele compared to 117 months (95% CI 54.6 – 179.8) in 
the group with a wild type ATM allele. Moreover, no patients with an ATM 
mutation survived beyond 128 months. The ten-year survival within this group 
was just 18% (95% CI 0% – 40.1%) compared to 54% (95% CI 33.3% -
76.3%) in patients with a wild type ATM allele. 
       I subsequently compared the treatment free survival between the two 
groups. There was no significant difference between the subgroups for this 
parameter (p=0.24) suggesting that the trend for a shorter overall survival in 
the subgroup of patients with an additional ATM mutation was due to the 
combination of a slightly shorter TFS but also a shorter survival post treatment 
with chemotherapy.  
     
5.5 Effect of a retrospective cohort  
     The ideal method to examine the prognostic significance of a biological 
marker, such as the mutation status of the ATM gene, would be to analyse 
each tumour sample at diagnosis and then follow up patient outcome 
prospectively. Unfortunately, since the median survival in CLL is greater than 
10 years, such a study would take many years and, therefore, all published 
studies investigating potential prognostic markers in CLL have taken a 
retrospective approach (Hamblin T et al, 1999, Dohner H et al, 2000, Wiestner 
A et al, 2003). However, there are disadvantages to retrospective studies. For 
example, if a biological marker has a detrimental effect on clinical outcome, 
then more patients with this marker in their tumour cells will have died before 
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the time of the analysis, than those without this marker, and therefore the 
biological marker’s prognostic value could be underestimated. 
      In order to investigate this possibility in the unselected cohort of 155 
patients, I divided the patients into three groups according to the ‘era of 
diagnosis’ and included this in multivariate analysis. The first era included 
those that were diagnosed before December 31st 1996, the second those that 
were diagnosed between the years 1997 and 2000 inclusively, and the third 
era those that were diagnosed years between the years 2001 and 2003 
inclusively (Table 5.3). After the inclusion of era of diagnosis, the hazard ratio 
(risk of death) for ATM mutations increased from 3.0 to 3.4, indicating that in 
this retrospective type of study, the effect of ATM mutations on OS is actually 
an underestimation.  
        
5.6 Timing of ATM mutations in the pathogenesis of CLL 
    The time at which an ATM mutation develops is important when assessing 
the impact of ATM mutations on clinical outcome and evaluating their potential 
role as a prognostic biomarker. If an ATM mutation is acquired some time 
during disease progression after the initial disease diagnosis, then any 
potential adverse effect of this mutation will be underestimated when using 
clinical outcome parameters that are measured from the time of diagnosis. 
Nevertheless, differences in clinical outcome might still be evident if the 
mutations lead to a marked effect on tumour cell behaviour. 
     I evaluated the timing of the ATM mutations in selected patients where 
tumour samples from more than one time point during the disease course 
were available.  Altogether, there were seven tumours (CLLs 77, 96, 07, 75, 
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152, 173 and 198) in which I had detected an ATM mutation where tumour 
material was available from a time-point earlier in the disease course and 
could therefore be examined for the presence of the same mutation as part of 
a ‘look back’ analysis (Table 5.8). In five cases (CLLs 77, 96, 07, 75 and 152), 
the ATM mutations were also detected in tumour material collected at an 
earlier date. For example in CLL 77, the mutation 5224G/C was present at 
diagnosis in 1998 as well as in 2002 and additionally this tumour also had the 
germ-line mutation 1058delGT indicating that both ATM mutations were 
present at the time the CLL was diagnosed. In the case of CLL96 the three 
mutations 2929ins 9, 5041A/G and 5044G/T were all present at diagnosis in 
1996 and as well as in 2002. In, CLL 07 the mutation 8600G/A was detected 
in 1995 at diagnosis as well as in 2002 and this tumour also had loss of the 
second ATM allele through a chromosome 11q deletion. In, CLL 75 the 
mutation 1009C/A was found both in 2000 at diagnosis and in 2002, and 
finally, in CLL 152 the mutation 8839A/T was found both in 1999 (one year 
following the diagnosis of the disease) and in 2002.   
    In two cases (CLL173 and 198), the ATM mutations were not detected in 
tumour material collected at an earlier date as part of the ‘look back’ analysis. 
In CLL173, the mutation 2417T/G was detected in 2001 but was not observed 
in 1995 at the time of diagnosis of CLL. Similarly, for CLL198, the mutation 
3651delG was detected in 2003 but was not present in 2001 at the time of 
diagnosis. Both these tumours also had loss of the second ATM allele through 
a chromosome 11q deletion (Figure 5.6).     
     Notably, all five tumours (CLLs 07, 75, 77, 96 and 152) analysed in this 
manner that originated from the unselected cohort had the ATM mutation 
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Table 5.8 - ‘Look Back Analysis’ to investigate the timing of the acquired 
ATM mutations 
 
 
Patient 
 
Date of 
diagnosis 
 
Date of earliest 
sample 
 
Presence or 
Absence of 
mutation in this 
sample 
 
 
Date of later 
sample 
 
Presence or 
Absence of 
mutation in this 
sample 
CLL 07 01.01.95 01.01.95 
 
8600G/A (A) 
(11q status - UK) 
25.04.02 
 
8600G/A (A) 
11q deletion 
CLL 75 02.02.00 23.02.00 
 
1009C/A (A) 
14.10.02 
 
1009C/A (A) 
CLL 77 14.01.98 14.01.98 
 
5224G/C (A) 
1058delGT (G) 
17.12.02 
 
5224G/C (A) 
1058delGT(G) 
CLL 96 11.11.96 1996 
 
5041A/G (A) 
5044G/T (A) 
2929ins9 (A) 
19.03.02 
 
5041A/G (A) 
5044G/T (A) 
2929ins9 (A) 
CLL 152 05.01.98 1999 
 
8839A/T (A) 
(11q status - UK) 
07.10.02 
 
8839 A/T (A) 
11q deletion 
CLL 173 07.09.95 10.10.95 
 
Not present 
(11q status - UK) 
01.08.01 
 
2417T/G (A) 
11q deletion 
CLL 198 01.01.00 26.03.01 
 
Not present 
(11q status - UK) 
05.02.03 
 
3651delG (A) 
11q deletion 
 
A = Acquired ATM mutation, G= Germline ATM mutation 
Uk - Unknown 
 
Figure 5.6 
 
The timing of the development of ATM mutations varied in different CLL 
tumours. In CLL198 the ATM mutation, 3651delC, was present in the tumour 
sample analysed in 2003 but absent from both germ-line material and the 
diagnostic sample in 2001. By comparison the two mutations, 5041A/G and 
5044G/T, in CLL 96 were also absent from the germ-line but they were 
present in diagnostic material from 1996. Thus acquired mutations in ATM 
can occur both early at disease onset and later during the progression of the 
CLL clone. 
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Figure 5.6
present in both the early and later sample. In a further three tumours (CLLs 
92, 113 and 81) the ATM mutations that were detected were known to have 
been present in diagnostic material. Thus, altogether, from 22 mutations in the 
18 patients in this cohort, there were ten mutations that were present within 
the tumour cells at the time of diagnosis. A further mutation was present in a 
sample collected at one year following diagnosis suggesting that it was also 
acquired early in the disease course. The timing of the remaining mutations 
was unknown but, nevertheless, these results indicate that ATM mutations are 
commonly early events in CLL. 
      Of the four tumours analysed by this analysis in the 11q-deleted cohort, 
two tumours (CLL 07 and 152) (these were common to both cohorts) had the 
mutation in both the early and later samples, whereas two tumours (CLLs 173 
and 198) only had the mutation present in the later sample. In this cohort, in 
addition to CLLs 07 and 152, there were a further eight tumours where the 
mutations was known to be present within one year of diagnosis. Altogether, 
the results from the selected 11q-deleted cohort suggest that although ATM 
mutations are present at diagnosis in a proportion of tumours, in others they 
may be acquired during disease progression.   
     Interestingly, in the two cases, CLLs 173 and 198, where it was possible to 
definitively confirm the acquisition of an ATM mutation at a time after the 
diagnosis of CLL, the patients had both received treatment with a DNA 
damaging chemotherapeutic drug, chlorambucil, between the earlier and later 
samples tested for ATM mutations.   
 
5.7 Conclusion  
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      In order to be clinically useful as a prognostic marker, ATM mutations 
should impact on disease outcome, provide independent prognostic 
information and ideally should be present at the time of clonal transformation. 
Here I have shown that within unselected CLL tumours, ATM mutations 
significantly impact on both TFS and OS in a manner that is independent of 
age, clinical stage, IGVH mutation status and TP53 mutation status.  
      I have also confirmed that there is an incomplete correlation between 
tumours with ATM mutations and those with 11q deletions in CLL. Therefore, 
this suggests that the detection of both patient subgroups would be 
complementary in the identification of patients that will have a poor clinical 
outcome. In this study there was also a trend, although this did not reach 
significance, which suggested that within the subgroup of patients with an 11q 
deletion, those patients that have an additional ATM mutation might have a 
poorer overall survival from diagnosis than the patients that retains one wild 
type copy of an ATM allele.  
     Finally, I have shown that ATM mutations are commonly early events in 
the pathogenesis of CLL suggesting that they would indeed have value as a 
prognostic marker. However in certain cases, perhaps particularly when they 
represent a second abnormality in the ATM gene they can occur after 
diagnosis and during disease progression. This suggests there maybe a step- 
wise development of abnormalities in the ATM gene in CLL.  
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Results 3 
 
 
The effects of the ATM mutations on the DNA damage 
response 
 
6.1 Introduction 
      In this part of my project I wanted to address the functional consequences 
of the ATM mutations which I had detected in the CLL tumour cells. One aim 
was to investigate potential assays that might allow the detection of those 
tumours that harbour ATM mutations via their functional responses. ATM 
coordinates an integrated cellular response to DNA DSBs and therefore it 
should be possible to study the effects of abnormal ATM activity at different 
levels in the DNA damage response pathway in CLL tumours (Kurz EU, Lees-
Miller S, 2004). For example, following DNA damage, defects in ATM function 
might be expected to impact on the early ATM dependent phosphorylation of 
substrates, the later up-regulation of total p53 levels and its transcriptionally 
regulated substrates, and the subsequent induction of apoptosis via the p53-
dependent intrinsic pathway. Since the phosphorylation of substrates is 
directly catalysed by ATM at early time points after the induction of DNA 
DSBs, this would be expected to most specifically reflect the ATM activity in 
the tumour cells. The assessment of the downstream consequences of the 
ATM mutations will also be important in order to validate their pathogenic 
nature and to determine their ultimate effect on cell fate following DNA 
damage.  
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       In my project, in addition to the detection of CLL tumours with bi-allelic 
ATM defects, I identified a proportion of tumours that had a mono-allelic ATM 
defect, either through a mutation or a deletion, in the presence of a second 
wild type ATM allele. Considering the poor clinical outcome of the whole 
group of tumours with an ATM mutation from the unselected cohort, I wanted 
to investigate whether there was any abnormality in the ATM function in those 
tumours that were found to have one mutant ATM allele and one wild type 
ATM allele. Similarly, from the cohort of tumours with an 11q deletion and 
hence loss on one ATM allele, I wanted to determine whether there was 
differential ATM activity between those tumours with an 11q deletion and a 
second mutant ATM allele from those with a second wild type ATM allele. 
        Having studied the effects of different combination of ATM defects on the 
cellular consequences to DNA damage with irradiation, I also wanted to 
investigate their effects on the response to chemotherapeutic drugs. 
Specifically, I wanted to study the role of ATM in the response to the purine 
analogue Fludarabine, which is currently a first-line therapy for CLL patients 
(Oscier D et al, 2004). Therefore, in this chapter I have investigated the role of 
fludarabine in the activation of the DNA damage response pathway and the 
effects of ATM mutations on the integrity of this pathway. I have also 
compared fludarabine-induced responses between tumours with two wild type 
ATM alleles, tumours with bi-allelic ATM defects and tumours with loss of one 
ATM allele through an 11q deletion with a remaining wild type ATM allele. 
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6.2 Functional assays to study the consequences of ATM mutations 
       
6.2.1 ATM dependent phosphorylation responses 
    I investigated ATM dependent phosphorylation responses by measuring the 
change in the amount of an ATM target protein that is phosphorylated 
following DNA damage with ionising irradiation (IR). I studied several target 
substrates using commercial phospho-specific antibodies, including 
phosphorylated ATM on serine 1981, p53 on serine 15, SMC1 on serine 966 
and Nbs 1 on serine 343. These substrates were chosen because they are 
known to be targets of ATM and also because they have been used in our 
laboratory both to evaluate the activity of various mutant ATM proteins as part 
of an in-vitro modelling system and to study residual ATM activity in certain 
AT patients (Kurz EU, Lees-Miller S, 2004 and unpublished data).   
     The activation of ATM is known to occur rapidly following the induction of 
DNA DSBs in response to IR (Bakkenist CJ, Kastan MB, 2003). Therefore, in 
the first instance, I assessed ATM dependent phosphorylation responses at 
15 and 45 minutes after IR in a range of CLL tumours that were known to 
have two wild type ATM alleles. For these experiments, I used antibodies to 
phosphorylated ATM and p53, and compared the level of the respective 
phosphorylated proteins after IR with the level in the un-irradiated cells (time 
0). I showed that following IR, the level of ATM phosphorylated on serine 
1981 was markedly increased by 15 minutes and in the majority of tumours 
remained phosphorylated at 45 minutes. The level of p53 phosphorylated on 
serine 15 was also increased by 15 minutes after IR but increased further at 
45 minutes (Figure 6.1). Altogether, I assessed these phosphorylation 
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Figure 6.1  
 
There is phosphorylation of ATM on serine 1981 and p53 on serine 15 at 15 
and 45 minutes following DNA damage with ionizing irradiation (5Gy)  in CLLs 
67, 35, 133, 157, 44 and 122, which all had two wild type ATM alleles. Actin is 
used as a loading control. This pattern of response was seen in all the 
tumours that were analysed that had two wild type ATM alleles.  
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Minutes post IR
Figure 6.1
responses in 17 independent CLL tumours, which were all known to have two 
wild type ATM alleles and confirmed this pattern of response in all the 
tumours tested.  
       In 5 CLL tumours with two wild type ATM alleles I went on to investigate 
the phosphorylation of the additional ATM targets SMC1 and Nbs1 after IR. In 
all these tumours, phosphorylation of these downstream targets could also be 
demonstrated at 15 and 45 minutes after DNA damage with IR and the 
pattern was similar to that seen with phosphorylated p53 (Figure 6.2). 
     Having confirmed the presence of these phosphorylation responses in CLL 
tumours at these early time points after IR, I next investigated the responses 
in tumours with ATM mutations. In this project, I had identified 23 tumours that 
would be predicted to have loss of both functional ATM alleles, either through 
2 ATM mutations (3 tumours) or through one ATM mutation and one allelic 
deletion (20 tumours). Viable cells were available in 12 of these cases and I 
was therefore able to study the phosphorylation responses in these tumours. 
In these experiments, I compared the DNA damage induced responses of 
tumours with ATM mutations with the responses of CLL tumours with two wild 
type ATM alleles and measured responses at 15 and 45 minutes after IR. I 
aimed to assess the phosphorylation of at least two substrates for each 
tumour.  
      I was able to demonstrate that there was impairment in the ATM 
dependent phosphorylation responses in all twelve tumours tested. As 
illustrated in Figure 6.3, there is impairment of phosphorylation of ATM and 
SMC1 or Nbs1 in the seven CLL tumours with an ATM mutation and an 11q 
deletion (CLLs 166, 198, 57, 180, 183, 152 and 182) compared to the CLL 
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Figure 6.2 
 
 
There is also phosphorylation of additional ATM substrates following IR (5Gy), 
namely, SMC1 at serine 966 and Nbs1 at serine 343 in CLLs 53, 122, 42, and 
61 and SMC1 at serine 966 in CLL 24. These tumours all have two wild type 
ATM alleles. The baseline level of the proteins SMC1, Nbs1 and ATM are 
shown in order to demonstrate the change in the proportion of cellular protein 
that is phosphorylated after DNA damage. 
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Figure 6.3a and 6.3b 
 
There is impairment in the phosphorylation of ATM on serine 1981 and SMC1 
on serine 966 following IR (5Gy) in CLLs 166, 198, 57, 180, 183, 152 and 
182, which all have loss of both ATM alleles through the combination of an 
11q deletion and an ATM mutation, in comparison to the phosphorylation 
responses demonstrated in CLLs 122, 53, 42 and 24, which all have two wild 
type ATM alleles. A similar pattern of impairment of phosphorylation of Nbs1 
is also seen in CLLs 166 and 198.  
There is reduced total ATM protein expression in the CLL tumours with bi-
allelic ATM defects (CLLs 166, 198, 57, 180, 183, 152, 182) but the levels of 
the proteins SMC1 (and Nbs1) are comparable between all the tumours 
regardless of the status of ATM. Therefore, the reduced level of 
phosphorylated ATM is due to both a decrease in the amount and function of 
the protein, but the reduced level of phosphorylated SMC1 (and Nbs1) is due 
to reduced function of ATM in the CLLs with bi-allelic ATM defects. 
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tumours with two wild type ATM alleles at 45 minutes after DNA damage with 
irradiation. I also demonstrated an impairment of phosphorylation of Nbs1 in 
CLLs 166 and 198. The remaining 2 tumours (CLLs 07 and 15) with an ATM 
mutation and an 11q deletion that were investigated in this manner 
demonstrated a similar pattern of impairment of phosphorylation of 
downstream substrates (data not shown). There was also impairment of 
phosphorylation of ATM and p53 in the three tumours (CLLs 11, 96 and 77) 
that were predicted to have bi-allelic ATM defects as a consequence of two or 
more mutations (Figure 6.4). The choice of substrates that I assessed was 
partly influenced by the efficacy of the phosphorylated antibodies. In addition, 
in the initial experiments, I only used antibodies to phosphorylated ATM and 
p53 and in subsequent experiments I also used antibodies to phosphorylated 
SMC1 and Nbs1.  
        In all the tumours that I investigated which had bi-allelic ATM defects 
there was invariably very low level ATM activity as assessed by these DNA 
damage response phosphorylation assays. Nevertheless, the retention of 
some residual phosphorylation of ATM target substrates could be a 
consequence of either the ATM activity present in any non-tumour cells in the 
sample or in the presence of a subclone of tumour cells that did not carry the 
11q deletion or the ATM mutation. Finally it is also possible that certain mis-
sense ATM mutations could encode for a mutant ATM protein that had some 
residual retained ATM activity.  
     In this study, amongst the subgroup of 11q deleted tumours that had an 
additional ATM mutation, the chromosome 11q deletion was present in the 
majority of the tumour cell population in the majority of cases. Amongst the 
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Figure 6.4 
 
There is reduced phosphorylation of ATM on serine 1981 and p53 on serine 
15 following IR (5Gy) in CLLs 11, 96 and 77, which have two or more ATM 
mutations, in comparison to CLLs 35, 133 and 76, which have two wild type 
ATM alleles. Thus the mutations have resulted in the inactivation of the ATM 
protein in CLLs 11, 96 and 77 and this suggests that there were bi-allelic ATM 
defects in these tumours.  
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nine cases in which I performed functional analysis, there was greater than 
90% of tumour cells with an 11q deletion in 6 cases (CLLs 166, 180, 07, 15, 
57 and 152), 84% and 69% of cells had an 11q deletion in CLLs 183 and 182 
respectively, while the percentage of cells with an 11q deletion was not known 
in CLL198. However, as discussed later, there were also three 11q-deleted 
tumours (CLLs 192, 203 and 173) in which an ATM mutation had been 
detected where the chromosome 11q deletion was present in less than 50% 
of cells (Table 5.6). Viable cells for functional testing were not available in any 
of these three tumours but in these cases one might expect higher levels of 
ATM activity as a consequence of a significant number of cells that do not 
carry the 11q deletion. In all the twelve tumours with bi-allelic ATM defects 
where I performed functional analysis, there was very low level ATM activity. 
This therefore suggests that the ATM mutations in these tumours were also 
likely to be present in either the entire clone or a large subclone and that 
these mutations were indeed exerting a pathogenic effect. 
        In conclusion, therefore, on the basis of all twelve tumours tested in this 
study, I was able to show that the measurement of these ATM dependent 
phosphorylation responses can readily discriminate between tumours with two 
wild type ATM alleles and tumours with bi-allelic abnormalities of the ATM 
gene due to either two mutations or a mutation and a deletion.  Therefore, this 
assay should allow the identification of tumours with abnormal ATM function 
as a consequence of ATM genetic defects.  
           
6.2 Up regulation of p53 and expression of p21  
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       The consequences of the ATM dependent phosphorylation of p53 on 
serine 15 and additional residues include the up regulation of the total p53 
protein level in the nucleus. Here p53 can act as a transcription factor and 
after DNA damage there is a p53 dependent increase in the expression of the 
p21 protein. Therefore, an alternative way to investigate ATM activity in CLL 
tumour cells is through the measurement of the change in total levels of p53 
and p21 after DNA damage, and, indeed, such an assay has been previously 
developed (Pettitt A et al, 2001). I assessed p53 and p21 levels following 
irradiation in 84 of the tumours that I had found to have wild type ATM and 
TP53. In 78 of these 84 tumours I observed low or undetectable levels of p53 
and p21 at time 0, and up regulation of both proteins at 8 hours after IR in a 
pattern that is consistent to previous reports (Figure 6.5) (Pettitt A et al, 2001, 
Stankovic T et al, 2002).  
     Interestingly, in 6 tumours, there was reduced or absent induction of p21 
expression, despite evidence of up regulation of p53. One explanation to 
account for these findings might be that the tumours had ATM mutations that 
had escaped detection by the DHPLC method. In 3 of these 6 CLL tumours, I 
was also able to examine the early ATM dependent phosphorylation 
responses after IR and in all three cases (CLLs 67, 153 and 39), there was 
evidence of phosphorylation of ATM on serine 1981 and of p53 on serine 15 
in a similar manner to the other tumours tested that had two wild type ATM 
alleles (Figure 6.6). Therefore, this result indicated that there was no 
impairment in ATM activity in these 3 tumours. These results suggest that the 
ATM dependent phosphorylation events may correlate better with the genetic 
status of ATM than the measurement of downstream events. It is possible that 
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Figure 6.5 
 
CLL tumours with wild type ATM and TP53 genes showed up regulation of 
p53 and p21 levels at eight hours after DNA damage with IR (5Gy). This 
pattern of response is shown for 20 selected CLL tumours and was seen in a 
total of 78 out of 84 tumours that were analysed in this genetic category. 
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Figure 6.6 
 
 
CLLs 67, 153 and 39 had wild type ATM and TP53 genes but showed an 
altered pattern of response. In these tumours there was reduced up regulation 
of p53 and absent induction of p21 at eight hours after IR (5Gy). This pattern 
was seen in 6 out of 84 tumours with wild type ATM and TP53 genes.  
Interestingly, CLLs 67, 153 and 39 all had retained phosphorylation responses 
after DNA damage. There was phosphorylation of ATM and p53 in all these 
tumours at 15 and 45 minutes after irradiation.  
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these 6 tumours had a polymorphism in the p21 protein, and this has been 
previously shown to affect its expression after DNA damage (Carter A et al, 
2006).  
        Having assessed the changes in p53 and p21 expression in tumours with 
two wild type ATM alleles, I subsequently assessed the responses in seven 
tumours with bi-allelic ATM defects. These included the three cases, CLLs 11, 
96 and 77 (Figure 6.7) that had two or more ATM mutations and four cases, 
CLLs 57, 152, 07 and 15 that had one ATM mutation in conjunction with a 
deletion of chromosome 11q (Figure 6.13). In all seven cases there was 
reduced up regulation of p53 and p21 expression, in a pattern reminiscent to 
that described for tumours with ATM mutations in previous reports. For these 
tumours, there was good correlation between p53 and p21 responses and the 
ATM dependent phosphorylation responses. Therefore, the impairment of 
ATM activity in these tumours as measured by two assays validates the 
pathogenic nature of the mutations. In addition the effects of the ATM 
mutations on downstream cellular responses such as the up regulation of p53 
and p21 will be predicted to impact on the induction of cell cycle arrest and 
the activation of apoptosis after DNA damage. 
 
6.2.3 Induction of apoptosis   
    In order to assess the onset of apoptosis following DNA damage, I 
measured the cleavage of the DNA repair protein PARP1 following IR. PARP1 
has been shown to be a target of the effector caspase 3 via the intrinsic 
apoptotic pathway (Norbury CJ, Hickson ID, 2001, Weston VJ et al; 2004). 
Initially, I wanted to confirm that PARP1 cleavage was indeed temporarily 
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Figure 6.7 
  
CLLs 11, 96 and 77, which were predicted to have bi-allelic ATM defects as a 
consequence of mutations demonstrated impairment in the up regulation of 
p53 and the induction of p21 at 8 hours after IR (5Gy) compared to the 
proficient response patterns in CLLs 33, 122 and 65, which had wild type 
ATM. 
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synchronised with p53 mediated gene expression and activation of caspases, 
in CLL tumours. Therefore, I studied the changes in levels of p53 and p21 
expression and also the levels of procaspase 7, cleaved caspase 3 and 
PARP1, in several tumours with wild type ATM at 8 and 24 hours after DNA 
damage with IR. I was able to demonstrate that the activation of p53-mediated 
apoptosis as indicated by the loss of procaspase 7 and the appearance of 
cleaved caspase 3, coincided with the loss of full length PARP1 and that 
these events followed the up regulation of p53 and the induction of p21 
expression. This indicated that the cleavage of PARP1 was occurring via p53-
mediated apoptosis in the CLL tumours (CLLs 53, 55 and 32) (Figure 6.8).     
     To evaluate the effects of ATM mutations on apoptosis, I compared the 
degree of PARP1 cleavage at 24 hours following IR in 12 CLLs with ATM 
mutations (and no mutation in the TP53 gene) with 70 CLL tumours that were 
known to have both wild type ATM and TP53 genes. Amongst these twelve 
tumours with ATM mutations, seven had bi-allelic ATM defects but ten had 
been demonstrated to have impairment of ATM function as indicated by the 
ATM-dependent phosphorylation responses following IR (see later). Loss of 
p53 function is known to lead to an apoptotic resistant phenotype in CLL 
tumours and, therefore, I also compared tumours with ATM mutations with the 
six tumours in which I had detected TP53 mutations.  
     To obtain a quantitative and comparative measure of apoptosis between 
the CLL tumours, I calculated the percentage of the level of PARP1 at time 0, 
which remained at 24 hours following irradiation. Levels were corrected for 
actin to account for any differences in protein loading. An unchanged level of 
uncleaved PARP1 (100%) at 24 hours indicated an absence of apoptosis in a 
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Figure 6.8  
 
The induction of the ATM / p53 response pathway following DNA damage with 
irradiation leads to the activation of apoptosis by the intrinsic pathway in CLL 
tumours. As illustrated for CLL53, 55 and 32 there is up regulation of p53 and 
p21 at 8 hours after irradiation. By 24 hours after IR (5Gy) there is evidence 
for the loss of procaspase 7 and the appearance of the active cleaved 
caspase 3. In addition there is also loss of the full length PARP1 by 24 hours 
after DNA damage. 
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tumour and a low level of uncleaved PARP1 at 24 hours indicated that a high 
number of tumour cells had activated apoptosis.  
     Total absence of apoptosis was observed in 67% (4/6) of tumours with 
TP53 mutations, 42% (5/12) of tumours with ATM mutations and also 16% 
(11/70) of ATM/TP53 wild type tumours. The median values for residual 
PARP1 levels at 24 hours following irradiation in the genetic subgroups were 
100% for TP53 mutant tumours, 69% for ATM mutant tumours and 36% for 
ATM/TP53 wild type tumours. These differences were statistically significant 
(Kruskal-Wallis test, p=0.019) (Figure 6.9 and 6.10).  
      Despite the significant differences between the genetic subgroups, there 
was a considerable degree of variation in the induction of apoptosis within 
each subgroup. Interestingly, twelve tumours that were ATM/TP53 wild type 
showed complete resistance to PARP1 cleavage. These tumours had been 
shown to have normal up regulation of total p53 protein levels and the 
induction of p21 after DNA damage with IR. Therefore, this suggests that 
there might be a defect or alteration in targets that are downstream from the 
activation of p53, such as the Bcl-2 family of proteins. Indeed, in CLL tumours 
both Bcl2/Bax ratios and Mcl1 levels have been previously implicated in 
apoptosis resistance (Pepper C et al, 1996). Furthermore, there is also recent 
data suggesting that the up regulation of DNA repair activity may also lead to 
a DNA damage apoptotic resistance phenotype in CLL cells. This could also 
be independent of both the ATM and TP53 mutation status (Derriano L et al, 
2005).  
      Amongst the tumours with ATM mutations, there was also variation in the 
induction of apoptosis following IR compared to the upstream events, such as 
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Figure 6.9 
 
Loss of full length PARP1 was assessed for tumours with ATM mutations, 
TP53 mutations and ATM /TP53 wild type genes as an indicator for the 
induction of apoptosis. CLLs 155, 80, 108, 34 and 33 all show loss of the full 
length PARP1 at 24 hours after DNA damage with IR (5Gy) compared to the 
level at time 0. Therefore these tumours have all activated apoptosis. By 
comparison there is impairment of the induction of apoptosis as indicated by 
the retention of full length PARP1 at 24 hours post IR in CLLs 130, 124 and 
96. CLL 96 has three ATM mutations, CLL 124 has a TP53 mutation and also 
an ATM mutation and CLL 130 has wild type ATM and TP53 genes.  
The percentage of the level of PARP1 at 0 that was present at 24 hours after 
irradiation, as measured by optical density, was calculated for each tumour. 
This value was then adjusted for any changes in Actin, which was used as a 
loading control. The values for optical density are shown beneath the protein 
band.  
For example, in CLL80, the adjusted percentage of PARP1 at 24 hours was 
calculated: 
            Percentage of PARP1 at 24 hours = 2.61/35.47 x 100 = 7.4% 
            Percentage of Actin at 24 hours = 21.57/24.22 x 100 = 89% 
            Adjusted Percentage of PARP1 at 24 hours = 7.4/89 x100 = 8.3% 
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 Figure 6.10 
 
The adjusted percentage of full length PARP1 at 24 hours was compared 
between the three genetic subgroups, namely ATM mutant, TP53 mutant and 
ATM/TP53 wild type. The two tumours with an ATM mutation and a TP53 
mutation were included in the category of TP53 mutant tumours. The median 
value for each genetic subgroup is shown.  
Tumours with TP53 mutations were the most resistant to apoptosis after DNA 
damage, and tumours with ATM mutations showed a pattern of resistance 
that was intermediate between those tumours with TP53 mutations and those 
with wild type ATM and TP53 genes. These differences were statistically 
significant (p=0.019). Notably there was a degree of variation in each genetic 
category and there were a number of tumours with wild type ATM and TP53 
genes that showed resistance to DNA damage induced apoptosis. 
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ATM dependent phosphorylation of substrates and changes in the level of p53 
and p21. Nevertheless, as a group, the tumours with ATM mutations did 
demonstrate an apoptotic resistant phenotype as measured by this PARP1 
cleavage assay, which is in line with previous findings (Stankovic T et al, 
2002).  
        In selected tumours with ATM wild type and ATM mutant genes, 
apoptosis was also assessed using an Annexin/Propidium iodide Fluorescent 
Activated Cell Sorting (FACS) method. This allowed the verification that the 
tumours with ATM mutations, identified in this cohort, did indeed have 
impaired activation of apoptosis. Fifteen ATM wild type tumours and seven 
ATM mutant tumours were analysed by this method and consistent with 
reduced PARP1 cleavage, ATM mutant tumours showed less efficient 
apoptosis. At 24, 48 and 72 hours following IR the mean levels of apoptosis 
among the ATM wild type tumours (after subtraction of any spontaneous 
apoptosis at these time points) were 36%, 53% and 73% respectively, 
compared to 22%, 31% and 39% in the ATM mutant tumours (p = 0.017, 
0.015 and 0.04) (This FACS analysis was performed by Dr. A. Alvi). 
      These results from both assays confirm that CLL tumours with ATM 
mutations have an apoptotic resistant phenotype following DNA damage 
compared to ATM wild type CLL tumours but, nevertheless, indicate that the 
measurement of apoptosis following IR would be both a relatively non-specific 
and insensitive method to detect CLL tumours that harbour ATM mutations. 
Since the activation of apoptosis is the final downstream event in the DNA 
damage pathway it is perhaps not surprising that it will be influenced by 
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numerous cellular factors in addition to the activity of the upstream ATM 
protein. 
 
6.3 Responses to IR in tumours with one remaining wild-type ATM allele 
       In this study, there were 44 tumours that were found to have an 
abnormality in a single ATM allele. In 33 cases this was due to a deletion of 
one copy of ATM through an 11q deletion but with a remaining wild type ATM 
allele, and, in 11 cases this was due to the presence of one mutant ATM allele 
and one wild type ATM allele. If ATM acts as a classical tumour suppressor 
gene, then it might be expected that the retention of one functional ATM allele 
would be adequate for normal ATM activity in the cell. I evaluated ATM 
activity in both these CLL tumour subgroups by assessing the responses to 
DNA damage with IR.  
 
6.3.1 Tumours with a deletion of one ATM allele 
       I studied this category of tumours with a deletion of one ATM allele but a 
second wild type allele in order to determine whether heterozygosity at the 
ATM locus had any functional consequences in CLL tumours. Viable cells 
were available on 11 tumours and therefore in these tumours I measured the 
early ATM dependent phosphorylation responses following IR. Interestingly, 
this subgroup could be shown to have preserved ATM activity and the 
tumours demonstrated phosphorylation of downstream targets following IR, in 
a similar pattern to that seen for tumours with two wild type ATM alleles. 
Reduced levels of total ATM protein were apparent in most cases consistent 
with heterozygous ATM expression, which led to reduced levels of 
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phosphorylated ATM after IR.  However, the proportion of the total ATM that 
was phosphorylated after IR was similar to that in the tumours with 2 wild type 
ATM alleles, indicating that the reduced level of phosphorylated ATM reflected 
the reduced ATM protein expression rather than impaired ATM function 
(Figures 6.11a and b).  
     Next, I wanted to assess whether the whole group of tumours with an 11q 
deletion could be divided into functional subgroups according to the status of 
the remaining ATM allele. Therefore, I quantified the phosphorylation 
responses, and compared the relative ATM activity of this subgroup of 11 
tumours with an isolated 11q deletion, with the subgroup of 9 tumours with an 
11q deletion and an ATM mutation, described previously. In order to quantify 
the response, I measured the change in the phosphorylated proportion of 
either p53 or SMC1 between time 0 and 45 minutes post IR for each tumour. I 
then expressed this value, for all the tumours with an 11q deletion, relative to 
the value for the control tumour on each western blot that had two wild type 
ATM alleles (Figure 6.12). 
      Compared to the very low ATM activity of all the tumours with two 
abnormal ATM alleles in this study, the tumours with an isolated 11q deletion 
all had higher levels of ATM activity. This was greater than 50% of the control 
tumour in all cases, and in some cases was equivalent or higher than that 
seen in the control tumours with two wild type ATM alleles. There was some 
variation in ATM activity amongst the tumours with the isolated 11q deletion 
and, since this assay was measuring relative activity, this may partly reflect a 
degree of variation between control samples.  
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Figure 6.11a and b. 
 
CLL198 with an 11q deletion and an ATM mutation demonstrates a deficient 
phosphorylation response following DNA damage with IR (5Gy) in comparison 
to CLLs185 and 175 that show phosphorylation of SMC1 that is equivalent to 
that seen in CLL53 that has two wild type ATM alleles. Similarly, CLLs 37 and 
25, with an 11q deletion and a second wild type ATM allele, demonstrate 
proficient phosphorylation of p53 after IR that is equivalent to the response in 
CLL13, with two wild type ATM alleles. Thus the retention of one wild type 
ATM allele is sufficient for normal ATM activity in these tumours.   
 
The change in the proportion of SMC1 that is phosphorylated, as assessed by 
optical density, was calculated for each tumour with an 11q deletion and 
expressed relative to the change in this proportion in the tumour with two wild 
type ATM alleles on the same blot.  
For CLL185: 
          Change in percentage of SMC1 which is phosphorylated between 45 
and 0 minutes = ((29.12/34.43) x 100) – ((0.02/15.32) x 100)) = 84% 
For CLL 53: 
          Change in percentage of SMC1 which is phosphorylated between 45 
and 0 minutes = ((16.21/22.91) x 100) – ((0.23/13.94) x 100)) = 69.5% 
 
Relative change in percentage of phosphorylated SMC1 for CLL185:  
                    = 84/69.5 x 100 = 121% 
    
SMC1 966p
ATM 1981p
11q deletion and 
no ATM mutation
Actin
SMC1
ATM
Minutes Post IR
2 Wt ATM
alleles
11q deletion and
an ATM mutation
11q deletion and 
no ATM mutation
CLL53
0      15      45
CLL198
0      15      45 
CLL185
0      15      45 
CLL175
0       15      45
0.23 16.21 1.00 0.21 0.02 29.12 1.01 11.75
13.94 22.91 17.40 10.10 15.32 34.43 19.10 22.12
Figure 6.11a
p53 15P
p53
ATM 1981p
11q deletion and 
no ATM mutation
Actin
ATM
Minutes Post IR
2 Wt ATM
alleles
11q deletion and 
no ATM mutation
CLL13
0       15      45
CLL37
0       15      45
CLL25
0       15       45
0.04 10.21 0.04 7.12 0.30 11.81
26.12 18.30 6.95 10.41 26.10 16.30
Figure 6.11b
Figure 6.12 
 
The relative ATM activity in the tumours with an 11q deletion is demonstrated. 
Tumours with an 11q deletion and an ATM mutation all had low levels of ATM 
activity. By comparison, tumours with an 11q deletion and a second wild type 
ATM allele had retained ATM activity. 
020
40
60
80
100
120
140
A
TM
 a
ct
iv
ity
 (p
er
ce
nt
ag
e)
C
LL
01
5 
 7
04
7C
/G
C
LL
00
7 
 8
60
0G
/A
C
LL
19
8 
 3
65
1d
el
G
C
LL
18
3 
 7
88
3d
el
5
C
LL
18
0 
 3
88
3d
el
G
C
LL
15
2 
 8
83
9A
/T
C
LL
18
2 
 8
24
9T
/C
C
LL
16
6 
 8
97
7C
/T
C
LL
05
7 
 2
30
8G
/T
C
LL
13
8
C
LL
01
9
C
LL
03
7
C
LL
02
5
C
LL
18
5
C
LL
17
5
C
LL
17
1
C
LL
19
4
C
LL
19
6
C
LL
16
4
C
LL
20
4
Tumours with an 11q deletion 
and a mutant ATM allele
Tumours with an 11q deletion 
and a wild type ATM allele
Figure 6.12
      These results indicated that the retention of one wild type ATM allele is 
sufficient for normal ATM activity in CLL tumour cells. However, with this type 
of semi-quantitative assay, it was not possible to exclude with certainty that 
heterozygosity at the ATM locus might not exert some effect on ATM activity.  
Nevertheless, it was possible to conclude that all these tumours with an 
isolated 11q deletion had much higher level of ATM activity than the group 
with a second mutant ATM allele and that the two subgroups could be readily 
distinguished.  
      Interestingly, there was a much greater variation in the percentage of cells 
in the CLL clone that carried the 11q deletion amongst this subgroup of 
tumours that did not have an ATM mutation in the second allele compared to 
the subgroup in which there was also an ATM mutation (Tables 5.6 and 5.7). 
Taking the two groups as a whole, the mean and median values for the 
proportion of the CLL clone that carried an 11q deletion was 87 and 78.25%, 
respectively, for the subgroup with an additional ATM mutation, compared to 
50 and 57.2%, respectively, for the subgroup with a second wild type ATM 
allele. Notably, amongst the tumours in the subgroup of 11q-deleted tumours 
with wild type ATM, I was able to demonstrate high levels of ATM activity in 
several tumours that had greater than 75% of CLL cells carrying the 11q 
deletion [CLL185 (90%), CLL19 (95%), CLL25 (97%), CLL138 (80%), CLL 37 
(75%)]. This indicated that it was indeed the residual wild type ATM allele that 
was accounting for the ATM activity in these assays rather than the presence 
of a large subclone of cells with two wild type ATM alleles.  
     By comparison, three of the tumours that I tested for ATM activity from this 
subgroup had only a small clone of cells with the 11q deletion [CLL171 (10%), 
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CLL175 (11%), CLL194 (23%)]. All these tumours also had retained ATM 
activity but, given the small size of the sub-clone with the 11q deletion, this 
pattern might be independent of the mutation status of the second ATM allele. 
Therefore, this type of assay might be unable to distinguish differences in 
ATM activity between 11q-deleted tumours, with and without ATM mutations, 
in those cases where there is only a small subclone that carries the 
chromosome deletion. However; as indicated in this study, those 11q-deleted 
tumours that also have ATM mutations invariably have a high percentage of 
cells carrying the 11q deletion (median 87%) and therefore these would be 
predicted to have impairment of ATM activity, which would thus be identifiable 
with this type of assay.  
      I also tested the up regulation of p53 and induction of p21 expression in 
three tumours with a deletion of 11q and a second wild type ATM allele 
[CLL65 (91% 11q deletion), CLL71 (60%) and CLL37 (75%)] and compared 
these responses to four tumours with a deletion of 11q and a second mutant 
ATM allele [CLL07 (92%), CLL15 (95%), CLL57 (90%), CLL152 (99%)]. Once 
again, the CLL tumours with loss of an ATM allele but with a second wild type 
ATM allele showed a pattern of up regulation of p53 and induction of p21 
expression at 8 hours post IR that was equivalent to that seen in tumours with 
two ATM wild type alleles. By comparison the four tumours with a second 
mutant ATM allele had a deficient response pattern (Figure 6.13). 
      Taken together, the results in this study indicate that CLL tumours with a 
deletion of chromosome 11q can be divided into two functional groups that 
are dependent upon the mutation status of the remaining ATM allele.  
 
 114
Figure 6.13 
  
There was also differential up regulation of p53 and induction of p21 
expression following DNA damage with IR (5Gy) in CLL tumours with an 11q 
deletion depending on the status of the second ATM allele. CLLs 07, 57, 15 
and 152 with an 11q deletion and an ATM mutation had impairment in the up 
regulation of p53 and induction of p21. In comparison, CLLs 37, 71 and 65 
with an 11q deletion and a wild type second ATM allele all demonstrated a 
proficient response. 
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  6.3.2 Tumours with a mutation in one ATM allele 
    There were eleven tumours with a single ATM mutation that had not been 
previously found to have a deletion of chromosome 11q in this study. These 
tumours are therefore also heterozygous at the ATM locus but as a result of a 
mutation rather than an allelic deletion. Viable cells were available in 9 of 
these cases and once again I assessed tumour cell responses to IR. 
    Interestingly, I found that there was a variable pattern of ATM activity in this 
group of tumours. In four cases (CLLs 119, 75, 69, 93), there was a marked 
reduction in ATM activity reminiscent of the situation in the tumours with loss 
of functional both ATM alleles (Figure 6.14). The mutations that gave rise to 
this pattern of impaired phosphorylation of ATM targets were, CLL119 
(9022C/T), CLL75 (1009C/A), CLL69 (6815delA) and CLL93 (5290delC). To 
confirm this pattern of responses, I investigated the phosphorylation of 
multiple downstream targets for CLLs 119 and 75 (Figure 6.15). By 
comparison with CLL138, which had an 11q deletion and a second wild type 
ATM allele, CLLs 119 and 75 both had impaired phosphorylation of ATM, 
SMC1, Nbs1 and p53 and this was particularly marked for CLL119. Indeed 
the responses in CLL119 were similar to those in CLL15 that had lost both 
functional ATM alleles despite the high level of expression of ATM protein and 
a certain degree of serine 1981 ATM phosphorylation in CLL119. 
     In the case of CLL 69, although the level of phosphorylation was 
significantly reduced relative to the control tumour, there nevertheless was 
evidence of some retention of low level ATM activity. The investigation of the 
change in p53 and p21 expression after IR confirmed that CLL 69 did indeed 
have a deficient response. Impairment in the up regulation of p53 and 
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Figure 6.14 
 
There are deficient phosphorylation responses following DNA damage with IR 
(5Gy) in CLL tumours 93, 75, 119 and 69 that all have a mutation in one ATM 
allele but with no loss of the remaining ATM allele, in comparison to CLL 
tumours 61, 158, 138 and 34, respectively, which have no ATM mutations. 
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Figure 6.15 
 
There is impairment of ATM dependent phosphorylation of mutiple targets in 
CLLs119 and 75 with one mutant and one wild type ATM allele in comparison 
to CLL138 with a deletion of chromosome 11q but no ATM mutation following 
IR (5Gy). The deficient responses in CLLs119 and 75 are comparable to the 
deficient response that is seen in CLL15 that has bi-allelic ATM defects. 
Interestingly, the baseline level of ATM protein in CLL119 was higher than in 
CLL138 and therefore this suggested that the deficiency in the 
phosphorylation of downstream substrates in this tumour was due to 
impairment in the function rather than the amount of ATM protein. 
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induction p21 expression was also seen for CLL tumours 119 and 75 (Figure 
6.16).  
      One explanation to account for the abnormal ATM function in these 
tumours is that the mutations are resulting in a dominant negative effect. In 
this situation, the ATM protein that is derived from the mutant ATM allele 
interferes with the activity of the wild type ATM protein. Such a mechanism 
could potentially apply to the mis-sense mutations 9022C/T (CLL119) and 
1009C/A (CLL75), in this study, and indeed a dominant negative effect has 
been previously reported for several ATM sequence changes (Scott SP et al, 
2002). By comparison, such a dominant negative mechanism could not 
explain the impairment of ATM function in the CLLs 93 and 69 that had 
truncating mutations. Thus, it was possible that these tumours harboured a 
second mutation that had escaped detection or that they had acquired a new 
11q deletion.  
     In order to confirm that there was no 11q deletion in the tumours at the 
time that I performed the functional analysis, I undertook FISH studies on 
three of these four tumours (CLLs 69, 75 and 119), where viable cells were 
available. In all three cases, I was able to demonstrate the presence of two 
ATM probes in the tumours cells, thus confirming that there was no deletion of 
chromosome 11q (Figure 6.17). 
      In a further 3 cases [CLL 124 (5228C/T), CLL 84 (8592C/T) and CLL 92 
(5980A/G)] from this genetic category with one wild type and one mutant ATM 
allele, there was some reduction in the level of phosphorylated ATM after 
DNA damage but normal phosphorylation of the downstream target p53.  Two 
of these cases CLL124 and CLL84 also had a mutation in the TP53 gene and 
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 Figure 6.16 
 
There is abnormal up regulation of p53 and induction of p21 expression 
following IR in CLLs 75, 119 and 69 with one mutant and one wild type ATM 
allele compared to CLLs 98, 24, 12 and 91 that all have with two wild type 
ATM alleles. 
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Figure 6.17 
 
There is no evidence of a deletion of 11q in CLLs 69, 75 or 119 using FISH 
analysis. In all three cases there are two red ATM probes as well as two 
green chromosome 11 centromeric probes in all of the tumour cells, 
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Figure 6.17
as such they had high basal levels of p53 protein, which is characteristic of 
tumours with mutant p53 protein (Pettitt AR et al 2001, Stankovic T et al, 
2002). As a result there was actually an increased level of p53 
phosphorylated on serine 15 in these tumours, compared to tumours with two 
wild type ATM alleles. The lower levels of auto-phosphorylated ATM in these 
tumours could indicate that, despite the preserved phosphorylation of one 
downstream target, the ATM mutation is interfering with certain specific 
aspects of ATM function (Figure 6.18). However, it is difficult to conclude that 
these tumours have an impairment of ATM activity based only on experiments 
that show reduced levels of ATM phosphorylation since many tumours that 
are heterozygous at the ATM locus, due to an 11q deletion, also have 
reduced levels of phosphorylated ATM after IR. Notably, however, in the case 
of CLL124 the defective up regulation of phosphorylated ATM did not appear 
to be simply due to a reduction in the level of ATM protein (Figure 6.18). In all 
three cases, I would ideally need to assess the phosphorylation of additional 
downstream targets to determine with certainty if there was defective ATM 
function. These experiments were not possible due to the lack of further viable 
cells. 
     In the remaining two cases, CLL 113(3964C/A) and CLL27(3383A/G), in 
this subgroup, all aspects of ATM function were equivalent to tumours with 
two wild type ATM alleles, suggesting retained ATM activity (data not shown).  
       Altogether I have shown that the group of tumours with one mutant ATM 
allele and one wild type ATM allele behaved heterogeneously with respect to 
the cellular ATM activity in this study. From the nine cases investigated, there 
was deficient ATM activity in four cases, with the possibility of impairment of 
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Figure 6.18 
 
There is an increased level of phosphorylated p53 on serine 15 in CLL124, 
which has an ATM and a TP53 mutation in comparison to CLL42 with wild 
type ATM and TP53 genes following IR (5Gy). By comparison there is a 
reduced level of phosphorylated ATM on serine 1981 in CLL124, despite 
normal levels of ATM protein. This suggests impairment in one aspect of ATM 
function in CLL124 as a consequence of the ATM mutation. 
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the function of ATM in additional cases and retained ATM activity in at least 
two cases.  
    All the tumours with one mutant and one wild type ATM allele were derived 
from the unselected cohort. In addition to these eleven cases, there were also 
seven tumours from this cohort that had abnormal ATM activity as a 
consequence of two abnormal ATM alleles (Table 4.3). Therefore, the majority 
of tumours that had ATM mutations from this unselected cohort could be 
demonstrated to have some impairment of ATM activity and this would 
suggest that loss of ATM function is the mechanism for the poor clinical 
outcome that I observed in this group of patients.  
 
6.4 Role of the ATM protein in the cellular response to fludarabine 
       Having investigated the functional consequences of ATM mutations in 
CLL tumours in the response to IR, I next assessed their impact on the 
response to fludarabine. Initially, I investigated the role of ATM in the 
response to fludarabine using primary CLL tumour cells that were known to 
have two wild type ATM alleles, and subsequently I assessed the effects of 
combination of mutations and deletion of ATM alleles on these responses.  
 
6.4.1 Induction of DNA breaks by fludarabine  
      To investigate whether fludarabine leads to the induction of double strand 
DNA (dsDNA) breaks in CLL tumour cells, I performed immunofluoresence 
experiments. Following DNA damage, a γH2AX focus will form at the site of 
each dsDNA break and, as such, the formation of these foci is a highly 
specific marker for the level of dsDNA breaks in each cell. I was able to 
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confirm the induction of γH2AX foci in two representative CLL tumours with 
wild type ATM genes following treatment with fludarabine. These foci were 
detectable after 8 hours of incubation with 10μM of Fludarabine and were 
more obvious after 24 hours of treatment. At 24 hours the frequency and 
prominence of γH2AX foci were similar to that seen in CLL cells 3 hours after 
irradiation (Figure 6.19).     
 
6.4.2 Induction of phosphorylation responses by fludarabine 
    Having demonstrated that fludarabine leads to production of DNA DSBs, I 
next wanted to assess whether there was evidence of induction of ATM 
dependent phosphorylation responses. Initially, I performed a time course 
experiment. In keeping with the timing of the induction of γH2AX foci, I 
showed that phosphorylation of both ATM and p53 could be detected after 4 
and 8 hours of treatment with 20μM fludarabine but these responses were 
maximal after 24 hours of treatment. There was also evidence of up regulation 
of the total p53 levels, indicating stabilisation of the p53 protein through 
phosphorylation, after 4 hours treatment with fludarabine which was again 
further increased after 24 hours (Figure 6.20). 
     In order to verify that these phosphorylation responses were an effect of 
the fludarabine rather than a non-specific effect of cell culture, I performed an 
experiment where CLL cells were cultured both in the presence and absence 
of fludarabine for up to 48 hours. I showed that, while there was 
phosphorylation of ATM, SMC1 or p53 in the cells treated with fludarabine, 
these targets were not phosphorylated after 24 hours of culture in the 
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Figure 6.19 
 
There is induction of γH2AX foci, as detected by immuno-fluorescence, 
following 8 and 24 hours of treatment with fludarabine in a CLL tumour. The 
numbers of foci within each CLL cell nuclei is greatest after 24 hours of 
treatment with fludarabine and at this time point the frequency of foci per cell 
are similar to that seen in CLL tumours cells at 3 hours after IR (5Gy). 
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Figure 6.20 
  
There is phosphorylation of ATM on serine 1981 and p53 on serine 15 
following treatment with fludarabine in CLLs 13 and 131 that had two wild type 
ATM alleles. This could be detected after 4 hours treatment with fludarabine 
but was maximal after 24 hours of treatment. 
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absence of the drug, therefore, confirming that the responses were indeed 
due to fludarabine (Figure 6.21).  
     In addition, I also assessed the cleavage of PARP1 as an indication of 
apoptosis in these tumours. I was able to demonstrate that there was only 
evidence of induction of apoptosis in the cells that were treated with 
fludarabine. This was evident after at 48 hours of fludarabine treatment, 
whereas the phosphorylation responses were present after 24 hours of 
treatment. Therefore, this affirmed that the activation of this DNA damage 
response pathway was a direct effect of fludarabine leading to the induction of 
dsDNA breaks, and not a non-specific late event resulting from DNA 
fragmentation in association with apoptosis (Figure 6.21). 
 
6.4.3 Effects of ATM mutations in the response to fludarabine  
     Although ATM is the principal protein in the cell that coordinates the 
response to dsDNA breaks there is also some redundancy between ATM and 
related proteins, most notably Ataxia Telangiectasia Related protein (ATR). 
ATM is known to be particularly important for a rapid kinetic response 
following DNA damage but other related proteins such as ATR can perform 
many of its functions but with slower kinetics (Helt CE et al 2005, Myers JS et 
al, 2006). Ionising irradiation leads to the immediate and simultaneous 
induction of a large number of DNA breaks whereas the kinetics of drug 
induced DNA damage are more complex. As I have demonstrated in the 
experiments above, DNA DSBs appear to accumulate over time in CLL 
tumours following fludarabine treatment. Therefore, there is a possibility that 
ATM is not an absolute requirement for the induction of the phosphorylation 
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Figure 6.21 
 
There is phosphorylation of p53 and SMC1 in CLLs 135 and 109, which have 
wild type ATM, following 24 hours of treatment with fludarabine. There is no 
phosphorylation of these targets in tumours cells that were cultured in the 
absence of drug.  
Cleavage of PARP1, as an indicator of apoptosis, occurs following 48 hours of 
treatment with fludarabine. There is no PARP1 cleavage in the cultured cells 
in the absence of fludarabine, indicating an absence of spontaneous 
apoptosis. 
Therefore, the phosphorylation responses are a direct effect of fludarabine. As 
these responses precede the onset of apoptosis, this indicates that 
fludarabine must be directly activating the DNA damage response pathway 
rather than the activation of this pathway occurring as a late event in 
association with apoptosis and non-specific DNA fragmentation. 
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responses that I had observed in the CLL tumours after fludarabine treatment. 
To clarify the specific role of ATM in the response to fludarabine, I 
investigated the activity in this pathway in tumours with ATM mutations that 
had been previously shown to have deficient responses to DNA damage with 
IR [Figures 6.3 (CLL152), Figure 6.4 (CLL11)]. 
    I demonstrated defective phosphorylation of the ATM targets including ATM 
on serine 1981, SMC1 on serine 966, p53 on serine 15 and Nbs1 serine on 
343, following treatment with fludarabine in the 2 tumours (CLLs152 and 11) 
with abnormal ATM function, consequent of bi-allelic ATM defects, in 
comparison to the proficient phosphorylation of these targets in 5 CLL 
tumours (CLLs 135, 32, 13, 131 and 109) with two wild type ATM alleles 
(Figure 6.22).  
       I next wanted to investigate whether there were differential responses, 
similar to those I had observed with IR, between the 11q deleted tumours with 
a second wild type ATM allele compared to those with a second mutant ATM 
allele. I studied the responses in 4 tumours with an 11q deletion and no 
mutation in the second ATM allele [CLLs 138 (80% of cells with an 11q 
deletion), 37 (75%), 25 (97%), 65 (91%)] and 4 tumours with both an 11q 
deletion and an ATM mutation [CLLs 07 (92% of cells with an 11q deletion), 
169 (100%), 152 (99%), 57 (90%)]. The tumours with loss of an ATM allele 
but with a remaining wild type allele demonstrated ATM phosphorylation of 
targets following fludarabine treatment that was equivalent to that seen in 
tumours with two wild type ATM alleles. However, the CLLs with an 11q 
deletion and a mutant ATM allele all demonstrated deficient responses to 
fludarabine (Figure 6.23).  
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 Figure 6.22 
 
There is deficient phosphorylation of ATM, SMC1, Nbs1 and p53 following 
treatment with fludarabine in CLL152 and 11, which have bi-allelic ATM 
defects, in comparison to the responses in CLLs 135, 32, 13, 131 and 109, 
which have 2 wild type ATM alleles. 
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 Figure 6.23 
  
There are differential responses to fludarabine according to the status of the 
remaining ATM gene in CLL tumours with an 11q deletion. CLLs 57, 169, 07 
and 152, with an 11q deletion and a mutant ATM allele, have impaired 
phosphorylation of both ATM and p53 following treatment with fludarabine at 
24 hours. In contrast, CLLs 138, 37, 25 and 65, with an 11q deletion but a 
second wild type ATM allele, have normal phosphorylation responses which 
are equivalent to CLLs 32, 109, 40 and 135 that have two wild type ATM 
alleles. 
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      These results, therefore, provide direct evidence for the role of ATM in the 
response to fludarabine, and indicate that proteins such as ATR cannot fully 
compensate for the function of ATM in CLL tumours with ATM deficiency. 
They also provide further evidence to suggest that CLL tumours with an 11q 
deletion form functional subgroups according the mutation status of the ATM 
allele and that this impacts on the responses to DNA damaging 
chemotherapeutic drugs as well as irradiation. 
 
6.5 Conclusions 
      In this chapter, I have demonstrated that those CLL tumours with two or 
more ATM genetic defects had impairment of ATM activity. It should therefore 
be possible to identify these tumours using functional measurements of ATM 
activity and I have shown that measurement of the early phosphorylation 
responses after DNA damage with irradiation was the most specific assay. I 
have also shown that ATM mutations have an impact on the downstream p53-
dependent apoptotic pathway, therefore validating the pathogenic nature of 
the mutations, which I had identified. 
       The functional consequences of an abnormality of a single ATM allele are 
less clear. The subgroup of tumours with one mutant allele and one wild type 
ATM allele behaved heterogeneously with respect to the responses to DNA 
damage. While several tumours had a deficient response, the response in 
other tumours was either normal or possibly partially deficient. In contrast, the 
subgroup of tumours with loss of one ATM allele through an 11q deletion but 
with a second wild type ATM allele behaved more homogeneously and had 
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retained ATM activity that was similar to that seen in tumours with two wild 
type ATM alleles.  
      The mechanism of action of many drugs used in treatment of CLL involves 
DNA damage. In this study I have shown that the chemotherapeutic drug, 
fludarabine induces DNA DSBs and leads to the induction of ATM dependent 
phosphorylation responses. In comparison to the tumours with two wild type 
ATM alleles, I observed impairment in these responses in those tumours with 
an ATM mutation and an 11q deletion but proficient responses in tumours with 
one retained wild type ATM allele. 
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Discussion 
 
 
     The purpose of my project has been to study the role of ATM mutations in 
the pathogenesis of chronic lymphocytic leukaemia. I have examined the 
prevalence of ATM mutations, their nature and distribution across the gene, 
the timing of their occurrence and both their clinical consequences in CLL 
patients and cellular consequences in CLL tumours. I would like to discuss my 
results by considering the value of ATM mutations as a prognostic marker in 
CLL patients and the implications of ATM mutations in the biology of CLL 
tumours. 
 
7.1 ATM mutations as a prognostic marker in CLL   
      Due to the marked clinical heterogeneity of CLL, an important focus of the 
research in this disease has been to identify biological markers that can both 
be useful in the clinical setting and also lead to an increase in the 
understanding regarding the nature of CLL.  
       In order for ATM mutations, or any other candidate parameter, to be 
potentially useful as a prognostic marker in CLL, they should ideally: 
a) Have a significant prevalence in CLL  
b) Impact on clinical outcome 
c) Occur early in the course of the disease 
d) Provide independent prognostic information  
e) Be readily detectable 
f) Provide an insight into the biology of CLL 
g) Guide therapeutic decisions 
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7.1.1 Prevalence of ATM mutations in CLL patients  
    I found ATM mutations in 18 out of 155 unselected CLL patients, which 
corresponds to a prevalence of 12%. This is lower than has been found in 
previous smaller cohorts. However, whereas previous studies have included 
more patients with aggressive disease features, my cohort was characterised 
by a high proportion of individuals with indolent disease (Stankovic T et al, 
2002, Schaffner C et al, 1999). For example, there were 70% of patients with 
mutated IGVH genes and just 20% had advanced stage B or C disease at 
diagnosis in my study.  
     My aim had been to establish a representative spectrum of CLL patients 
that is seen in haematology departments in order to investigate the proportion 
of the patients that had ATM mutations. The type of cohort that I established 
in this project will include more patients with indolent disease than a cohort 
that is based on the identification and follow up of all patients diagnosed with 
CLL. This is because in my cohort, which included all patients that currently 
had CLL at a given time period, more patients with indolent disease than with 
aggressive disease will have survived in order to be included in the cohort. As 
a result, if the mutations have a detrimental effect on survival, then the 
prevalence of ATM mutations in a group of CLL patients at any one time will 
be lower than the frequency of CLL patients that actually develop ATM 
mutations.  
      The number of mutations detected will also be affected by the sensitivity 
of the analysis method that is utilised. I used DHPLC for mutation screening 
and this method has been previously reported to have a sensitivity that is as 
high as 90% for the detection of mis-sense changes or small deletions and 
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insertions in the ATM gene (Bernstein JL et al, 2003).  However, to achieve 
such a high sensitivity requires the analysis of certain exons with complex 
denaturing profiles at more than one temperature. In this study, due both to 
the large size of the ATM gene and the large number of CLL and control 
cases that were analysed, a compromise temperature for each exon was 
chosen and this may have led to a reduction in the sensitivity for mutation 
detection for certain ATM exons. However, I was able to reliably detect the 
common polymorphisms that are known to occur in the ATM gene, and I also 
found a large number of less common polymorphic variants suggesting that 
the DHPLC method was indeed detecting the vast majority sequence changes 
that were actually present in the ATM gene in this study. 
        Mutation detection by DHPLC relies on the development of 
heteroduplexes and thus requires the presence of both alleles of a gene. 
Therefore, in all cases that were known to have an 11q deletion I performed 
mixing experiments as outlined in the methods. However, since the 11q status 
was not known for all the tumours in the cohort, this could also have 
potentially resulted in a failure to detect a mutation that was in fact present. 
Nevertheless, I do not think that this had a major effect on the sensitivity of 
mutation detection in this cohort. Given the known prevalence of 11q 
deletions in CLL, it is unlikely that there would have been a significant number 
of tumours with an unknown chromosome 11q deletion. Furthermore, 
heteroduplexes were still detected in the majority of tumours that were known 
to have an 11q deletion even in the absence of mixing experiments. 
Previously, it has been shown that only 5% of the cells present need to have 
two alleles in order to allow heteroduplex detection by DHPLC (Xiao W, 
 126
Oefner PJ, 2001). Notably, in CLL tumours that have an 11q deletion there is 
frequently a small sub-clone that retains both intact chromosomes, as 
presented in the results of this study (Dewald GW et al, 2003). Finally, the 
ability to detect an ATM polymorphism in any sample indicates that it was 
possible to form heteroduplexes and, therefore, it should also be possible to 
detect a mutation. In this study one or more ATM polymorphisms were 
detected in 107 patients from the cohort 155 of patients.  
      Thus, in summary, I found that ATM mutations do indeed affect a 
significant proportion of all CLL patients. My results indicate that within an 
unselected population of CLL patients, approximately 12% of patients are 
likely to carry an ATM mutation at any point in time. This would therefore 
represent the commonest single genetic defect to be identified in CLL 
patients. However, as discussed above, the proportion of the total population 
of patients diagnosed with CLL that acquire an ATM mutation at some time in 
their disease is almost certainly higher than this prevalence of patients with an 
ATM mutation at a given time point. This is clearly an important consideration 
when determining the prospective value of a biological marker. 
  
7.1.2 The impact of ATM mutations on clinical outcome 
     The most fundamental characteristic of a prognostic marker is its ability to 
predict outcome. The consequences on clinical outcome of ATM mutations in 
CLL patients have not been previously assessed. I analysed the effects of 
ATM mutations on the overall survival (OS) of CLL patients from diagnosis 
and on the time for requirement of treatment, namely, the treatment free 
survival (TFS).   
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       Outside the context of a clinical trial, the OS and TFS from diagnosis are 
established ways to assess the effects of a biomarker on clinical outcome and 
have been previously used to validate various prognostic markers in CLL, 
such as IGVH mutation status, Zap-70 expression and cytogenetic 
abnotmalities (Damle RN et al 1999, Hamblin T et al 1999, Dohner H et al 
1999, Wiestner A et al, 2003). Parameters such as the attainment or 
persistence of complete or partial remissions are more difficult to assess 
outside a trial because CLL patients will typically have received a wide variety 
of different treatment schedules (Oscier D et al, 2004). OS and TFS reflect 
different aspects of disease biology and ideally a prognostic marker will 
impact on both parameters. 
     OS from diagnosis encompasses both the need for treatment together with 
the degree and persistence of any initial and subsequent treatment 
responses. However, not all deaths in CLL patients will be related to their 
underlying disease due to the high median age of onset of this disease. In 
addition, the distinction between leukaemia-related deaths and unrelated 
deaths is not always straightforward because immune dysregulation can 
increase the risk of infection, auto-immune disease and also secondary 
malignancies (Oscier D et al, 2004). However, any non-leukaemia related 
deaths would be expected to occur in equal proportions in all subgroups.  
     TFS reflects the extent and severity of the disease because only CLL 
patients that have a significant disease burden leading to clinical symptoms 
will receive treatment. However, TFS clearly does not encompass either the 
degree of response to treatment or the persistence of that response. It is also 
less objective than OS because there may be inter-physician variation in the 
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threshold for initiating treatment and the decision to commence treatment 
might be influenced by factors such as patient age and co-morbidity, in 
addition to the severity of the CLL (Oscier D et al, 2004). 
      This study was largely a retrospective study, where the tumours samples 
were collected and analysed for ATM mutations over a given time period but 
survival parameters were measured from the time of diagnosis to the time of 
either death or treatment or, if these had not occurred, to the time of the data 
analysis. Such a retrospective approach has been used to evaluate the 
impact of several prognostic markers in CLL and although a prospective study 
would be advantageous, it would take many years to accumulate data due to 
the long median survival of CLL patients (Damle RN et al 1999, Hamblin T et 
al 1999, Dohner H et al 1999, Wiestner A et al, 2003). A retrospective 
approach assumes that the biomarker that is being evaluated was in fact 
present at the time of diagnosis and is stable over time. Furthermore, as 
discussed above, in retrospective studies there is the potential for the impact 
of a marker to be influenced by the fact that more patients with indolent 
disease will survive to be included in a cohort.  
      By the approach taken in this study I was able to show that patients with 
ATM mutations had a statistically significant reduction in both treatment free 
survival and overall survival compared to patients that retained wild type ATM 
genes. This is a novel finding and provides key clinical evidence to support 
the hypothesis that the loss of function of ATM is important in influencing the 
behaviour of the CLL tumour cells. Since ATM mutations had a clear impact 
on both parameters, this indicates that ATM mutations influence the behaviour 
of the tumour before treatment as well as the extent of treatment responses.  
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     The timing of ATM mutations is discussed below, but one would assume 
that any mutations developing after diagnosis would lead to an under- rather 
than over-estimation of their effect on a parameter that is measured from the 
time of diagnosis. To investigate the effect of the retrospective nature of my 
cohort on the clinical consequences of the ATM mutations I included the ‘era 
of diagnosis’ as a parameter in the multivariate analysis.  By this method, I 
was able to confirm that the retrospective nature of the cohort had resulted in 
an underestimation of the impact of ATM mutations on OS and that the true 
effect might be even higher. 
 
7.1.3 The timing of ATM mutations  
      In order to have value as a biomarker the development of an ATM 
mutation would ideally have to be an early event in the pathogenesis of CLL 
and would have to pre-date the clinical signs of an aggressive phenotype 
such as advanced stage or rapid lymphocyte doubling time.  
      I investigated the timing of the development of ATM mutations in this 
study by assessing germ-line material and also by performing a ‘look back’ 
analysis in those tumours where material was available that had been 
collected at earlier times during the disease course. Altogether, germ-line 
mutations were detected in 5 CLL patients, 3 from the original unselected 
cohort and 2 from the cohort of 11q-deleted tumours. Clearly these mutations, 
by definition, would be present at the time of diagnosis of the disease. As part 
of the look back analysis, I found that 7 out of the 9 acquired ATM mutations 
assessed were present in the earlier sample, which in most cases had been 
collected around the time of diagnosis. However, two of the acquired 
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mutations could be demonstrated to have occurred at a time after diagnosis 
and, notably, in both cases this late development of an ATM mutation 
occurred in tumours that also had an 11q deletion.  
      Thus, these results indicate that ATM mutations are often early events in 
the pathogenesis of CLL suggesting they would indeed pre-date clinical signs 
of more rapid disease progression and have predictive value. However, this is 
not exclusively the situation and in certain tumours, possibly more commonly 
in those that already have an 11q deletion, ATM mutations can occur at a 
later stage during disease progression. Interestingly, both 17p and 11q 
deletions have also been reported to occur at stages after the initial diagnosis 
and these markers are established prognostic markers in CLL, suggesting 
that there is still predictive value in detecting these changes because they 
may herald a change in disease behaviour (Cuneo A et al, 2002, Chevalier P 
et al, 2002). The relationship between the timing of development of ATM 
mutations compared to 11q deletions is discussed later. 
       
7.1.4 Association with existing prognostic markers 
     ATM mutations could impact adversely on survival due to their association 
with other poor prognostic factors such as age, stage, IGVH mutation status, 
TP53 mutations, CD38 expression, Zap-70 expression and cytogenetic 
abnormalities. Ideally, in order to have novel value as a prognostic marker, 
they should provide information that is independent of existing markers.   
     In this study there was no association between ATM mutations and either 
age or clinical disease stage at diagnosis, and the prognostic value of ATM 
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mutations was not affected by either of these parameters in the multivariate 
analysis. 
     Previously, ATM mutations had been found to occur exclusively in CLL 
tumours with unmutated IGVH genes (Stankovic T et al, 2002). In this study, 
there was a positive association between ATM mutations and unmutated 
IGVH genes, but I also identified tumours with mutated IGVH genes that had 
ATM mutations. Furthermore, by using Cox regression multivariate analysis, I 
was able to demonstrate that ATM mutations still had an adverse prognostic 
effect regardless of IGVH mutation status, therefore indicating that they were 
providing independent prognostic information. One explanation to account for 
this finding is that tumours with IGVH unmutated genes may be more likely to 
acquire ATM mutations but that once an ATM mutation has occurred in a CLL 
tumour it exerts a detrimental effect regardless of the IGVH mutation status of 
that tumour. 
      The presence of ATM and TP53 mutations in the same tumour had not 
been previously reported in CLL tumours, suggesting that these genetic 
defects were occurring in distinct CLL subgroups. In this cohort of 155 
tumours I found that two of the eighteen tumours with ATM mutations also 
had mutations the TP53 gene. In addition, I found TP53 mutations in a further 
4 independent tumours. When I compared OS and TFS between the three 
genetic subgroups, namely ATM mutant, TP53 mutant and ATM/TP53 wild 
type, I was able to show that the differences in both OS and TFS between the 
three groups were highly statistically significant for both parameters. For this 
comparison the two tumours with ATM and TP53 mutations were included in 
the TP53 mutant subgroup and therefore these results indicate that ATM 
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mutations are identifying a subgroup of CLL tumours with a poor outcome that 
is independent of the presence of TP53 mutations. The OS in patients with 
ATM mutations could be shown to be intermediate between patients with 
TP53 mutations and patients with wild type ATM and TP53 genes, while the 
TFS survival for ATM mutant patients was similar to that of patients with TP53 
mutations.  
      The relationship between ATM mutations and Zap70 status and CD38 
status was not specifically addressed in this study, and this warrants 
investigation in the future. 
      Thus, I demonstrated that ATM mutations provide prognostic information 
that is independent of age, clinical stage, IGVH mutation status and TP53 
mutation status in CLL tumours. These results therefore indicate that ATM 
mutations are identifying a subgroup of CLL tumours that have a poor 
outcome as a direct consequence of the mutation.  
 
7.1.5 Relationship between ATM mutations and 11q deletions 
     The relationship between CLL tumours with ATM mutations and those with 
a deletion of chromosome 11q is of interest since all tumours found to have 
an 11q deletion will have loss of one ATM allele as it is an ATM probe that is 
used to detect the deletion. Therefore, if the ATM gene behaved as a classic 
tumour suppressor gene, it might be expected that there would be a close 
correlation between those CLL tumours with an 11q deletion and those with 
ATM mutations. Evidently if both were markers were identifying the same CLL 
tumour subgroup then there would be no additional prognostic value in 
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assessing the mutation status of the ATM gene over and above identifying 
tumours with 11q deletions.  
     In the cohort of 155 unselected CLL patients only four tumours that had 
ATM mutations also had a chromosome 11q-deletion. In addition there were 
also five tumours that had been found to have an 11q-deletion but where no 
ATM mutation was identified. However, since the 11q status was not known 
on all the tumours from this cohort it was not possible to perform statistical 
analysis, such as that used with the IGVH status, to assess if ATM mutations 
provide prognostic data that is independent of 11q-deletions in CLL. 
      Therefore, in order to further investigate the relationship between ATM 
mutations and 11q deletions I studied a second cohort of 53 tumours that all 
had a chromosome 11q-deletion. I detected ATM mutations in 20 of these 
tumours which corresponds to a prevalence of ATM mutations in CLL tumours 
with an 11q deletion of 39%. This result indicates that ATM mutations are 
around three fold more common in CLLs that have an 11q deletion than in 
unselected CLL tumours. This prevalence of 39% is higher than previously 
found in a smaller study where ATM mutations were identified in 5 of 22 
tumours with an 11q deletion, and this probably reflects the fact that in the 
previous study mutation analysis was restricted to a ‘C’ terminal portion of the 
ATM coding sequence (Schaffner C et al, 1999).  Nevertheless, this study 
corroborates my own results in suggesting that many 11q-deleted tumours do 
not have a mutation in the second ATM allele. These results, together with the 
findings in this study which show that a majority of tumours with ATM 
mutations do not have an 11q deletion, demonstrates that there is only a 
partial correlation between those CLL tumours with an 11q-deletion and those 
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with an ATM mutation. Thus, although there is an association between these 
two genetic defects, an 11q deletion is not a surrogate marker for the 
presence of an ATM mutation. 
       Since not all of 11q-deleted tumours have an ATM mutation I was 
interested to know if ATM mutations could stratify these tumours into two 
subgroups. In other words, could the presence of an ATM mutation provide 
additional prognostic information in this group of patients that are already 
known to have a poor outcome? Therefore, I analysed OS and TFS in the 
second cohort, where all patients had a deletion of chromosome 11q. 
Interestingly, there was a trend for a poorer overall survival, which 
approached significance, in those patients that had an ATM mutation in 
addition to an 11q-deletion compared to those that had a remaining wild type 
ATM allele. However, there was no significant difference in TFS between the 
two subgroups, although this was also slightly shorter in the patients with an 
additional ATM mutation in this study.  
     There are number of explanations to account for these results. Firstly, 
there may be a genuinely worse outcome in the patients with an 11q deletion 
and an additional ATM mutation, compared to those with a second wild type 
ATM allele, but because this difference is a relatively small it would require a 
study of a larger size to confirm. Alternatively, there may be no difference 
between the subgroups, suggesting that the effect of ATM function is not the 
principal factor that influences clinical outcome in these patients with an 11q 
deletion. As discussed later, the poor outcome in these patients could be 
related to the loss of other genes on chromosome 11q since the minimally 
deleted region, which has been defined, spans from 11q22.3 to q23.1 and 
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contains a large number of genes (Stilgenbauer S et al, 2006). Finally, it is 
possible that these two subgroups are not entirely stable over time. Thus, 
certain patients whose tumours have an 11q deletion could acquire an ATM 
mutation during the course of the disease and this would make longitudinal 
comparisons of survival measured from diagnosis between the two 
‘subgroups’ difficult to interpret. The timing of ATM mutations and their 
functional consequences in this group of 11q-deleted CLL tumours are 
considered later in this discussion. 
     The possibility that ATM mutations could stratify clinical outcome in 
patients with 11q deletions is an interesting and potentially important question 
with translational implications. One way to address these issues would be to 
analyse a more homogeneous group of patients with an 11q-deletion in their 
tumour cells. For example, this could involve the ATM mutation analysis of 
samples that had been collected at the time of diagnosis, which were found to 
have a deletion of chromosome 11q, with subsequent follow up of outcome. 
Although interesting, such a study would take time to accumulate data. An 
alternative approach would be the analysis of the ATM gene in a group of 
11q-deleted tumour samples that had all been collected prior to the 
commencement of the first treatment, ideally that were part of a clinical trial. 
This would then allow the assessment between the mutation status of the 
remaining ATM allele and the degree of treatment response in patients with 
an 11q deletion. Furthermore, the analysis of trial samples would ensure a 
uniformity of treatment schedules between patient groups and the effect of 
ATM status could also be correlated to efficacy of the different treatment 
arms. 
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      Thus, I have shown that ATM mutations are associated with 11q-deleted 
tumours, and occur three times more commonly in this subgroup of CLL 
tumours than in unselected CLL tumours. However, there is only a partial 
correlation between those tumours with an 11q deletion and those tumours 
with ATM mutations. In addition, my results indicate that ATM mutations might 
clinically stratify the group of patients with 11q deletions and this will be a very 
interesting area to study in the future. 
          
7.1.6 Identification of ATM mutant tumours by functional analysis     
       Prognostic markers that will have value in the clinical setting need to be 
readily detectable. ATM is a very large gene and therefore mutation screening 
is expensive and time-consuming. In addition the mutations detected in this 
analysis were distributed across the whole gene with only minimal clustering 
of the missense changes towards the ‘C’ terminus of the gene. This indicates 
that restricting analysis to just that section of the ATM gene, as previously 
reported, will significantly reduce the sensitivity of detection (Schaffner C et al, 
1999). It is also unlikely that simple PCR-based tests, such as that developed 
to detect the V167F mis-sense mutation in the JAK2 gene in 
myeloproliferative disorders, can be developed for the ATM gene because the 
mutations in ATM are not characterised by one or several recurrent changes 
(Kralovics R et al, 2005). Therefore, widespread mutation screening of the 
ATM gene in CLL tumours may not be possible outside the setting of a 
research laboratory. Instead, functional assays that reliably identify those 
tumours harbouring ATM mutations might have greater clinical potential. 
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      The most specific role of the ATM protein in the cell is the very early 
response to DNA damage in the form of DSBs and ATM signals this damage 
by directly catalysing the phosphorylation of serine or theronine residues on 
numerous target substrates (Kurz EU, Lees-Miller SP, 2004). Therefore, it is 
likely that the assessment of these responses will most reliably reflect ATM 
function. One of the target substrates for ATM in this pathway is the p53 
protein and as a consequence of ATM-dependent phosphorylation the level of 
p53 in the nucleus is up regulated (Meek D, 2004). The effects of both ATM 
and TP53 mutations in CLL tumours have been previously investigated by 
assessing the levels of p53 and its transcriptional target, p21, following DNA 
damage with ionising irradiation. Recently, however, it has been shown that a 
polymorphism in the p21 protein can also influence its own level of expression 
in CLL tumours after IR, potentially making this functional test less useful for 
the classification of CLL tumours according to their underlying ATM status 
(Pettitt AR et al 2001, Carter A et al, 2006).  
        In this project I evaluated the effects of ATM mutations on the early 
phosphorylation of substrates after DNA damage with IR. I demonstrated that 
in tumours with wild type ATM there was phosphorylation of a range of 
downstream substrates that could be detected by 15 minutes after irradiation 
and were further increased by 45 minutes. By comparison, all of the tumours 
with bi-allelic ATM defects, which might be predicted to have impaired ATM 
function, had deficient phosphorylation of these downstream substrates at 
these time-points in this study.  
     I compared these early phosphorylation responses with the later changes 
in p53 and p21 levels after DNA damage with IR. Amongst the tumours with 
 138
bi-allelic ATM defects, there was a good correlation between these two 
assays. Interestingly, however, several of the tumours in which no ATM 
mutations had been detected exhibited impairment in the up regulation of p53 
and failed to induce p21 expression. In three of these tumours I also assessed 
the early phosphorylation responses and in all three cases the ATM 
dependent phosphorylation of substrates was preserved. This suggested that 
the early ATM dependent phosphorylation responses might be a better 
reflection of ATM activity than the downstream changes in p53 and p21 levels.  
      Thus, I have demonstrated that measurement of the early ATM dependent 
phosphorylation of substrates after DNA damage with irradiation is a reliable 
method to assess ATM function in CLL tumours and that this assay might be 
more specific for the presence of ATM genetic defects than the later changes 
in p53 and p21 levels. I found that there was a good correlation between the 
phosphorylation of different target substrates following IR. I initially compared 
the phosphorylation of ATM and p53 and subsequently also studied the 
targets SMC1 and Nbs1. Generally my results indicated that the use of two 
downstream substrates such as SMC1 and p53 were the most reliable in 
order to assess ATM activity. This was partly due to the efficacy of the 
antibodies against these proteins but in addition because the assessment of 
the level of phosphorylated ATM after DNA damage will reflect the level of 
ATM protein as well as its activity. I also found that the reliability and 
objectivity of these assays was improved by expressing the level of each 
phosphorylated protein in relation to the total level of the respective protein at 
each time point, therefore controlling for any differences in the baseline level 
of these target substrates between tumours.  
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       In all these experiments I have measured the changes in the expression 
of protein and phosphorylated protein using Western blotting. Interestingly, a 
recent publication assessed the changes in p53 and p21 levels after DNA 
damage using a FACS approach in order to classify CLL tumours (Carter A et 
al, 2004). This may be more convenient in a clinical diagnostic laboratory and 
it is possible that a similar FACS assay could be developed to measure the 
ATM dependent phosphorylation of substrates. This might have improved 
specificity and would also have the advantage of a much shorter time course 
for the assessment of the response to DNA damage. Furthermore, the assay 
could also be adapted to use agents such as etoposide or neocarcinostatin to 
induce the DNA DSBs, which would avoid the requirement of irradiation (D 
Oscier - unpublished data).   
      Such a functional assay could provide a means of routinely testing CLL 
tumours for deficient ATM function in a prospective manner. Although there 
are practical advantages for this type of functional test, there are also certain 
advantages for a genetic screening approach. These include the objectivity of 
the results and the lack of requirement for viable cells. Assays measuring 
ATM function may also not identify all CLL tumours with ATM mutations. 
There may be tumours with a single ATM mutation and no loss of 
heterozygosity, where the mutation does not impact on the ATM function in 
the tumour cell. Furthermore, it is possible that an ATM mutation and / or a 
loss of an ATM allele may only be present within a sub-clone of the entire CLL 
tumour clone, and this could also lead to the appearance of retained ATM 
function using an assay that measures ATM activity on the whole tumour 
clone.  
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      In this study the poor clinical outcome was related to the whole group of 
patients that had ATM mutations but, as discussed later, the identification of 
those tumours that have deficient ATM function might be the most clinically 
relevant with regard to treatment decisions. 
 
7.1.7 Insight into the biology of CLL  
       The mechanisms through which prognostic markers might differentiate 
CLL tumours into subgroups have been studied for several existing 
biomarkers including IGVH status, CD38 and Zap70 and have thus increased 
the understanding of the biology of this tumour (Hamblin TJ et al, 1999, 
Damle RN et al, 1999, Dohner H et al, 2000, Wiestner A et al, 2003). In the 
second section of this discussion, I will consider the mechanisms by which 
ATM mutations affect the biology of CLL and how the status of the ATM gene 
might influence therapeutic decisions in the future. 
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7.2 The implications of ATM mutations in the biology of CLL tumours 
      ATM mutations may impact on the biology of B-CLL by having a role in the 
development of the CLL clone as well as by affecting the behaviour of the CLL 
clone once it has been established.  
 
7.2.1 The role of ATM in the development of the CLL clone 
     The molecular basis underlying the genetic predisposition in CLL has not 
been established (Sellick GS et al, 2006). The ATM gene has been 
considered to be a candidate gene due to its high frequency in CLL tumours 
and also because AT patients are known to have a 200-fold increased 
incidence of lymphoid tumours, including those of B-cell origin. In addition, 
germ-line ATM mutations have been reported to occur in CLL tumours and 
certain specific ATM polymorphisms have also been found to associate with 
CLL patients versus controls (Stankovic T et al, 2002, Rudd MF et al, 2006). 
Furthermore, in addition to the potential role of germ-line ATM sequence 
changes in the predisposition to CLL, there is also a possibility that acquired 
ATM mutations could contribute to the development of the B-CLL tumour 
clone if they arose at or before the time of clonal transformation. 
 
7.2.1.1 Germ-line ATM mutations 
      A previous study reported a higher than expected incidence of germ-line 
ATM mutations in CLL patients, based on the known incidence of 
heterozygous ATM mutation carriers in the UK. This raised the possibility that 
germ-line ATM mutations could predispose individuals to the development of 
CLL (Stankovic T et al, 2002). Speculation for a role of germ-line ATM 
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mutations in the causation of cancer is not new but a majority of research has 
focussed on the role of ATM mutations and sequence variants in the 
predisposition to breast cancer (Thortenson Y et al, 2003, Dork T et al, 2001). 
In this regard, a recent study has confirmed that individuals who inherit a 
single ATM allele containing a mutation which is known to cause ataxia 
telangiectasia when present in a homozygous or compound heterozygous 
state have a relative risk of for the development of breast cancer of 2.37 (95% 
confidence interval = 1.51-3.78, p=0.0003) (Renwick A et al, 2006) 
      To investigate the potential role of germ-line ATM mutations in CLL I 
made a direct comparison between the frequencies of germ-line ATM 
mutations in CLL patients with the frequency in a control population. I found 
that germ-line ATM mutations were present at a frequency of 2.5% in the CLL 
patients. This was lower than in the previous report where the prevalence of 
germ-line mutations was 6%, based on a population of 50 CLL patients 
(Stankovic T et al, 2002). In this study, I found germ-line ATM mutations were 
present at a frequency of 1.5% in the control population. These differences 
were not statistically significant and notably, the prevalence of germ-line ATM 
mutations in both the patient and control populations was higher than the 
previously estimated level of ATM heterozygote carriers in the UK population 
of 0.5% (Stankovic T et al, 1998). Clearly, due to the relatively small numbers 
of patients and controls analysed, these findings could have occurred by 
chance. In addition, due to the difficulty in distinguishing germ-line mutations 
from polymorphisms, the possibility remains that not all these sequence 
changes were in fact true mutations and highlights the importance of a 
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functional assay to prove that a germ-line sequence change has a detrimental 
effect on protein function.  
      An in vitro modelling system to assess the effects of specific sequence 
changes in the ATM gene has been developed in our laboratory and it would 
be important to use this system to assess the pathogenicity of the germ-line 
ATM mutations detected in this study. The modelling system involves the 
induction of expression of the ATM protein with the mis-sense change that is 
being investigated in an ATM null LCL cell line followed by the assessment of 
the activity of the corresponding ATM protein. The sequence change of 
interest is first generated using a site directed mutagenesis kit (Stratagene 
XL11). The mutant ATM coding sequence is then cloned into the multiple 
cloning site of the mammalian expression vector, pMEP4. This has an 
inducible promoter allowing the expression of the gene of interest to be 
controlled by, for example, the addition of the heavy metal ZnCl2. The 
construct containing the mutated ATM gene is stably transfected into an LCL 
which is null for ATM. ATM protein expression is then induced and the activity 
of the ATM protein can be determined by measuring the phosphorylation of 
downstream substrates following DNA damage with irradiation. This system 
has been successfully utilised to confirm the pathogenic nature of the 
5228C/T sequence change, detected in this study, and the 7181C/T sequence 
change that I detected in a multiple myeloma tumour as part of an 
independent study (Barone G, personal communication).  
       The differences in the frequency of germ-line ATM mutations between the 
patient and control populations in this study were very small and suggest that 
if ATM germ-line mutations do predispose to the development of CLL it is 
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likely to be a low penetrance effect that would require a significantly larger 
case-control study to demonstrate.  Such a low penetrance effect would be in 
keeping with the findings of several previous small studies that did not find 
clear evidence to support a role for germ-line ATM mutations in the 
predisposition for the development of CLL. These included a study of the 
relatives of AT patients, which did not identify any cases of CLL, and a study 
of CLL family pedigrees, which failed to observe any segregation of ATM 
mutations within affected family members (Thompson D et al 2005, Yuille M et 
al, 2002).  
.   
7.2.1.2 ATM polymorphisms  
       A recently published study has provided evidence to support a potential 
role of ATM polymorphic changes in the causation of CLL (Rudd MF et al, 
2006). This study used SNP arrays to perform a genome-wide comparison 
between polymorphisms in 992 CLL cases and 2707controls. The ATM gene 
was found to be one of only three genes that contained polymorphisms that 
were significantly associated with CLL patients. These two polymorphisms 
were the 2572T/C (F858L) change (OR=2.28, P=3.1x10-5) and the 3161C/G 
(P1054R) change (OR=1.68, P=6.0x10-4). Furthermore, the remaining two 
genes containing polymorphisms associated with CLL patients were also DNA 
damage response proteins, namely Chk2 and Brca1.   
      I compared the prevalence of polymorphisms in the ATM gene between 
CLL patients and controls in this study by using a screening approach that 
had the potential for detecting new or rare candidate polymorphisms that 
could have associations with CLL patients. Interestingly, although I found that 
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the 2572T/C alteration was more common in CLL patients than controls, the 
3161C/G alteration was actually more frequent in the control population in this 
case-control series and neither polymorphism was significantly associated 
with patients or controls. The only sequence change that was significantly 
associated with CLL patients was the IVS62-8A/C polymorphism. Due to its 
intronic location the only possible potential mechanistic explanation for this 
finding is that this change could interfere with exon splicing. This has not been 
previously reported but warrants further investigation.    
        
7.2.1.3 Acquired ATM mutations  
     Acquired ATM mutations could also contribute to the development of CLL if 
they occur at or before the time of clonal transformation. A previous study has 
reported on two patients that had ATM mutations detected in their tumour 
cells and which were shown to be absent from the patients’ germ-line but 
present in non-tumour cells including T-lymphocytes and monocytes 
(Stankovic T et al, 2002). This suggested a potential role of acquired ATM 
mutations in the process of clonal transformation.  
     In this study I was able to confirm that a number of the acquired ATM 
mutations were already present in the tumour cells at diagnosis. The timing of 
the clinical diagnosis of CLL cannot be directly related to the initial 
transformation but these findings also suggest that these acquired ATM 
mutations could have contributed to the initial clonal transformation. 
Furthermore, in two patients there was more than one inactivating ATM 
mutation present in diagnostic material indicating that ATM function had 
already been lost in the tumour cells at this early stage. In one of these 
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patients CLL77 this was due to one germ-line mutation (1058delGT) and one 
acquired mutation (5224G/C (A1742P) and in the second patient CLL96, it 
was due to acquired mutations (2929Ins9, 5041A/G, 5044G/T) only. 
 
7.2.1.4 Potential mechanisms by which ATM mutations contribute to the 
development of the B-CLL clone 
    The mechanism by which ATM sequence changes might contribute to the 
development of CLL is unknown.  
     It has been found that within the lymph node the level of ATM expression 
is much higher within the mantle zone compared to the germinal centres of 
the B cell follicles (Starczynski J et al, 2003). The level of p53 expression is 
also reduced within the germinal centre and this has been shown to be partly 
mediated via the transcriptional repressor BCL6 (Phan RT, Dalla-Favera R, 
2004). It has been postulated that reduced p53 expression might be important 
in the germinal centre cells in order to allow cells to tolerate the DNA breaks 
required for immunoglobulin class switch recombination and somatic 
hypermutation without inducing a p53-dependent apoptotic response (Phan 
RT, Dalla-Favera R, 2004). In a similar manner, physiological down regulation 
of ATM might also occur to protect cells from DNA damage induced apoptosis 
in the germinal centre.     
       Interestingly, the B-cell tumour subtypes that have commonly been found 
to have ATM mutations, such as Mantle Cell lymphoma, are derived from B 
cells that usually have high ATM expression (Schaffner C et al, 2000, 
Starczynski J et al, 2003). By comparison, abnormalities of the ATM gene 
have not been found in follicular lymphoma and Hodgkin’s lymphoma, which 
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are derived from B cells with low physiological ATM expression (Lossos IS et 
al, 2002, Lespinet V et al, 2005).  This suggests that the inactivation of ATM 
through mutation has a greater tumorigenic potential within those B-
lymphocytes that have high physiological ATM expression. However, 
conversely, both ATM and TP53 mutations have been reported in diffuse 
large B cell lymphomas which are also derived from germinal centre 
lymphocytes and typically have low ATM and p53 expression (Gronbaek K et 
al, 2002, Leroy K et al, 2002). These lymphomas are also characterised by 
de-regulation of BCL6, which suggests that the kinetics controlling the 
regulation of p53 and the DNA damage induced apoptotic response might be 
important in the clonal evolution of this lymphoma subtype (Cattoretti G et al, 
2005).  
       A previous study found that within CLL tumours, ATM mutations occurred 
exclusively in the subcategory that had unmutated IGVH genes. This led the 
authors to suggest that loss of ATM might be particularly important for the 
transformation at the pre-germinal stage of B-cell differentiation (Stankovic T 
et al, 2002). The findings in my study do not fully support this interpretation, 
since I found ATM mutations in CLL tumours with both unmutated and 
mutated IGVH genes although they were still significantly more common in 
CLL tumours with unmutated IGVH genes. The precise origin of the B-
lymphocyte that becomes clonally transformed in CLL remains uncertain and 
microarray analysis has recently demonstrated that both IGVH mutated and 
unmutated CLL tumours have an expression profile that most closely 
resembles memory B cells (Rosenwald A et al, 2001, Klein U et al, 2001). 
CLL tumours with mutated IGVH genes are thus now believed to have been 
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derived from B-lymphocytes that are antigen experienced and have passed 
through the germinal centre, whereas CLL tumours with unmutated IGVH 
genes are thought to have arisen from B-lymphocytes in the marginal zone 
that have undergone a T-cell independent antigen-recognition process (Klein 
U, Dalla-Favera R, 2005). The ATM expression within these marginal zone 
lymphocytes is not known but one could speculate that if defects in ATM 
expression do indeed contribute to the clonal transformation process in IGVH 
unmutated CLL tumours there might be high physiological ATM expression in 
these B-lymphocytes.    
     It is interesting that, while ATM mutations are present at a high frequency 
in CLL tumours, B-CLL has not been reported within individuals with AT. One 
explanation for this finding is that AT individuals have a short life expectancy 
and therefore do not live for long enough in order to develop CLL (Taylor AM, 
and Byrd P, 2005). However, the rarer MCL and T-PLL, which are also 
characterised by high numbers of sporadic ATM mutations, are both seen at 
increased frequencies in AT patients. Furthermore, T-PLL is also seen in a 
younger age group in AT patients compared to sporadic cases (Taylor AMR et 
al, 1992). The principal mechanism thorough which loss of ATM activity is 
believed to predispose to the development of lymphoma in AT patients is 
through the development of chromosomal translocations consequent of the 
defective repair of DNA DSBs during VDJ recombination (Taylor AM et al, 
1975). Since, the formation of the specific chromosomal translocations 
involving the T-cell receptor or the immunoglobulin genes, respectively, are 
believed to be key events leading to the formation of the T-PLL and MCL 
clones, it might be predicted that AT patients would be particularly 
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predisposed to the development of such lymphoid tumours (Taylor AM et al, 
1992, Camacho E et al, 2002). By comparison, chromosomal translocations 
are relatively uncommon in CLL tumours and when present they are often late 
events occurring after the initial transformation process. Thus, an alternative 
explanation for the observation that CLL is not over represented in AT 
patients is because the development of chromosomal translocations is not 
vital for the initial clonal transformation process (Klein U, Dalla-Favera R, 
2005, Finn WG et al, 1998, Mayr C et al, 2006).  
       From this discussion it can be seen that the extent to which ATM 
mutations actually predispose and contribute to the transforming event in CLL 
tumours is still uncertain. Nevertheless, the possibility remains that ATM 
mutations, either germ-line or acquired, could predispose to the 
transformation process through the failure to activate an apoptotic response in 
a B-lymphocyte that has acquired site non-specific DNA damage. As 
discussed below, it is possible that the loss of ATM function might occur as 
part of a multi-step process in the ontogeny of CLL, and that this step-wise 
loss of ATM function might be initiated both before and after the 
transformation of the B-cell clone.   
 
7.2.2 The role of ATM in the biology of the established CLL clone  
      Whether or not ATM mutations have a role in the development of CLL, the 
marked effect of ATM mutations on clinical outcome in CLL patients that I 
detected in this project suggests that they certainly have an impact on the 
biology of the disease once the tumour clone has developed. 
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7.2.2.1 Mechanism of action of ATM mutations in CLL tumours     
       The mechanism of action by which ATM mutations might impact on the 
behaviour of the CLL clone has been previously investigated. As described 
earlier, CLL tumours with bi-allelic ATM mutations have been shown to fail to 
up regulate p53 or p21 following DNA damage with IR, and in addition they 
have also been shown to exhibit a defective apoptotic response to DNA 
damage in the form of DSBs (Pettitt AR et al, 2001). This apoptotic defect is 
less pronounced than the defect in apoptosis seen in CLL tumours with TP53 
mutations and I confirmed this previously observed pattern of apoptotic 
responses in this project (Stankovic T et al, 2002). Furthermore, the pattern of 
defective apoptosis in tumours with ATM mutations that is intermediate 
between tumours with TP53 mutations and those with wild type ATM and 
TP53 genes mirrors the pattern in clinical outcome that I have shown in this 
study according to the same genetic subgroups.   
       My results, and previously published studies, suggest that an important 
mechanism through which ATM mutations exert a pathogenic effect in CLL 
tumours is through impairment of apoptosis following DNA damage. However 
uncertainties have remained as to whether or not these functional effects 
relate only to tumours with abnormalities of both ATM alleles or whether there 
were also functional consequences of mono-allelic ATM defects in CLL 
tumours (Stankovic T et al 2002, Stankovic T et al 2004).   
          
7.2.2.2 A deletion of an ATM allele in the absence of a mutation  
       I studied the early phosphorylation responses after DNA damage with 
irradiation to assess the function of the ATM protein. I demonstrated that the 
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chromosome 11q deleted tumours that had a remaining wild type ATM allele 
had retained ATM function and exhibited phosphorylation of downstream 
substrates after IR that was comparable to the responses in tumours with two 
wild type ATM alleles. Although there was a degree of variation, the tumours 
with an 11q deletion but a second wild type ATM allele could be clearly 
distinguished from those 11q-deleted tumours with a mutation in the 
remaining ATM allele, which all had very low level ATM activity. This indicated 
that 11q-deleted tumours form two functional subgroups in terms of their ATM 
activity. In representative tumours I also demonstrated that this differential 
ATM activity translated into differential downstream responses. Notably, the 
up regulation of p53 and induction of p21 was proficient in 11q-deleted 
tumours with a second wild type allele but impaired in all the tumours 
analysed with a second mutant ATM allele. 
       There was a degree of variation in the size of the subclone that carried 
the 11q deletion between different CLL tumours. The prognostic significance 
of variations in the size of the subclone that carries the chromosome deletion 
has not been reported. Interestingly, in my series a higher proportion of cells 
with an 11q deletion was seen within the whole tumour population when the 
clone had a mutation of the second ATM allele in comparison to clones that 
retained a wild type ATM allele. Indeed, it was uncommon to find a tumour 
with only a small subclone of cells carrying an 11q deletion if that clone 
carried an additional ATM mutation. This pattern did not occur in any of the 
tumours where viable cells were available for functional analysis of ATM 
activity. This suggests that the development of an ATM mutation in a tumour 
cell with an 11q deletion might lead to a more aggressive or faster growing 
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subclone of tumour cells. Notably, however, there were also several examples 
of tumours that had between 80 and 100% of tumour cells carrying the 11q 
deletion despite a remaining wild type ATM allele. These tumours all had 
proficient ATM activity thus confirming that the single wild type ATM allele was 
sufficient for normal ATM function in these CLL tumours, at least at the level 
of sensitivity of the assays used in this study. This implies that the expansion 
of the subclone with the chromosome 11q deletion in these tumours may have 
been independent of the ATM activity.  
     
7.2.2.3 One mutant ATM allele and one wild type ATM allele 
     There were several tumours that I identified in this project that had one 
mutant ATM allele but retained a wild type second allele. Assuming that the 
presence of this wild type ATM allele is sufficient for normal ATM-dependent 
DNA damage induced phosphorylation responses, as the results above 
indicate, then it would be expected that these tumours would also have 
retained ATM function. However, this group included four tumours that had 
deficient ATM-dependent phosphorylation responses after DNA damage and 
in three of these cases I was able to demonstrate that they also had impaired 
up regulation of p53 and induction of p21 expression. Furthermore, I 
confirmed that in three of these tumours there had been no new development 
of an 11q deletion to account for this pattern of functional response. 
      I considered the possibility that the mutations could be exerting a 
dominant negative effect. Since ATM exists as a dimer in the cell, such a 
concept is feasible and a dominant negative effect has been previously 
reported for certain ATM mutations (Scott SP et al, 2002). Dominant negative 
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effects occur with mis-sense mutations that result in the production of a full-
length stable protein containing an amino acid alteration and, therefore, such 
an effect could apply to CLLs 119 and 75 in this study that contained the mis-
sense mutations 9022C/T (R3008C) and 1009C/A (R337S) respectively. To 
investigate this possibility would require an in vitro modelling system similar to 
that described earlier to test the function of specific mutations. However, in 
this situation the vector containing the mutant ATM gene would be co-
transfected with a vector expressing an ATM wild type gene into an ATM null 
cell line. This would allow the assessment of the effect of the mutant protein 
on the function of the wild type ATM protein. 
 
7.2.2.4 Mechanism for poor outcome in patients with mono-allelic ATM 
defects  
      Interestingly, in this study the whole group of patients with an 11q deletion 
had a poor outcome and similarly, the entire group of patients with ATM 
mutations had a poor clinical outcome compared to CLL patients with neither 
of these defects. However, as discussed, a considerable proportion of each 
group only had a defect in one ATM allele and furthermore, the majority of 
these individuals with a mono-allelic defect had retained ATM function in their 
cells. In the group of patients with 11q deletions, those patients that had an 
additional ATM mutation showed a trend towards a poorer survival but this 
was not significant and in addition there was no significant difference in 
treatment free survival between the two 11q- deleted subgroups. Due to low 
numbers it was not possible to make a similar comparison in clinical outcome 
between patients with both an ATM mutant allele and a second ATM allelic 
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defect with those that had an ATM mutant allele and a second wild type ATM 
allele. Furthermore, this comparison would have been conceptually more 
complex due to the fact that four patients with one mutant and one wild type 
ATM allele had deficient ATM function. 
      My results therefore suggest that CLL patients with a mono-allelic ATM 
defect also have a poor outlook. One possible explanation is that defects in 
the two ATM alleles may be acquired in a stepwise manner in some CLL 
tumours. Therefore, tumours with bi-allelic ATM abnormalities could represent 
a later stage in the disease course compared to those with a mono-allelic 
change. Indeed, in two patients in this study I showed that the ATM mutations 
had arisen in tumour cells during disease progression. Each of these cases 
also had an 11q deletion but, because the timing of the loss of chromosome 
11q was not known for either tumour, it was not possible to be sure that the 
two genetic events had occurred sequentially. However, another tumour that 
had been previously identified to have two ATM mutations (2114insA, 
4393insA) in a separate study could be shown to have acquired these defects 
in a step-wise sequential manner. In this case, one of the mutations 
(2114insA) was present in a sample collected from the time of diagnosis and 
the other mutation (4393insA) was only detected in a sample collected several 
years later (Austen B et al, 2005). The late development of chromosome 11q-
deletions in CLL has also been previously described suggesting that the 
development of an ATM mutation or an 11q deletion might occur in either 
order (Cuneo A et al, 2002). 
       The step-wise development of ATM allelic defects could also partly 
account for the partial correlation that I observed between tumours with an 
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ATM mutation and tumours with an 11q deletion. This is unlikely to explain 
this finding completely since in certain tumours both ATM alleles will be 
inactivated by mutations. Furthermore, in this study over half of the patients 
with an 11q deletion had a second wild type ATM allele even though these 
included a number of long-lived patients in which the sample analysed had 
been collected many years out from diagnosis. This, therefore, suggests that 
a significant proportion of patients with one ATM defect in their tumour cells 
may never acquire a second ATM allelic defect.  
        Further indirect evidence to support the concept of the sequential 
development of ATM allelic defects is related to the three-fold higher 
proportion of 11q-deleted tumours that had ATM mutations compared to 
unselected CLL tumours in this study. This suggests that loss of one 
functional allele at the ATM locus predisposes to the subsequent development 
and clonal expansion of tumour cells with a second ATM abnormality. Clearly, 
any tumour cells that are already heterozygous at the ATM locus will lose 
ATM function if they acquire a mutation in the remaining ATM allele. Loss of 
ATM function would then be predicted to render the tumour cell resistant to 
DNA damage induced apoptosis, thus providing a cellular survival advantage. 
This could then lead to expansion of a subclone that has acquired bi-allelic 
ATM defects and would be consistent with the observation in this study that 
there is frequently a larger subclone carrying an 11q deletion in those tumours 
that have an ATM mutation in the second allele compared to those that have 
a second wild type ATM allele. 
      Interestingly, in all three tumours where it was possible to confirm the late 
development of an ATM mutation, the patient had received treatment with 
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DNA damaging chemotherapeutic drugs between the date of the initial sample 
that lacked the mutation and the second sample where the mutation was 
present. Therefore, in these tumours the use of DNA damaging drugs may 
have provided an additional selective pressure for the survival of a tumour cell 
that had developed a second allelic ATM defect. 
       In order for the initial mono-allelic ATM defect that has occurred via an 
11q deletion or ATM mutation to be maintained in the tumour clone they must 
presumably also convey a survival advantage to the cell. Although ATM 
mutations may have occurred at the time of clonal transformation, deletions of 
chromosome 11q are commonly acquired after the initial clonal 
transformation, as indicated by the fact that in many CLL tumours they are not 
present in the total tumour cell population. Therefore for cells carrying this 
deletion to have expanded to form a subclone they must have induced a 
survival or proliferative advantage. If ATM function is indeed entirely normal in 
these cells this survival signal might be independent of ATM function. The 
region of deletion on chromosome 11q spans 2-3 Mb and contains a number 
of genes (Stilgenbauer S et al, 1996). At the current time, no mutations have 
been found in any of these alternative candidate genes but heterozygosity at 
certain genetic loci could also have a pathogenic effect in CLL tumours (Auer 
RL et al, 2005, Celeste A et al, 2003). Therefore the short survival in some 
patients with an 11q deletion who do not have an ATM mutation could be due 
to a defect that is independent of ATM. Alternatively, it is possible that the 11q 
deletion does have some subtle effect on ATM function which was not 
detectable by the assay used in this project, and it is this effect that leads to 
the maintenance of the 11q deletion within the CLL clone. Nevertheless, the 
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tumour would still be predicted to attain a further survival advantage and 
behave more aggressively following the subsequent development of the 
second ATM defect.  
       In this study there were two tumours that had one mutant ATM allele and 
also carried a mutation in the TP53 gene. It is therefore conceivable that 
heterozygosity at the ATM locus could have predisposed to the development 
of a mutation in an alternative DNA damage response, namely the TP53 
gene. Unfortunately, it was not possible to determine the sequential timing of 
these genetic events for either tumour. Since abnormalities in p53 have a 
more marked effect on apoptosis than ATM mutations, one might consider the 
possibility that there would be no additional survival advantage to a cell that 
already had a TP53 mutation by the subsequent development of the ATM 
mutation. Notably, however, ATM activates numerous p53-independent as 
well as p53-dependent cellular pathways. Furthermore, the BH3-only domain 
pro-apoptotic protein BID, which is member of the BCL2 family of proteins that 
act downstream of p53 in the intrinsic apoptotic pathway, has recently been 
found to be a direct target for ATM dependent phosphorylation (Kamer I et al, 
2005). So there may indeed be a further survival advantage to a CLL cell with 
a TP53 mutation by the later development of a defect in ATM function. This 
concept is also supported by murine studies that have demonstrated that ATM 
and p53 are not congruent but rather can cooperate in their tumour 
suppressive functions (Westphal CH et al, 2002).  
 
7.2.3. Effects of ATM mutations on the response to Fludarabine 
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       The defect in DNA damage-induced apoptosis that I have observed 
following irradiation in the tumours with ATM mutations is likely to contribute 
to the poor clinical outcome in patients. For example, these tumours may fail 
to activate this DNA damage response pathway following treatment with 
certain chemotherapeutic drugs which would therefore lead to chemo-
resistance. However, evidence for a direct effect of ATM mutations on the 
response to DNA damaging chemotherapeutic drugs is lacking. 
       In order to investigate the effects of ATM mutations on the response to 
fludarabine, I initially studied the role of fludarabine in the induction of DNA 
DSBs and the activation of the DNA damage response pathway. The 
mechanism of action of the purine analogue fludarabine relies on its 
incorporation into DNA. In non-cycling CLL cells, where there is no DNA 
synthesis, this incorporation might occur during DNA repair processes such 
as mismatch repair or base excision repair following spontaneous or drug 
induced DNA damage (Pettitt AR, 2003). Once incorporated into DNA, 
fludarabine has been shown to signal the activation of p53-dependent 
apoptosis (Achanta G et al, 2001, Rosenwald A et al, 2004, Rao VA, Plunkett 
W, 2001). However, the role of ATM in the response to fludarabine in CLL 
cells has remained uncertain.  
       In this project, I have demonstrated that fludarabine leads to the induction 
DNA DSBs in CLL tumour cells and that these DSBs, as indicated by γH2AX 
foci, are present after 8 hours of culture but are more frequent after 24 hours 
of culture with fludarabine. I also showed that fludarabine led to the activation 
of the DNA damage response pathway that resulted in the phosphorylation of 
substrates that were known to be targets of the ATM protein. Furthermore, 
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tumours with bi-allelic ATM defects failed to phosphorylate these substrates 
indicating that the phosphorylation responses were dependent on functional 
ATM in an analogous way to the responses induced by irradiation. These 
results imply that the loss of ATM function could not be compensated for by 
the activity of related proteins such as ATR, at least in terms of the 
phosphorylation of these target substrates in the CLL tumours cells. There is 
known to be some redundancy between the function of ATM and ATR in the 
slower kinetic responses to DNA DSBs and the lack of compensation for loss 
of ATM in CLL tumours might be explained by the fact that ATR has been 
shown to be down regulated in non-cycling CLL tumour cells (Lin K et al, 
2002). Under these circumstances functional ATM might be important for both 
rapid and slower responses to DNA DSBs. 
      In line with the irradiation experiments, I have also demonstrated in this 
project that tumours that had a retained wild-type ATM allele had responses 
to fludarabine that were equivalent to tumours with two wild type ATM alleles. 
Thus the group of tumours with an 11q-deletion showed an ATM-dependent 
response not only to irradiation but also to DNA damage induced by 
fludarabine. 
      These results therefore provide evidence indicating that a decrease in the 
response to the DNA damaging chemotherapeutic agent fludarabine is indeed 
one reason for the poorer outcome in CLL patients with absent ATM function. 
Furthermore, the use of these agents in tumours with impaired ATM function 
could actually be detrimental since the delayed or defective responses to the 
DNA damage could promote the generation of further genetic defects and 
hence an acceleration of tumour progression.  In addition, as discussed 
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earlier, using these agents in tumours with loss of one ATM allele might also 
be detrimental as they could provide a selective pressure for the emergence 
of subclones that have acquired a defect in the second ATM allele. 
   
7.3 Final conclusions and clinical implications  
      As a part of my PhD project, I have demonstrated that the detection of 
ATM mutations in CLL tumours has prognostic value. With a prevalence of 
12%, ATM mutations represent the commonest single gene defect to be 
identified in CLL and, indeed, the frequency of CLL tumours that acquire ATM 
mutations prospectively may be even higher. ATM mutations lead to an 
aggressive clinical phenotype resulting in a significant reduction in both TFS 
and OS in CLL patients and they provide prognostic information that is 
independent of age, clinical stage, the mutation status of the IGVH genes and 
TP53 mutations.  
       The timing of the ATM mutations and their relationship with CLL tumours 
with an 11q deletion is interesting and provides clues into their mechanism of 
action in the pathogenesis of the disease. In certain cases, they represent 
germ-line changes and in other tumours appear to be present very early in the 
disease course raising the possibility that they might contribute to the initial 
process of clonal transformation. By comparison, they can also occur during 
disease progression and this appears to be more common when they occur 
as the second defect in the ATM gene, leading to the loss of cellular ATM 
activity.   
      There is only a partial correlation between tumours with mutations in the 
ATM gene and those with loss of one ATM allele via an 11q deletion at any 
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point in time. Thus, the category of tumours with an 11q deletion forms two 
distinct subgroups based on the status of the remaining ATM gene and this 
has functional significance in terms of the responses to DNA damage. 
Interestingly, the presence of an 11q deletion also appears to lead to an 
increased predisposition for the subsequent development of an ATM 
mutation. 
        ATM is an important DNA damage response protein and when 
inactivated there is impairment in the activation of p53 and p53-dependent 
responses, including apoptosis. This has important implications for the use of 
DNA damaging drugs in the treatment of CLL tumours. As demonstrated in 
this study, chemotherapeutic agents such as Fludarabine activate the ATM 
dependent DNA damage responses and there is impairment in this response 
in tumours with bi-allelic ATM defects. These results indicate that chemo-
resistance is likely to be an important mechanism accounting for the poor 
outcome in CLL patients with ATM mutations. 
         The identification of tumours with ATM mutations would therefore predict 
patients that will have a poor clinical outcome and are likely to require early 
treatment for their disease. However, it would also identify those tumours that 
might be resistant to standard treatments and, as such, would benefit from 
alternative therapeutic strategies that do not involve the ATM/p53 damage 
response pathway. Functional assays could be used to readily identify 
tumours with impairment of ATM function, which will principally be tumours 
with bi-allelic ATM defects. Such assays could, therefore, be used before 
each treatment episode, to guide the choice of therapeutic agents. 
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        There may also be clinical value in the identification of CLL tumours with 
mono-allelic ATM defects, either through a mutation or an 11q deletion. These 
tumours would be predicted to be sensitive to DNA damaging drugs, but there 
is the possibility that the use of these drugs might provide a selective pressure 
for the emergence of sub-clones that have acquired bi-allelic ATM defects, 
which would in turn be associated with a more aggressive cellular phenotype.   
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Future Work 
      An interesting aspect of this work that I would like to develop is the study 
of the proposed subgroups of 11q-deleted tumours based on the mutation 
status of the remaining ATM allele. Specifically, within the research group we 
have already initiated the ATM mutation screening of a cohort of 100 tumours 
that all have an 11q deletion, which were collected from CLL patients entering 
the recent UK CLL 4 trial. This group of patients were all previously untreated 
and the samples to be genetically analysed were collected prior to the 
patients starting one of three therapeutic options, namely chlorambucil, 
fludarabine, or fludarabine and cyclophosphamide, according to the trial 
protocol.  Therefore, it will be possible to relate treatment responses in these 
patients with the mutation status of their ATM genes prior to starting 
treatment. Since all these patients had an 11q deletion, any ATM mutation 
detected will be expected to result in the loss of ATM function in the tumour 
cells. 
        In addition, we will continue expanding the cohort of non-trial patients 
with an 11q deletion to assess whether it is possible to demonstrate any 
significant differences in survival between the two subgroups of patients in a 
larger, more powerful study.  
        Viable cells from both patient series will also be used to compare 
responses in vitro to the chemotherapeutic drugs used in the CLL4 trial. We 
will be interested to assess whether there are differential responses to 
chlorambucil and cyclophosphamide in addition to the differential responses 
that I observed to fludarabine between the two 11q-deleted subgroups. 
Furthermore, we propose to study not only the early ATM-dependent 
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phosphorylation responses but also the downstream effects on p53 
dependent transcription, as assessed by gene expression profiling, and the 
induction of apoptosis following treatment with each of these agents. 
         Where possible, it will also be interesting to assess serial samples from 
more patients to assess whether a step wise loss of functional ATM allele is a 
common phenomenon in these patients and, importantly, whether this might 
relate to the prior use of DNA damaging therapeutics. Given the role of ATM 
in the repair of DNA breaks, as well as the activation of apoptosis, it would 
also be interesting to assess whether tumours that lose ATM function are 
predisposed to the development of further genomic instability such as 
chromosomal translocations. This might also provide an explanation, in 
addition to the resistance to chemotherapeutics, to account for the 
significantly poorer outcome in patients with ATM mutations. Such potential 
genomic instability could be assessed via karyotyping or by using more 
sensitive techniques such as comparative genomic hybridisation or SNP 
arrays.  
       In this project, I also identified a group of tumours with an impairment of 
apoptosis following DNA damage with irradiation despite the presence of wild 
type ATM and TP53 genes. The mechanism to account for this observation 
warrants further investigation. One explanation could be that there is up-
regulated DNA repair in these tumours, as highlighted in a previous report, 
and it will be interesting to study repair assays, particularly the status of NHEJ 
and DNA-PK activity in these tumours (Deriano L et al, 2005). Alternatively 
there may be defects in the activation of p53-mediated downstream functions, 
based on differential interaction of p53 with specific promoters (Meek D, 
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2004). These possibilities will be investigated in our research group in the 
future. 
      One of the aims of this project was to investigate the contribution of germ-
line ATM defects to the development of CLL. Due to limitations of the study, it 
was difficult to make firm conclusions with respect to this part of my project. 
Nevertheless, there remains the possibility that ATM mutations may have a 
low penetrance effect in the causation of CLL. The ongoing screening of CLL 
patients for ATM mutations in our laboratory will provide further cumulative 
information and any potential differences between the proportions of germ-line 
ATM mutations between CLL patients and controls can be re-assessed. As 
alluded to earlier, these alterations could also be modelled to confirm their 
pathogenic nature.  
        To aid ATM mutation analysis, we also intend to develop a FACS test to 
screen CLL tumours to allow the rapid detection of tumours with impairment in 
the DNA damage response. Those tumours with deficient responses will 
subsequently be screened for ATM mutations. This will allow the ongoing 
detection of tumour with mutations, which is important for our future research, 
but will also identify patients that may benefit from novel therapeutic agents, 
which bypass the ATM/p53 pathway, and are available as part of Phase 1 and 
2 clinical trials. 
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